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ABSTRACT OF DISSERTATION 
 
 
 
STUDY OF THE MECHANISM OF ACTION FOR 
Ru(II) POLYPYRIDYL COMPLEXES AS POTENTIAL ANTICANCER  
AGENTS 
 
 
Application of chemotherapeutic agents in current cancer treatment has been limited by 
adverse effects as poor selectivity results in systemic toxicity; most chemotherapy approaches also 
experience inherited or acquired drug resistance which lead to reduced treatment outcome. 
Research efforts have focused on the discovery of novel chemotherapies that overcome the 
limitations mentioned above. Ru(II) polypyridyl complexes with anti-cancer properties have been 
extensively studied as traditional cytotoxic agents and photodynamic therapy agents due to their 
photophysical and photochemical characteristics.  
Most research has focused on the design of Ru(II) polypyridyl complexes that have 
affinities to nucleic acids as inspired by the classic small molecule metal complex cisplatin. Though 
modifying the structures of ligands on the ruthenium metal center, the hydrophilicity, charge state 
and photochemical properties can be tuned, resulting to Ru(II) polypyridyl complexes that act 
through cellular targets other than DNA.  
Understanding the mechanism of action and identifying functional targets remain the 
challenging and complex research topic in the design and study of novel medication or candidates. 
With the development of semi-high throughput cytological profiling in a bacterial system, rapid 
investigation of the mechanism of action can be achieved to distinguish anti-cancer agents which 
possess different mechanisms of actions. Ru(II) polypyridyl complexes with different scaffolds 
have been studied and suggested to have anti-cancer properties through DNA damage response, 
and/or translational inhibition. 
 
KEYWORDSs: Ru(II) polypyridyl complex, cancer, chemotherapy, mechanism of action, 
cytological profiling  
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Chapter 1 Introduction 
1.1 Cancer and current treatments. 
 Cancer, by definition, is a group of diseases in which the abnormal cells grow and divide 
without control, and invade other tissues through the lymphatic and circulatory system. Failure of 
regulation of normal cell division and differentiation results in uncontrolled cell growth and 
proliferation. In recent years, cancer has remained the second leading cause of death in the United 
States and worldwide.1, 2 In 2017, it is estimated that over 4,600 people will be diagnosed with 
cancer every day, leading to a total number of 1,688,780 new cases in the United States.1 Cancer 
deaths in the US are projected to be 600,920 for 2017, which means more than 1,600 people die of 
cancer every day.1 According to the statistics from National Cancer Institute's (NCI's) Surveillance, 
Epidemiology, and End Results (SEER) Program, the top three caner types in female are: breast 
cancer, which is responsible for 30% of incidences, and 14% of deaths; lung cancer, which is 
responsible for 12% of incidences, and 25% of deaths; and colon cancer, which leads to 8% of both 
incidences and deaths. In males, the top three cancer types are: prostate cancer, resulting in 19% of 
incidences and 8% of deaths; lung cancer, which is responsible for 14% of incidences and 27% 
deaths; and colon cancer, which leads to both 9% of both incidences and deaths.1 
 Current cancer treatments consist of surgery to physically remove the tumor for localized 
tumors, radiation therapy, and chemotherapy that typically damages a portion of cancerous cells.3 
Clinical treatments typically utilize a combination of the three methods, with multiple components 
in the chemotherapy prescribed, known as chemotherapy regimens. A chemotherapy regimen 
typically includes the type and dosage of medications used, the duration of treatment, and the 
frequency. In current clinical application, multiple types of drugs of different mechanisms of 
actions are used in combination to produce synergistic effects.4, 5 The first successful chemotherapy 
regimen was MOPP, which was introduced in 1963 to treat Hodgkin's disease. This particular 
regimen includes mustargen, oncovin, procarbazine, and prednisone; they are administrated in a 
four-week cycle for several cycles by intravenous (IV) injection and oral dose.6, 7 One component 
that is commonly included in many chemotherapy regimen is platinum agents, including cisplatin, 
oxaliplatin, and carboplatin, which have been applied in over 30 chemotherapy regimens.7 Among 
the three platinum agents, cisplatin is the most commonly prescribed species in treatments of 
testicular cancer (BEP: bleomycin, etoposide, and cisplatin), bladder cancer (MVAC: methotrexate, 
vinblastine, doxorubicin, and cisplatin), lymphoma (DHAP: dexamethasone, cytarabine, and 
cisplatin), and lung cancer (MVP: mitomycin, vindesine, and cisplatin; PEI: cisplatin, etoposide, 
and ifosfamide).8, 9, 7 
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Recent advances in drug discovery have provided novel treatment approaches, including 
immunotherapy, that have seen promising results, and there are chemotherapeutic agents that are 
able to target certain biomarkers of cancer cells. A majority of the targeted therapies approved by 
the FDA are small molecule kinase inhibitors, such as imatinib mesylate, commonly used under 
brand name Gleevec. This is a small molecule tyrosine kinase inhibitor that effectively inhibits the 
fusion protein kinase Bcr-Abl in Philadelphia chromosome-positive chronic myelogenous 
leukemia (CML) and acute lymphoblastic leukemia (ALL).10, 11, 12, 13 Positive results associated with 
such selective drugs include increasing survival rates with fewer side effects, but there are also 
challenges in targeted therapy. Cancer cell resistance occurs with targeted therapy by mutation of 
the targets, and the development of precision medication for certain targets can be difficult and 
time consuming.14, 11, 15 For these reasons, the systemic chemotherapy that generally damages 
common cell targets remain the main stream for current chemotherapy.  
1.2 Cisplatin is a commonly used chemotherapeutic agent. 
Cis-diamminedichloroplatinum (II), also known as cisplatin (brand name Platinol), is one 
of the most widely used metal-based chemotherapeutic agents for cancer (Figure 1A). Barnett 
Rosenberg’s study showing E. coli cell division inhibition led to the discovery of cisplatin in 1965, 
and he also demonstrated the anti-tumor activity of this platinum based small molecule in later 
research.16,17,18 Following the approval by FDA in 1978 for the treatment of testicular and ovarian 
cancer, cisplatin has been used to treat various types of cancer since then, including bladder, lung, 
and head and neck cancer, and provides an overall cure rate of testicular cancer higher than 90%.19,20 
The discovery of cisplatin also led to the extensive study of platinum and other metal based 
compounds for their biological properties and potential medical applications.21, 22 
The generally accepted mechanism of action of cisplatin is DNA damage induced by 
covalent platinum - DNA adducts; therefore, DNA has been considered the primary functional 
target of cisplatin. Cisplatin mainly enters cells by passive diffusion,23,24 the chloride ligands on 
platinum are then displaced by water molecules in the cell, generating an active aquated species, 
which is positively charged, and has higher affinity to DNA molecules. The active species binds to 
DNA with loss of the water ligands and forms stable covalent bonds primarily with purine bases at 
the N7 position, causing intrastrand (on a single strand) and interstrand (on two strands) crosslinks, 
as shown in Fig. 1B.25 The DNA - cisplatin adducts lead to distortions of DNA structure, which are 
recognized by damage recognition proteins including HMGB proteins, DNA damage repair 
proteins, and transcription factors. This triggers DNA repair pathways, whose failure leads to 
apoptosis, a form of programmed cell death.26 
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Figure 1.1 DNA damaging mechanism of cisplatin. A) Formation of cisplatin diaqua active species 
via hydrolysis. B) The diaqua form of cisplatin forms covalent cisplatin-DNA adducts at N7 
position of guanine and results in both interstrand and intrastrand crosslinks of DNA. 
 
Similar to many chemotherapeutic agents, cisplatin has a limited spectrum of anticancer 
activity, and the utilization of cisplatin in cancer treatment is also largely limited by adverse-effects 
due to its non-selectivity. Since cisplatin affects normal cells as well as cancer cells, it causes 
several systemic toxicities.26 Cisplatin affects the kidneys of patients, resulting in nephrotoxicity; 
it also causes neurotoxicity and ototoxicity, severe nausea and vomiting, and myelosuppression. 
These side-effects have limited the clinical application of cisplatin.26 Another major limitation of 
cisplatin treatment is the intrinsic or acquired drug resistance of cancer cells. The mechanism of 
cisplatin resistance is complex and is currently not fully understood. Several different mechanisms 
have been shown to be associated with resistance behavior, including but not limited to decreased 
cellular accumulation, inactivation of cisplatin by sulfur containing molecules, enhanced nucleotide 
excision DNA repair mechanism, and defects in signaling pathways leading to apoptosis. In most 
cisplatin resistant cells, there is more than one mechanism involved.27 Reduced cellular 
accumulation of cisplatin is mainly caused by decreased uptake. Recent research shows copper 
transport protein (CTR1) assists in the uptake of cisplatin, and increased CTR1 expression level 
results in increased cisplatin accumulation and cytotoxicity.28 Cisplatin resistance due to reaction 
with sulfur compounds has been shown with glutathione. Glutathione is a short peptide consisting 
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of three amino acid residues: cysteine, glutamic acid, and glycine. Cisplatin is able to covalently 
bond to the thiolate anion of glutathione, and as a result, loses the ability to crosslink DNA, which 
leads to tolerance of cisplatin. In cisplatin resistant bladder tumor cells, elevated levels of 
glutathione are observed while the glutathione levels are lower in testicular cells, which are 
intrinsically sensitive to cisplatin treatment.29 Other cysteine-rich proteins such as metallothioneins 
also contribute to the inactivation of cisplatin through a similar mechanism.27 
In cisplatin resistant cells, the ability to repair cisplatin - DNA adducts and to tolerant the 
DNA lesions is enhanced; in other words, sensitivity to cisplatin is decreased. Nucleotide excision 
repair (NER) is responsible for removal of most DNA lesions caused by cisplatin.4, 30 In mammalian 
cells, NER requires about 20 proteins to excise the damaged nucleotides, reconstruct the DNA by 
replacing new nucleotides, and sealing the repaired strand.31 Deficient NER is usually associated 
with cisplatin sensitivity, while cisplatin resistant cells exhibit increased NER proficiency to repair 
cisplatin - DNA lesions. The increased repair efficiency in cisplatin resistant cells is also positively 
correlated with specific enzymes, including XP complementation group A (XPA) and excision 
repair cross-complementation group 1 (ERCC1). These two enzymes are key players in nucleotide 
excision repair. It has been reported that cisplatin resistance is correlated with overexpression of 
ERCC1 and XPA.32, 33 In addition to NER, another repair mechanism, mismatch repair (MMR) 
detects the cisplatin induced DNA damage. MMR fails to repair the damage which leads to 
apoptotic signaling, so this repair mechanism serves more as a signaling pathway, and it has been 
reported that cisplatin resistant cells usually have a defect in MMR. In cisplatin resistant cells, there 
are more changes in signaling pathways other than the mismatch repair that inhibit apoptosis caused 
by cisplatin treatment. Some studies suggest that cisplatin resistant cells fail to activate several 
mitogen activated protein kinase (MAPK) family members, for example, P38 MAPK and c-JNK, 
and therefore result in deficient apoptotic signaling.34,35 Many cisplatin resistant cells express high 
level of apoptosis inhibitors or low levels of proapoptotic proteins.36 It has been reported that 
cisplatin resistant ovarian cancer cells express reduced levels of the proapoptotic protein Bax.37 In 
addition, the cisplatin sensitive testicular cancer cells express high levels of Bax to promote 
apoptosis and low level of apoptotic inhibitor Bcl-2.38 
1.3 Alternative platinum complexes as anticancer agents. 
 After the discovery and clinical application of cisplatin, platinum based small molecules 
have been the focus of intense research to design novel molecules that retain anticancer activity 
with reduced systemic toxicity and drug resistance.39 Investigation of molecules with a platinum 
center generally have similar features: (i) neutral complexes; (ii) square planar structures; (iii) two 
cis amine groups and two cis-coordinated leaving groups.21, 40, 41 Several analogous drugs acting 
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through similar DNA binding mechanisms have been developed and approved by drug 
administration agencies around the world for cancer treatments (Figure 1.2). 
 Carboplatin is a second-generation platinum drug that was approved by the FDA in 1989 
for treatment of multiple types of cancer including ovarian cancer, lung cancer, and breast cancer. 
The alteration in the chelating ligand, dicarboxylate replacing the two chloride ligands in cisplatin, 
makes the leaving group bigger and more stable than chloride. This slows drug metabolism, and 
reduces the side effects compared to cisplatin. The major side effects of carboplatin include nausea, 
vomiting, and myelosuppression.21, 42, 43 Another platinum based drug that has been globally 
approved for clinical application is oxaliplatin (Figure 1.2). Here, the platinum center in oxaliplatin 
coordinates with a 1,2-diaminocyclohexane (DACH) ligand and a bidentate oxalate ligand. 
Developed as an improvement of cisplatin, oxaliplatin has a shifted anticancer spectrum compared 
with the first and second generations of platinum drugs. It has been mainly used to treat colorectal 
cancer and gastrointestinal cancers that are resistant to cisplatin and carboplatin.44, 5 The altered 
anticancer spectrum of oxaliplatin has been thought to be associated with the alteration in DNA 
binding and DNA damage responses.22, 45 Recent researches, however, have indicated the 
differences could be a result of novel mechanisms relating to ribosome biogenesis that are not 
associated with cisplatin and carboplatin mechanisms of action.46, 44 The side effects of oxaliplatin 
includes peripheral neurotoxicity, nausea, vomiting, and fatigue.47, 48 
 Nedaplatin, heptaplatin, and lobaplatin are cisplatin analogous drugs that are approved for 
clinical treatments in certain countries. Nedaplatin is currently approved for treatments of lung 
cancer, head and neck cancer in Japan.49, 50 This molecule has greater water solubility due to the 
glycolate chelating group that replaces the two chloride ligands in cisplatin (Figure 1.2). 49, 21 
Heptaplatin is now approved by Korean drug administration agency for treatment of gastric cancer, 
the platinum center is chelated to a malonate group and a 2-(1-methylethyl)-1,3-dioxolane-4,5-
dimethanamine group which contains a seven-numbered ring.21, 51 The efficacy of heptaplatin in 
cisplatin resistant gastric cancer cells has been reported to be associated with less involvement of 
metallothionein.51 Lobaplatin is currently approved in China to treat breast cancer, lung cancer, and 
chronic myelogenous leukemia (CML).52, 21 Lobaplatin contains a 1,2-
bis(aminomethyl)cyclobutane ligand and a lactic acid serves as the leaving group, it is formulated 
as a diastereometric mixture.53, 21 
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Figure 1.2 Platinum based drugs that have approved for clinical treatments of cancers.   
Platinum based drugs such as carboplatin and oxaliplatin which are analogous to cisplatin, 
however, do not completely eliminate side-effects and drug resistance.54, 55, 56, 57 More platinum 
containing molecules with modified structures have been studied for possible medical 
applications.21 Besides the cisplatin analogous drugs that have approved for clinical applications, a 
number of platinum compounds have been developed and studied for their anticancer properties. 
The possibility of using platinum (IV) compounds as prodrugs to release platinum (II) compounds 
that are analogous to cisplatin has been explored, and several candidates have entered clinical trials 
for their therapeutic applications. Tetraplatin (tetrachloro(trans-1,2-diaminocyclohexane) platinum 
(IV)), also known as ormaplatin, is reduced to an active platinum (II) species dichloro(trans-1,2-
diaminocyclohexane) platinum (II) that is similar to oxaliplatin.21, 58 In Phase I clinical trials, it 
showed activity against cisplatin-resistant cancers, but severe neurotoxicity was observed as well.59, 
60, 61 Iproplatin (cis,trans,cis-dichlorodihydroxobis(isopropylamine)platinum (IV)) also produces 
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active platinum (II) species that covalently bind to DNA and induces cytoxicity against cancer cells. 
Iproplatin has been studied in Phase I to III clinical trials for ovarian cancer, head and neck cancer, 
with the major side effects of iproplatin being myelosuppression, nausea, and vomiting.21, 62, 63 
Satraplatin (trans,cis,cis-bis(acetato)amminecyclohexylaminedichloroplatinum (IV)) is featured as 
an oral bioavailable agent. It is reduced in the bloodstream, producing six different platinum (II) 
species that are DNA crosslinking agents.21, 64 Phase II clinical trial in lung cancer and head and 
neck cancer patients showed reduced neurotoxicity and nephrotoxicity side effects.65, 66, 21  
1.4 Non-platinum metal compounds as potential anticancer agents. 
Besides all the efforts invested on platinum based anticancer agents, non-platinum based 
drugs with alternate metal centers also have been the subject of increasing research interest as they 
offer the possibility of novel targets and mechanisms of action with reduced drug resistance and 
general toxicity.67, 68 The availability for expanded coordination chemistry, and the photophysical 
and photochemical properties of transition metals make them favored research candidates for the 
medicinal chemistry field.69, 70 Molecules with anticancer properties have been prepared and studied 
with transition metals including iron (Fe), cobalt (Co), copper (Cu), nickel (Ni), ruthenium (Ru), 
rhodium (Rh), palladium (Pd), gold (Au), osmium (Os), and iridium (Ir).71, 70, 41 While none of these 
transition metal compounds have been approved by FDA for clinical treatment, they have been 
studied in clinical trials and preclinical studies with not just DNA associated mechanism, but also 
novel mechanisms of action.72 
Dinuclear cobalt compounds with alkyne ligands have been reported to exhibit cytotoxicity 
in multiple cancer cell lines;73, 72 furthermore, it was revealed that the cytotoxicity didn’t correlate 
with the DNA binding property. The lead compound, [2-acetoxy-(2-
propynyl)benzoate]hexacarbonyldicobalt (Co-ASS, Figure 1.3A), a cobalt alkyne compound with 
an aspirin derivative, has shown ability to inhibit cyclooxygenase enzymes (COX-1 and COX-2); 
and the COX inhibition has correlated well with the cytotoxicity in cancer cells.74, 75 Further studies 
have proved additive and synergistic effects of Co-ASS in combination with the tyrosine kinase 
inhibitor, imatinib.76, 72 Efforts have been invested in cobalt (III) compounds that are activated by 
the hypoxia environment and the slightly acidic pH in cancer cells to cause cytotoxicity.77, 72 Cobalt 
(III) compounds containing nitrogen mustards (Figure 1.3B) are reduced to cobalt (II) compounds 
in hypoxic cells, releasing the nitrogen mustard ligand to damage DNA of cancer cells.78, 79 
Copper plays essential roles in a number of cellular events and regulatory pathways, 
besides its role as an enzyme co-factor. Copper (II) compounds have received considerable research 
interests as they exhibit activities in cancer cells through mechanisms that differ from cisplatin.71, 
70 It has been generally considered that the cytotoxicity of copper compounds are the result of the 
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reactive oxygen species (ROS) generation and oxidative DNA cleavage.71, 70 It is also notable that 
copper compounds containing dithiocarbamates (Figure 1.3C) selectively target the proteasome in 
cancer cells.80, 71, 81  
Research on ruthenium compounds has drawn increasing research interest as the octahedral 
coordination geometry and three dimensional architecture of ruthenium offers the potential for 
higher degrees of site selectivity towards biological molecules such as DNA and protein compared 
to the square planer geometry of most platinum based compounds. This may lead to lower toxicity 
and possible reduced adverse effects.82, 83, 84, 85 Current ruthenium compounds studied for anticancer 
properties act through both DNA dependent and independent mechanisms. Two ruthenium (III) 
compounds, NAMI-A (imidazolium trans-imidazoledimethyl sulfoxide-tetrachlororuthenate, 
Figure 1.3E) and KP1019 (trans-[tetrachlorobis(1H-indazole, Figure 1.3F) ruthenate]) have been 
studied in clinical trials. Both NAMI-A and KP-1019 form various ruthenium species in the 
biological environment and the active species generated readily react with biological molecules 
including DNA.72, 86, 87 It has been reported that both compounds induce DNA damage responses 
and apoptosis in cancer cells, though the mechanism is not fully understood. NAMI-A is primarily 
effective in inhibiting tumor metastasis in vivo, while KP1019 is active against both primary and 
metastatic tumors.88, 89, 90  
Ruthenium (II) arene compounds containing 1,3,5‐triaza‐7‐phosphoadamantane ligands, 
also known as RAPTA compounds (Figure 1.3D), are another type of ruthenium compounds with 
favorable anticancer properties.82, 91 RAPTA compounds have exhibited similar anti-metastasis 
properties as NAMI-A both in animal studies and in cell migration and invasion assays, and they 
have also shown strong interactions with protein but relatively low affinity with DNA, suggesting 
the possible mechanism is not through DNA, as with classical platinum compounds. It has been 
reported that RAPTA compounds binds to the histone proteins of chromosomes.91, 71, 40, 82  
Ruthenium (II) polypyridyl compounds have been investigated for their photophysical and 
photochemical properties as photodynamic therapy agents, and their nucleic acid affinity is 
responsible for their use as DNA damaging agents.92, 71 Recently, a novel type of ruthenium (II) 
photosensitizer TLD1433 (Figure 1.3H) has been studied in Phase I clinical trial for bladder cancer 
and has received positive results. TLD 1433 has shown the capability to generate singlet oxygen as 
a type II photosensitizer. Inspired by work from the Glazer group93, 94, 95, McFarland and co-workers 
have also made multifunctional ruthenium (II) polypyridyl compounds (Figure 1.3G) capable of 
both photo induced DNA covalent binding and singlet oxygen generation by introducing steric 
bulk.96, 97 
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Figure 1.3 Representative metal compounds currently in researches as potential anti-cancer agents. 
 
1.5 Current drug discovery and mechanistic studies. 
With the advancement of techniques in synthetic chemistry and analytical chemistry, the 
numbers of new molecules have been hugely increased, which calls for the development of 
biochemical approaches for mechanistic studies with increased efficiency and comprehensive 
understanding. Of all the chemotherapy related research areas, mechanism elucidation remains one 
of the most challenging ones, as it requires complex approaches including analytical chemistry, 
biochemistry, and molecular and cell biology to study an enormous number of biomolecules in 
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complex cell environments.98, 99 As a fully understanding of mechanism of action is not required 
by FDA, there are a considerable number of medications that have been approved and prescribed 
without much knowledge of their mechanism, and this could be a major concern for clinical 
prescriptions since understanding mechanism helps to better determine the appropriate dosing and 
predict potential side effects.100 Knowledge of the mechanism is a vital component in drug 
discovery as it offers insights on clinical application. Lack of this knowledge could ultimately lead 
to failure of clinical trials for novel drug candidates and undesired adverse effects for medications 
currently in use.98, 100 Most commonly, mechanistic studies are achieved by direct biochemical 
methods including affinity based binding and activity studies; cell biology approaches to 
understand the cellular events in responses to treatments, and more comprehensive genomic and 
proteomic approaches to gain a system level understanding.101 With all these methods, the 
efficiency in both time and cost remains a major challenge to overcome. 
Another approach is high-content screening (HCS), employing automated imaging and 
data processing. This phenotypic analysis has aided drug discovery for separating agents with 
potential novel mechanism by classifying molecules with known mechanisms of action and 
identifying active molecules that fall into potential new catagories.26, 102 First described by Giuliano 
et al. in 1997103, the technique didn’t gain significant application until the late 2000s when 
automated high resolution imaging techniques were more commonly applied. High-content 
screening utilizes multiple fluorescent reporters in living cells and automated microscopy to probe 
biological phenotypic changes such as cell viability, metabolism, and morphology.104, 105 Compared 
with current approaches, HCS is superior in probing the effects of drugs in living whole cells, not 
evaluating interactions with an isolated single target, which offers the possibility to discover 
unexpected targets and mechanisms as well as confirming engagement of a drug candidate with 
desired biological entities.106, 105 The technique is also favored over other cell-based assay because 
of the fact that it is highly multiplexed, allowing for combination of multiple fluorescent labels and 
image analysis systems. HCS is able to provide up to one hundred parameters from a single 
experimental set up, which radically expands the quantity of temporal and spatial data obtained 
compared with single pathway analysis.107, 105, 108 The highly automated imaging and analysis 
system also enables the ability of HCS to reduce human bias,109, 110 though the potential still persists 
depending on specifics of experimental design factors prior to imaging analysis. 
High-content screening, however, does have certain limitations when it is applied in drug 
discovery and target validation. One major challenge of utilizing HCS is the huge amount of data 
generated, as the multi-channel fluorescence microscope typically takes thousands of images that 
are 512 x 512 to 2048 x 2048 pixels. As a result, these image sets can be over 50 TB in file size.111, 
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112 Proper storage and management of these data therefore requires continuous caution. Another 
factor that limits application is that the data formats obtained using instruments from different 
manufactures don’t translate well, which adds to the difficulty of analyzing the large data sets.113, 
114 Many parameters in HCS are calculated using multiple quantifiable features directly extracted 
from the imaging including compartment/organelle morphologies (nucleus, mitochondria, golgi 
apparatus, endoplasmic reticulum), these morphological features are usually described by a set of 
properties produced by statistics and software algorithms and are sometimes subtle compared with 
classical cell morphological descriptors. Commonly used data analysis methods also include 
normalizing different fluorescent intensities to cell nuclei staining in cells while the cell itself is 
also defined by computational algorithms estimating the plasma membrane. These highly 
manipulated data therefore lead to false-positive and false-negative results, making it a challenge 
to interpret the data sets.108, 112 
A related analytical approach is cytological profiling, a type of phenotypic analysis in 
bacterial cells, which has been used to evaluate mechanisms of action for antibiotics and discover 
novel anti-bacterial agents115, 116. It has been demonstrated that antibiotics with mechanisms of 
action involving different biological processes induce distinct phenotypic changes117, 118. 
Accordingly, antibiotics inhibiting replication, transcription, or translation can be distinguished by 
analysis of specific phenotypic features. Historically, the discovery of cisplatin by Rosenberg was 
first motivated by the observation of the antibacterial activity of cisplatin on E. coli.  More studies 
have also confirmed the biological activities of natural product antitumor antibiotics in bacteria, 
especially in E. coli.119, 120, 121 Notably, in the bacterial cytological profiling by Pogliano and 
coworkers, molecules were tested that are commonly used anti-cancer agents targeting DNA 
replication and transcription; however, although phenotypic changes consistent with molecules 
with a similar mechanism of action were observed in their studies, there was a failure to make the 
connection between the anti-cancer agents and their biological activities in bacteria.116 These 
studies support the possibility to use bacteria as a cytological profiling system for mechanistic 
studies of anti-cancer agents targeting the biological processes common in both prokaryotic and 
eukaryotic cells. Given the genetic simplicity of the bacterial system, it can be quickly determined 
if an anti-cancer agent works through a target that has a prokaryotic analogue. Furthermore, it can 
be proposed that by classifying phenotypic feature changes induced by compounds with known 
biological effects, bacterial cytological profiling would be capable of distinguishing anti-cancer 
agents whose mechanisms involve conserved biological processes utilized by both eukaryotic and 
prokaryotic cell type. This would offer a rapid and convenient approach to predict mechanisms of 
action for newly synthesized or discovered molecules. 
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Both high-content screening and the cytological profiling are based on the phenotypic 
changes in responses to the drug/chemical treatments, which is recognized as reverse chemical 
biology, in contrast to the commonly applied target based approach in drug discovery (forward 
chemical biology).122, 123, 124 While target-driven approaches have been considered as streamlined 
and efficient in drug discovery, Swinney and Anthony discovered in their investigation of 
therapeutic agents the FDA approved during 1999 to 2008 that the majority of new molecular 
entities (NMEs) were discovered through the phenotypic based approaches.125, 122 In both HCS and 
cytological profiling, the observations are reflections of complex biological effects of treatments 
and the global responses from the whole cell/organism. It is important to realize the phenotypic 
changes are indications of possible targets and mechanisms, and conclusions may be drawn only 
from comparison to agents with known mechanisms of action, as the phenotype does not directly 
identify cellular targets and mechanisms. 
In this report, mechanistic studies of light activated ruthenium compounds synthesized in 
the Glazer lab as potential anticancer agents will be discussed. Some of these ruthenium-based 
compounds can be selectively activated by light of certain wavelengths only in the desired 
treatment region, offering increased selectivity and decreased adverse effects, and may also provide 
potentially novel mechanisms of actions. Others behave as traditional cytotoxic agents that do not 
require light activation. Three types of ruthenium polypyridyl complexes, representing different 
classes of compounds with different scaffolds, charge states, and biological activities, were studied 
in vitro and in vivo (with cell assays) to elucidate their biological targets and mechanism of action. 
Eukaryotic cell studies and bacterial cytological profiling were carried out to understand the 
mechanism of action for different ruthenium polypyridyl complexes. Two classes of ruthenium 
compounds were found to act through mechanisms and biological targets that have been reported 
for metal based anticancer agents. In contrast, ruthenium complex with hydroxyquinoline ligands 
exhibited a novel translation inhibition related mechanism, as demonstrated through bacterial 
cytological profiling and confirmed in cancer cells.  
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Chapter 2. Mechanistic studies of Ru(II) polypyridyl compounds with disparate charge 
state and hydrophilicity 
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2.1 Introduction. 
Metal complexes have been studied for decades as potential cytotoxic agents, because of 
the unprecedented and continued success of cisplatin as a chemotherapeutic.126, 127 Investigations 
into Ru(II) polypyridyl complexes have been particularly extensive, because of their ease of 
synthesis, appealing chemical, physical, and photophysical characteristics, and their high affinities 
for nucleic acids. Most early studies focused on characterizing the in vitro interactions of these 
complexes with DNA,128, 129, 130, 131 and quantifying the potencies of the compounds both as 
traditional cytotoxic agents and as light-activated agents for photodynamic therapy (PDT) or 
phototherapy. In recent years, attention has shifted to understanding the cellular localization132, 133, 
134, 135 properties of Ru(II) complexes, along with their mechanisms of cellular uptake135, 136 and 
cytotoxicity, providing a deeper understanding of how these compounds elicit their biological 
activities. 
An attractive feature of Ru(II) polypyridyl complexes that makes them particularly useful 
for applications as biological probes and effectors is the diversity of the chemical structures that 
are readily available through modifications of the coordinated ligands.137 However, most biological 
studies have focused on complexes that carry an overall charge of +2 or greater. This significantly 
limits the chemical structures and physical properties of the molecules under investigation. A 
question that occurred to us was this: To what degree could the biological properties of a chemically 
inert Ru(II) complex be tuned by chemical modification of the ligands surrounding the metal center? 
To address this question, we have investigated the biological activities, cellular uptake, 
localization, and mechanism of cell killing of two simple Ru(II) complexes that are commonly used 
dyes for solar cell research or biological staining, but have not been previously explored as PDT 
agents. Ru(bathophenanthroline)3 (1; Figure 2.1) is a hydrophobic molecule with a high DNA 
binding affinity,138, 139 while Ru(bathophenanthroline disulfonate)3 (2; Figure 2.1) is hydrophilic 
and possesses a high affinity for proteins.140, 141, 142 Both complexes are efficient singlet oxygen (1O2) 
generators with the same quantum yields for 1O2 production (ΦΔ) and similar molar extinction 
coefficients (ε).143 Both are luminescent, allowing for analysis by fluorescence microscopy. 
However, although the photophysical properties of the compounds are almost identical, the 
physical properties of the two Ru(II) compounds are quite dissimilar (see Table 2. 1). Compound 
1 carries an overall charge of +2, while 2 has an overall charge of −4. They also have very different 
hydrophilicities, as indicated by their partition coefficient or log P values. Given the radically 
different physical properties of the complexes, we anticipated differences in their biological effects 
that could provide information for future rational design of lightactivated cytotoxic agents. 
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Figure 2.1 Structures of Ru(II) compound 1 Ru(bathophenanthroline)3 and compound 2 
Ru(bathophenanthroline disulfonate)3 
 
Considering the established dogma of the field, it would be expected that the negatively 
charged compound 2 would not enter cells144 and would suffer low efficacy, while the positively 
charged, DNA-binding compound 1 would prove the more effective PDT agent. Instead, our 
findings run counter to this prediction. Here, we show large differences in potency, cellular uptake, 
localization, and mechanism of cytotoxicity of these agents, illustrating that radical modulation of 
biological properties is possible with ligand modifications of simple homoleptic Ru(II) polypyridyl 
complexes that are substitutionally inert. Most importantly, our results also prove that a 
significantly greater range of charge states and physical properties of Ru(II) complexes are 
compatible with potential application as PDT agents. 
 
 Table 2.1 Physical and photophysical properties of 1 and 2 
Property Compound 1 Compound 2 
Charge +2 -4 
Log P 1.8  0.02 -2.2  0.12 
λmax (nm) 460a  462a 
ε (M-1cm-1) 29,500a 29,300a 
λem (nm) 632a 632a 
ΦPL 0.101b 0.176c 
Φ 0.42
a,d 0.43a,d 
   aFrom ref. 145; bFrom ref. 146; cFrom ref. 147; dDetermined in D2O. 
 
2.2 Investigation of DNA damage and cytotoxicity induced by both Ru(II) compounds. 
 As both 1 and 2 are efficient catalysts for the light-activated generation of 1O2 (ΦΔ = 0.42, 
0.43),145 it was expected that the two compounds would act as sensitizers for PDT. Accordingly, 
their DNA damaging properties were assessed with pUC19 plasmid DNA and analyzed by gel 
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electrophoresis (Figure 2.2). Each compound was incubated with plasmid and irradiated with 40 
J/cm2 of visible light (>400 nm) or kept in the dark. Compound 1 is known to bind strongly with 
DNA, and precipitation of DNA with the complex was observed at concentrations above 31.3 µM 
both in the light and in the dark (Figure 2.2A). In contrast, 2 is a much more hydrophilic molecule, 
and the negatively charged sulfonate functional groups were anticipated to cause electrostatic 
repulsions between the complex and the negatively charged backbone of the DNA. Consistent with 
low DNA affinity,148 no DNA precipitation or smearing was observed with up to 500 μM of 2 
(Figure 2.2B). When exposed to light, both 1 and 2 induced single strand DNA breaks, creating 
relaxed circular plasmid. This is likely due to the photogeneration of 1O2 that mediates the DNA 
damage. However, for 2, the amount of relaxed circle plasmid did not exhibit any concentration 
dependence above 125 μM, suggesting either a reduction in ΦΔ as the concentration of the complex 
is increased, or alternative quenching mechanisms that impede DNA damage.  
As both compounds are capable of light-induced DNA damage, the cytotoxicity of 1 and 2 
were evaluated in the A549 human non-small cell lung cancer, the HL60 human promyelocytic 
leukemia, and the Jurkat human T lymphoblastoid cell lines in the presence and absence of 7 J/cm2 
of >400 nm light. The IC50 values across the cell lines for 1 ranged from 0.62 to 3.75 μM in the 
dark. Upon irradiation, potency was increased to a range of 0.075 to 0.35 μM, resulting in an 
average phototoxicity index (PI = IC50 (dark)/IC50 (light)) of 10- to 20-fold (Figure 2.2, Table 2.2). 
In marked contrast to the high toxicity of 1 in the absence of light, no toxicity was observed 
in the dark with 2 across all cell lines at concentrations up to 300 μM. However, compound 2 was 
effective in killing cells when irradiated, with IC50 values ranging from 3.3 μM to 17.3 μM, 
consistent with the concentrations required for in vitro DNA damage. This provides for a large 
therapeutic window, as no cell death is observed for samples in the absence of irradiation.  
Surprisingly, not only was compound 1 toxic to cells upon irradiation, it also induced cell 
death far more rapidly in HL60 cells than traditional DNA damaging agents such as cisplatin. 
Complete cell death was observed within 2 h of irradiation with 1 (see Figure S1.1 in Appendix). 
The compound also induced cell death in the dark, but more slowly, with ∼30% viable cells 
remaining at 24 h. In marked contrast to 1, compound 2 induced cell death after irradiation only 
after a long delay, with 70% viable cells remaining at 24 h and 55% remaining at 48 h.  
The significant disparity in the potency, phototoxicity index (PI), and rates of cell killing 
for the two compounds despite their equivalent abilities to sensitize 1O2 strongly suggested that 
they were acting through different cellular mechanisms, possibly by interacting with different 
biological targets. As the compounds are substitutionally inert, they are unlikely to covalently 
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modify biomolecules. This complicates target identification by isolation of protein or nucleic acid 
components of the cells, so the subcellular localization was investigated instead. 
 
 
Figure 2.2 Agarose gel electrophoresis of pUC19 with increasing concentrations of (A) 1 and (B) 
2 in the dark or irradiated (λ > 400 nm). Lanes 1 and 12: DNA molecular weight standard; lane 2: 
linear (reaction with EcoRI); lane 3: relaxed circle (reaction with Cu(phen)2); lanes 4−11: 0, 8.25, 
16.5, 31.3, 62.5, 125, 250, and 500 μM compound. Cytotoxicity dose response of (C) 1 and (D) 2 
in the dark (open squares) or irradiated (closed circles). HL60 cells were incubated for 72 h with 
compound prior to quantification of viability. 
 
Table 2.2 Cytotoxicity IC50 values (μM) in various cell linesa 
Compound HL60 Light HL60 Dark A549 Light A549 Dark 
1 0.35 ± 0.18 3.75 ± 0.18 0.11 ± 0.02 0.62 ± 0.08 
2 9.81 ± 1.09 >300 17.25 ± 9.82 >300 
Cisplatin 3.1 ± 0.2 3.1 ± 0.2 3.4 ± 0.6 3.5 ± 0.2 
aIC50 values are averages from three measurements. 
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Table 2.2 Cytotoxicity IC50 values (μM) in various cell linesa (continued) 
Compound Jurkat Light Jurkat Dark 
PIb 
Jurkat 
1 0.075 ± 0.004 1.63 ± 0.11 21.7 
2 3.31 ± 0.36 >300 >90 
Cisplatin 0.5 ± 0.07 0.5 ± 0.07 1 
aIC50 values are averages from three measurements. bThe phototoxicity index (PI) is the ratio of the 
dark and light IC50 values. 
 
2.3 Altered cellular uptake and subcellular localization of Ru(II) compounds.  
Both 1 and 2 are emissive, allowing for direct visualization in cells. Flow cytometry and 
fluorescence microscopy were used to provide relative uptake values, the time dependence of 
compound uptake, and information on the subcellular localization of the compounds. To optimize 
signal intensity, 1 was assayed at 5 μM while 20 μM was required for 2. Flow cytometry with A549 
cells revealed greater uptake of 1 compared with 2 at time points of 2 and 24 h, with an 11.6-fold 
and 8.2-fold difference in signal, respectively (see Figure S1.2 in Appendix). Between the time 
points of 2 and 24 h, the average emission of cells incubated with 1 increased by 2.8-fold while the 
amount of 2 increased by 4-fold. This data was supported by direct quantification of the number of 
ruthenium atoms per cell using inductively coupled plasma−optical emission spectroscopy (ICP-
OES; see Tables S1.1 and S1.2 in Appendix). The relative amount of compound 1 in cells versus 
the cell media increased ∼4-fold from 2 h to 24 h, from 5.4% to 22%.149 Much less of compound 2 
entered the cells, with a maximal uptake of 0.7% at 24 h. While low, this degree of uptake of the 
−4-charged 2 is comparable to cisplatin, a neutral compound, dosed at the same concentration (20 
μM, 0.8% at 24 h). 
The emission of 1 and 2 was also measured in A549 cells using an ApoTome microscope 
(the adherent cell line was chosen to facilitate the required wash steps to allow for the use of 
fluorescent reporters). The relative rates of uptake of each of the complexes were analyzed as a 
function of time, and both 1 and 2 were visible inside cells as early as 2 h after compound addition 
(see Figure S1.3 in Appendix), consistent with the flow cytometry and ICP-OES results. Images 
were taken at 2, 8, 18, and 24 h, and intracellular levels of both complexes appeared to plateau at 8 
h. The uptake data showed good agreement between the three techniques and two cell lines, 
suggesting similar behavior in adherent and suspension cell lines. 
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Figure 2.3 ApoTome microscopy showing subcellular localization of 1 and 2 at 8 h. Co-localization 
of 1 and 2 in mitochondria or lysosomes is indicated by the apparent yellow emission. (A) 
Mitotracker Green FM was used to image mitochondria. (B) Lysotracker Green DND-26 was used 
to image lysosomes. Red color denotes intrinsic emission of 1 and 2, whereas blue color denotes 
Hoechst staining of the nucleus. The yellow color occurs due to overlap of the red emission from 
the ruthenium complexes and green emission of the organelle-specific dyes, indicating 
colocalization. Compound 1 localizes in both the mitochondria and the lysosomes while 2 was not 
predominantly found in either organelle. 
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Differences in the intracellular localization of 1 and 2 were evaluated by determining 
colocalization of luminescence of the compounds and fluorescent markers of organelles in A549 
cells. Overlap in signals between the compounds, nucleus, mitochondria, and lysosome was 
measured over a 24 h period. Compounds 1 and 2 have very different localization profiles, as 
exemplified by the imaging 8 h after dosing (see Figure 2.3). Compound 1 substantially localized 
to lysosomes and the mitochondria in the absence of light, while 2 remained primarily in the cytosol. 
Exposure to light did have an impact on compound localization, where 1 induced nuclear 
localization of both the mitochondrial and lysosome markers (see Figures 2.3A and 2.3B, top), 
indicating that photoinduced damage mediated by 1 reduced the integrity of the nuclear membrane. 
In contrast, 2 was primarily observed in lysosomes after irradiation, and did not co-localize with 
mitochondria (Figures 2.3A and 2.3B, bottom). In addition, irradiation in the presence of 2 did not 
result in the appearance of organelle markers in the nucleus, suggesting the nuclear membrane 
remained intact. Neither 1 nor 2 was found to associate with the plasma or nuclear membranes. 
2.4 Mitochondrial function and time dependence for cell death.  
As compound 1 appeared to localize within mitochondria, it was hypothesized that this 
may account for its high toxicity in the absence of irradiation. To determine if either 1 or 2 caused 
a reduction in mitochondrial function, mitochondrial membrane potential was measured using 
tetramethylrhodamine ethyl ester (TMRE) (see Figure 2.4). TMRE is a cationic dye that 
accumulates in active mitochondria as a result of the negative membrane potential (Δψm). Inactive 
or depolarized mitochondria exhibit a decreased membrane potential, and TMRE does not localize 
in these organelles. Compound 1 induced rapid and complete depolarization of mitochondria both 
in the dark and upon irradiation (Figure 2.4B, C). However, surprisingly, cell viability did not 
parallel mitochondrial potential. While mitochondrial function was completely impaired at 2 h post 
treatment with 1 in the dark, viability decreased slowly, with 44% ± 6% viable cells remaining after 
24 h. In contrast, both mitochondrial function and cell viability fell to 0% within 2 h of irradiation. 
Thus, while 1 completely impedes mitochondrial function within 2 h even in the absence of light, 
irradiation induced additional damage that results in rapid cell death, along with the loss of 
mitochondrial function. 
In contrast to compound 1, 2 did not significantly reduce the mitochondrial potential over 
a 24 h period either when irradiated or kept in the dark. Irradiation did reduce cell viability to 70% 
± 12% at 2 h and 59% ± 4% after 24 h, but this occurred without a significant decrease in the 
relative mitochondrial potential (Figure 2.4E), indicating that 2 does not act through inhibition of 
mitochondrial function. These results strongly suggest that mitochondrial failure plays a role in the 
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dark toxicity of 1, and the lack of mitochondrial localization and inhibition may explain the 
comparatively low dark toxicity of 2. 
 
 
Figure 2.4 (A) Example images and quantification of the emission of tetramethylrhodamine ethyl 
ester (TMRE) in the presence and absence of 1 and 2. Compound 1 does not show increased TMRE 
emission over background emission of 1, while compound 2 does not add to the TMRE emission. 
Mitochondrial potential and cell viability of A549 cells as a function of time for (B) 1, in the dark; 
(C) 1, irradiated; (D) 2, in the dark; and (E) 2, irradiated. TMRE was used to quantify membrane 
potential; values are relative to a no-compound control value of 100. 
 
2.5 Ru(II) compounds induce cell death through disparate mechanisms.  
Most compounds used for PDT that generate singlet oxygen induce apoptosis. Given the 
different cellular localization properties and time profiles for cell death induced by 1 and 2, the 
mechanism of cell death was investigated. Indicators of apoptotic cell death (activation of PARP 
and caspase 3 through proteolysis) were determined in HL60 cells treated with either 1 or 2 (Figure 
2.5A). The known apoptotic-inducing compounds, cisplatin and doxorubicin, were run in parallel. 
Compound 1 induced the proteolytic activation of both PARP and caspase 3 within 2 h of irradiation 
(Figure 2.5A). In the absence of light, cleaved PARP and caspase 3 were observed with 1, but only 
after 18 and 24 h, and to a lesser degree. In the absence of irradiation, the amount of inactive 
procaspase 3 did not change. 
Exposure of 2 to light also induced PARP cleavage as early as 2 h, but unlike 1, increasing 
amounts of cleaved PARP were observed over the course of 24 h (Figure 2.5A). The increase in 
the level of activated caspase 3 also occurred on a slower time scale than PARP cleavage, with the 
protein initially observed at 18 and 24 h. This suggests that the irradiated samples undergo 
apoptosis that is not primarily signaled through caspase 3. Conversely, cells treated with 2 and 
protected from light did not display PARP or caspase 3 cleavage, which is consistent with viability 
measurements indicating no cytotoxicity in the absence of light. The level of procaspase 3 also did 
not change over 24 h, further confirming a lack of cytotoxicity under these conditions. 
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Figure 2.5 (A) Western blot of cleaved PARP, caspase 3, and pro-caspase 3. GAPDH is used as a 
loading control. (B) Agarose gel electrophoresis of genomic DNA harvested from HL60 cells after 
treatment with various agents. Lanes 1 and 9: ladder; lane 2: no compound control; lane 3: 10% 
EtOH, 24 h (necrosis control); lane 4: cisplatin, 24 h (apoptosis control); lane 5: 1, irradiated, 8 h; 
lane 6: 1, in the dark, 8 h; lane 7: 2, irradiated, 24 h; and lane 8: 2, in the dark, 24 h. 
 
Since 2 showed strong PARP induction without significant caspase 3 activation, as 
compared to 1 and cisplatin or doxorubicin, a mechanism of cell death through necrosis was 
explored. The level of an alternate 55 kDa PARP fragment was determined by immunoblot as a 
marker for necrosis (see Figure S1.6 in Appendix), with 10% (v/v) ethanol used as a positive 
control.150 Exposure of HL60 cells to 1 produced this fragment at significant levels both when 
protected from light and when irradiated, which is consistent with necrosis. Cisplatin and 
doxorubicin also produced this cleavage product, indicating that some cells had progressed into 
necrosis (Figure S1.6 in Appendix). In contrast, cells exposed to 2, both in the presence and absence 
of irradiation, produced a lower level of the 55 kDa PARP fragment, similar to the untreated cells, 
suggesting necrosis is not a significant cell death pathway for this compound. 
To support the assessment of the disparate mechanisms of cell death induced by 1 and 2, 
the degradation pattern of genomic DNA was investigated. DNA laddering is observed as a result 
of DNA fragmentation stemming from the executionary phase of apoptosis. In contrast, necrotic 
cell death lacks this characteristic laddering effect, allowing differentiation between these two 
mechanisms. HL60 cells were exposed to both Ru(II) complexes, cisplatin, and 10% ethanol, 
followed by genomic DNA isolation and resolution by gel electrophoresis. As expected, the 
apoptosis inducer, cisplatin, initiated DNA fragmentation, resulting in a laddering pattern on the 
gel (Figure 2.5B). This laddering was absent in the cells treated with ethanol and compounds 1 and 
2 in the dark. However, both compounds 1 and 2 displayed similar laddering patterns as cisplatin 
when irradiated, suggesting apoptosis is a contributing cell death pathway for both compounds 
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when irradiated. In contrast, given the cytotoxicity of 1 in the dark and the presence of the 55 kDa 
PARP fragment, it appears that necrotic cell death is a significant pathway for 1. For compound 2, 
the absence of DNA laddering is a result of the lack of cytotoxicity of the negatively charged 
compound. 
Flow cytometry was also employed to further corroborate the assessment of the mechanism 
of cell death using Annexin V/propidium iodide (PI) or Annexin V/Hoechst staining to differentiate 
apoptotic versus necrotic cell death. Fluorescent Annexin V conjugates recognize the translocation 
of phosphatidylserine to the outer leaflet of the cell membrane during apoptosis. PI and Hoechst 
were used as nuclear stains to distinguish between live and dead cells; while PI is most commonly 
used, Hoechst was also applied, because of spectral interference of 1 and 2 with PI. The presence 
of significant populations of PI positive cells in the absence of Annexin V staining for 1 both in 
light and in the dark demonstrate that necrosis is a significant cell death pathway for this compound 
(see Figures S1.7 and S1.8 in Appendix; 5% and 14%, respectively, at 2 h). In contrast, compound 
2 produced large populations of Annexin V positive cells (55% at 24 h), showing an apoptotic 
pathway (see Figures S1.9 and S1.10 in Appendix). Similarly, Hoechst staining was consistent with 
necrosis as a contributing pathway for 1 in the dark and in light, while 2 induced apoptosis. 
2.6 Conclusion. 
The goal of phototherapy is to achieve cell death in cancerous or abnormal tissues that are 
irradiated, while protecting healthy tissues that are not exposed to light. As a result, the compounds 
developed for this application should possess large “therapeutic windows” where the toxicity in the 
dark is minimized. This has proven to be challenging for many inorganic agents developed for PDT 
applications. The rational design of new and more efficacious compounds would be facilitated by 
(1) a better understanding of the mechanisms of action that induce dark 
toxicity for promising PDT agents, and (2) the identification of chemical features that eliminate 
dark toxicity. The investigations of the biological activities of these two simple Ru(II) complexes 
provide guidance for both approaches toward improved PDT agents. 
While compound 1 demonstrated notable potency when irradiated (0.075−0.35 μM, 
depending on cell line), the toxicity of the compound in the dark (0.62 to 3.75 μM) reduces its 
potential as a PDT agent. Imaging studies showed both mitochondrial and lysosomal localization, 
and assessment of mitochondrial potential indicated that 1 immediately inhibits mitochondrial 
function. However, the disconnect between the time dependence of the inhibition of mitochondrial 
function and the reduction in cell viability in the dark shows that disruption of mitochondrial 
membrane potential does not lead to rapid cell death. It is possible that the cells treated with 1 and 
kept in the dark survive for several hours, despite the complete abrogation of 
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mitochondrial function, due to the Warburg effect, where cancer cells exhibit a reduced reliance on 
oxidative phosphorylation and increased dependence on glycolysis for energy production. 
After 72 h, cell death is complete for 1 in the dark. The obliteration of mitochondrial 
function would explain the observation of necrotic cell death in this case.151 In contrast, when 1 is 
irradiated, it appears that a combination of necrotic and apoptotic pathways are activated. Cell death 
is so rapid (with most cells undergoing death at 2 h, as indicated by Trypan Blue staining) that 
necrosis is likely to be a primary pathway for a majority of cells. The breakdown of membrane 
integrity is apparent not only for the plasma membrane, but also for the membranes of organelles, 
as cells treated with 1 and irradiated showed nonspecific nuclear localization of both Mitotracker 
and Lysotracker. The high dark toxicity, mitochondrial localization, and induction of necrotic death 
pathways may reduce the potential of compounds structurally similar to 1 for PDT. 
In marked contrast, compound 2 was found to possess several features that encourage 
further exploration of derivatives or similar compounds. While uptake was low, it was comparable 
to that of cisplatin, despite the overall charge of −4. Most importantly, 2 exhibited IC 50 values on 
the order of 3.3−17.3 μM when exposed to light, with no observed toxicity in the dark. A slight 
increase in intracellular accumulation was observed upon irradiation, possibly due to induction of 
plasma membrane damage that facilitated compound uptake. Once inside the cell, the compound 
remained in the cytosol, with no observable localization to the mitochondria or inhibition of 
mitochondrial function. Furthermore, the light-induced cell death mediated by 2 occurred by 
apoptosis, in contrast to the mitochondrial targeting of 1, which resulted in necrosis. One possibility 
to explore is that PDT compounds that avoid mitochondrial localization will exhibit lower toxicity 
in the absence of light than those that associate with the mitochondria. It is anticipated that 
structural modifications that result in a modest increase in cellular uptake could sufficiently drive 
down potency to make improved derivatives of 2 that maintain large therapeutic 
windows. 
 Given the high binding affinities of most Ru(II) complexes for DNA (Kb > 106), it was 
previously believed that the compounds would preferentially localize in the nucleus, and indeed 
several do.132, 133, 152, 153, 154 However, recent fluorescence and electron microscopy studies have 
shown localization of several Ru(II) compounds in the mitochondria, suggesting it is a common 
target.155, 156 Other reports indicate membrane accumulation and disruption,135, 157 along with 
apoptosis pathways that are mediated by the mitochondria.158, 159 Gasser and co-workers have 
shown in a recent report that this mitochondrial localization was, in fact, required for cytotoxicity 
for a lead compound in a structure− activity relationship study of a family of Ru(II) polypyridyl 
complexes.160  
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While mitochondrial accumulation results in cytotoxicity, this mechanism is not likely to 
be compatible with a PDT-type approach where such redox-active compounds are required to be 
essentially nontoxic in the absence of photons. Alternatively, targeting moieties such as nuclear 
localization signals can be conjugated to the coordinated ligands to affect the affinity of the 
complex for biological molecules and regulate cellular uptake and subcellulation localization.136d, 
160, 161 This approach requires significant chemical modifications, and the targeting often fails to 
increase cytotoxicity. 
While microscopy is a powerful tool to assess compound localization, imaging experiments 
can cause relocalization of compounds that induce production of 1O2 or perform other 
photochemical reactions when exposed to light.162 Previous studies on porphyrins used for PDT 
applications also have demonstrated this phenomenon,163 including uptake and relocalization of an 
anionic tetrasulfonated porphyrin.164 For this reason, it is important to perform imaging using a 
minimum of light exposure, and to probe for compound relocalization by comparing to conditions 
where the treated cells have been exposed to significant light doses. 
This current study shows that simple ligand modifications produce complexes with 
divergent physical properties and, correspondingly, different biological activities. Compound 1, 
despite its high DNA affinity, localizes to the mitochondria and induces rapid membrane 
depolarization and necrotic cell death. It is possible that this will be a common problem for 
compounds containing the bathophenanthroline ligand. Compound 2, despite its overall charge of 
−4, is taken up into cancer cells to a sufficient degree to mediate light-induced cell death through 
an apoptotic pathway. The absence of mitochondrial localization may be the factor that eliminates 
the dark toxicity of this Ru(II) complex. The incorporation of the sulfonic acids into the ligands is 
likely responsible for the alteration in subcellular localization, suggesting a possible general 
approach to reducing dark toxicity for other Ru(II) complexes developed for applications in 
phototherapy. 
2.7 Materials and methods. 
Materials. Ru(bathophenanthroline)3 (1) and Ru-(bathophenanthroline disulfonate)3 (2) 
were synthesized using previously established procedures.141, 145 All cell lines were purchased from 
ATCC. Cell culture media, heat-inactivated fetal bovine serum (FBS), 4−20% tris-glycine precast 
gels, Dulbecco’s phosphate buffered saline (DPBS), penicillinstreptomycin solution (pen-strep), 
and 0.4% Trypan Blue solution were from Invitrogen. 35 mm wide, 4-compartment CELLview cell 
culture dishes were obtained from USA Scientific. Serum supreme was from Lonza. Hoechst 33342, 
Lysotracker Green DND-26 and Mitotracker Green FM were purchased from Invitrogen. 
Propidium iodide (PI) and FITC-Annexin V were obtained from BD Science. Trimethylrhodamine 
26 
 
ethyl ester (TMRE) was purchased from Sigma−Aldrich. Antibodies for PARP-1, procaspase 3, 
and GAPDH were from Santa Cruz Biotechnology, Inc., while cleaved PARP and cleaved caspase 
3 was from Cell Signaling Technology. RIPA buffer was purchased from Santa Cruz 
Biotechnology, Inc. Clarity Western ECL Substrate was from Bio-Rad. An apoptotic DNA-ladder 
kit was purchased from Roche Applied Science. 
DNA gel electrophoresis. Compounds were mixed with 40 μg/mL pUC19 plasmid DNA 
in 10 mM potassium phosphate buffer, pH 7.4. To determine the effect of light, samples were 
irradiated with light (>400 nm) from a 200 W light source for total light doses of 40 J/cm2. Samples 
were then incubated for 12 h at room temperature in the dark. Single- and double-strand DNA break 
controls were prepared, and the DNA samples were resolved on agarose gels, as described 
previously.165 In brief, samples were resolved on a 1% agarose gels prepared in tris-acetate buffer 
with 0.3 μg of plasmid/lane. The gels were stained with 0.5 μg/mL ethidium bromide in tris-acetate 
buffer at room temperature for 40 min, destained with tris-acetate buffer, and imaged on a 
ChemiDoc MP System (Bio-Rad). 
Cell cytotoxicity determination. Human alveolar adenocarcinoma cell line A549, Human 
promyelocytic leukemia cell line HL60, and Human T lymphocyte cell line Jurkat cells were 
maintained in media supplemented with 10% FBS and 50 U/mL pen-strep at 37 °C with 5% CO2, 
with DMEM used for A549 cells, and IMDM and RPMI 1640 used for HL60 and Jurkat cells 
respectively. Cells were assayed in Opti-MEM supplemented with 1% serum supreme and 50 U/mL 
pen-strep and seeded into 96 well plates at a density of 1.5 × 103 cells/well for A549 cells, 2 × 104 
cells/well for HL60 cells, and 1 × 104 cells/well for Jurkat cells followed by a 6 h incubation at 
37 °C, 5% CO2. Cells were dosed with serial dilutions of compound and incubated for 18 h. They 
were then irradiated with 7 J/cm2 light (>400 nm) in 30 sed pulses or kept in the dark. Cell viability 
was determined 72 h later by measuring the conversion of resazurin to resorufin,165 using a 
SpectraFluor Plus Plate Reader (Tecan). 
Intracellular measurement of Ru complexes by flow cytometry. A549 cells were seeded in 
Opti-MEM with 1% serum supreme at a density of 2 × 105 cells/ml in 25 cm2 cell culture flasks 
and incubated overnight. A concentration of 5 μM of 1 and 20 μM of 2 were added to the cells and 
incubated for 2 or 24 h protected from light; the concentration of 20 μM was selected for 2 to 
correspond with the IC50 of the complex when irradiated with light. A concentration of 5 μM was 
used for 1 for compatibility with fluorescent imaging. After 2 and 24 h the media was removed, 
cells were washed twice with DPBS, trypsinized, and collected by centrifugation at 125 × g for 4 
min. The cells were resuspended in Opti-MEM, filtered through 40 μm cell strainers, and analyzed 
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on a FACSCalibur (Becton−Dickenson) with an excitation wavelength of 488 nm and emission 
measured at 650 nm. A minimum of 30,000 events were measured for each sample. 
ApoTome structured illumination imaging of Ru complex uptake. The ApoTome 
microscope was used to resolve fine features of cellular structure. This instrument averages the 
fluorescence of three separate images to greatly reduce out-of-plane fluorescence. A549 cells were 
seeded in 35 mm, four-compartment CELLview culture dishes at a density of 5 × 104 cells per 
compartment in a 500 μL volume and incubated for 24 h in Opti-MEM containing 1% FBS, 
followed by the addition of 5 μM 1 or 20 μM 2 and time points measured at 2, 8, 18, or 24 h. Media 
was removed at each time point, cells rinsed with DPBS, and incubated in Opti-MEM with 16 μM 
Hoechst 33342 and 0.15 μM Lysotracker Green DND-26, or 16 μM Hoechst 33342 and 0.2 μM 
Mitotracker Green FM. Cells were incubated for 30 min, then washed three times with DPBS and 
imaged at 50× magnification using an ApoTome structured illumination fluorescent microscope 
(Carl Zeiss AG). 
Mitochondrial membrane potential measurement. A549 cells were seeded at 2 × 104 
cells/well in 24 well plates and incubated for 18 h, followed by the addition of 5 μM 1 or 20 μM 2. 
They were incubated for an additional 8 h, and then irradiated with light as described for cell 
cytotoxicity measurements or kept in the dark. The cells were incubated for an additional 2, 8, 18, 
or 24 h, washed with DPBS, followed by the addition of 0.5 μM TMRE in Opti-MEM, and 
incubated for 30 min. The cells were then washed twice with DPBS and imaged. The change in 
TMRE signal was determined by the difference in fluorescence between compound treated cells in 
the presence and absence of TMRE. Fluorescence was measured at 10× magnification using an 
ApoTome microscope in normal fluorescence mode. Images were processed and the average cell 
fluorescence was calculated using ImageJ software. Samples dosed with 1 and 2 were compared to 
untreated A549 cells (n =3) to give the relative mitochondrial potential. 
Cell viability as a function of time. HL60 cells were seeded in Opti-MEM at a density of 1 
× 106 cells/mL and incubated for 2 h. The cells were then dosed with 1 or 2, incubated for 8 h, 
irritated as above or protected from light, and incubated for 2, 8, 18, 24, or 48 h. As HL60 cells 
grow in suspension, Trypan Blue staining was employed in place of resazurin to simplify and 
accelerate cell viability analysis. At each time point, a 10 μL cell suspension was mixed with an 
equal amount of Trypan Blue solution and cell viability determined by manual counting with a 
hemocytometer. 
Apoptosis marker immunoblotting. HL60 cells were cultured, dosed with 1 and 2, then 
irradiated as above or protected from light. Cells were harvested 0, 2, 8, 18, or 24 h after treatment, 
pelleted by centrifugation at 124 × g for 5 min, washed twice with DPBS, and lysed in RIPA buffer 
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supplemented with 5 mM sodium pyrophosphate for 15 min on ice. The insoluble fraction was 
removed by centrifugation at 20,800 × g for 10 min at 4 °C. The supernatant was collected and the 
protein concentration determined by BCA assay. 10 μg of protein was loaded onto 4−20% tris-
glycine gels, followed by transfer to nitrocellulose membranes. After blocking with 5% nonfat milk 
in DPBS with 0.1% Tween20 (PBST) for 1 h at room temperature, the membrane was 
immunoblotted with PARP-1 at a 1: 500 dilution, procaspase 3, cleaved caspase 3, and cleaved 
PARP at 1: 1,000 dilutions, or GAPDH at a 1: 2,000 dilution in 5% nonfat milk overnight at 4 °C. 
Immunoblots were washed with PBST for 10 min four times and incubated for 1 h with secondary 
antibodies at a 1: 10,000 dilution for GAPDH and at a 1: 5,000 dilution for all other antibodies. 
Detection was performed using Clarity Western ECL substrate and imaged with the ChemiDoc MP 
System.  
DNA laddering gel electrophoresis. HL60 cells were cultured, dosed with 1 and 2, then 
photoactivated or protected from light as detailed above. Cells were harvested 2 h after 
photoactivation for 1 or after 24 h for 2, pelleted by centrifugation at 124 × g for 5 min, washed 
twice with DPBS, and prepared with an apoptotic DNA-ladder kit as per manufacturer instructions. 
Gel electrophoresis was carried out using a 1% agarose gel containing 0.5 μg/mL ethidium bromide 
with 1 μg DNA loaded per lane and run for 90 min at 75 V. Gel imaging was performed with the 
ChemiDoc MP System. 
Quantification of metal complex uptake by ICP-OES. HL60 cells were seeded in Opti-
MEM at a density of 1 × 106 cells/mL in 25 cm2 cell culture flasks, cultured overnight, then dosed 
with 5 μM 1, 20 μM 2, or 20 μM cisplatin. Cells treated with Ru complexes were incubated for 8 
h, protected from light before irradiating or kept in the dark. Cells were collected after 2 and 24 h 
by centrifugation at 124 × g for 5 min. The cell media was transferred to separate 15 mL centrifuge 
tubes, and cells were washed twice with DPBS. 2 mL of concentrated HNO3 was added to media 
samples while cell pellets were resuspended in 5 mL of 20% (v/v) HNO3. All samples were heated 
at 110 °C for 3 h. After digestion, the volume of all cell samples was adjusted to 5 mL and media 
samples were adjusted to 10 mL with deionized (DI) water. The metal content was analyzed using 
a VISTA-PRO CCD simultaneous inductively coupled plasma optical emission spectrometer 
(Varian, Inc.) with detection at 240.272, 245.657, and 267.876 nm for ruthenium and 214.424, 
217.468, and 265.945 nm for platinum, with a replicate reading time of 60 sec. Yttrium (1 ppm) in 
1% nitric acid was employed as an internal standard. The percentage intracellular metal ratio in 107 
cells was calculated by normalizing the metal amount to 107 cells, and then divided by the total 
metal amount in both media and cells. 
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Cell death by flow cytometry. HL60 cells were cultured, dosed with 1 and 2, then irradiated 
or protected from light. Cells were harvested 2 and 24 h after treatment, pelleted by centrifugation 
at 124 × g for 5 min, washed twice with DPBS, stained for 15 min with FITC-Annexin V and PI or 
FITCAnnexin V and Hoechst 33342, because of the interference between the emission of 1 and PI. 
Cells were analyzed with a FACSCalibur (Becton−Dickenson). A minimum of 20,000 events were 
measured for each sample.  
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Chapter 3. Mechanistic studies of Ru (II) polypyridyl compounds that form DNA adducts 
as potential photodynamic therapy agents 
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3.1 Introduction. 
The fortuitous observation of filamentous growth of E. coli by Barnett Rosenberg led to 
the discovery of cisplatin, one of the most important and widely used chemotherapeutic agents.16-
18 Cisplatin, and its later generation analogues, are essential components in the clinical treatment 
of ovarian, testicular, small cell lung, and head and neck cancers.24, 25, 166 The administration of 
platinum drugs, however, is limited by adverse side-effects, including nephrotoxicity, neurotoxicity, 
ototoxicity and other complications.39, 167 Drug resistance (either intrinsic or acquired) compromises 
the efficacy of platinum drugs as well.36, 168, 27 These deficiencies have necessitated the development 
of new chemotherapeutic agents to overcome such obstacles. 
A great deal of effort has been applied in the field of medicinal inorganic chemistry to 
identify cytotoxic agents that replicate the efficacy of cisplatin, with the hope of adding to our 
current arsenal of chemotherapeutic drugs.169, 170, 41 While many of the new chemical entities show 
promise, the understanding of their biological activities is often incomplete. The very nature of 
inorganic agents (with variable charge states, geometries, and coordination numbers, all of which 
can be altered by speciation) adds to the challenge, and can result in polypharmacology.170, 171 As a 
result, elucidation of the biological effects of potential medicinal inorganic agents has lagged far 
behind chemical innovation. Organic or inorganic agents developed through target-based drug 
discovery avoid some of these pitfalls, but undesired off-target effects are prevalent for these 
systems as well. Thus, mechanistic studies are necessary even for compounds designed to inhibit 
single, well-validated targets.172, 122, 173 
Despite multiple technological advances, the identification of the mechanism of action for 
cytotoxic compounds remains a time consuming and challenging process. While simple in vitro 
systems can provide key insights, there are undeniable advantages to work in living cells. Bacteria 
are intrinsically simpler systems than eukaryotic cells, with E. coli containing only 4,288 genes,174, 
175 as opposed to the approximately 30,000 genes found in the human genome.176, 177 Essential 
processes are homologues between bacteria and eukaryote, including DNA replication, 
transcription and translation. It is well known that many agents that are toxic to eukaryotic systems 
also have antibacterial activities, though many orthogonal variations do exist between the two.178, 
179 
Rosenberg's classical experiment illustrated that a simple prokaryotic system could be 
employed to discover anticancer agents. Recently, other groups, including those of Lippard and 
Brabec, have utilized E. coli phenotypic assays as a qualitative means to characterize potential 
anticancer agents, and as with cisplatin, showed a good correlation between activity in the 
prokaryotic system and cancer cells.180, 181, 182 We also have an interest in simple biological systems, 
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to utilize them as a tool to investigate mechanistic details of anticancer agents. Our premise is that 
compounds which are found to be active in mammalian cells but not E. coli can be expected to 
affect processes or targets absent in the simpler biological system. Alternatively, compounds which 
show similar activities in the two cell types can be logically deduced to inhibit processes common 
to both. Thus, it should be possible to use E. coli as a first pass screen to radically reduce the number 
of likely biological entities or processes targeted by cytotoxic agents. Furthermore, E. coli is readily 
amenable to genetically encoded reporter systems, allowing for additional phenotypic analysis to 
be used to rapidly parse mechanistic features of active compounds.122, 183 This approach could 
greatly expedite mechanism of action studies. 
 
 
Figure 3.1 Thermal hydrolysis of A) cisplatin and B) the photochemical hydrolysis of compound 1 
Here we describe studies that demonstrate that E. coli is an excellent model for mammalian 
systems to investigating the effects of metal complex inhibition of cell growth, and phenotypic 
changes consistent with DNA damage. A promising light-activated Ru(II) complex developed in 
our laboratory165 (Compound 1, Figure 3.1) was compared to cisplatin, along with three organic 
antibiotics. Noteworthy differences were observed between the inorganic compounds and organic 
compounds in the bacterial system; these differences directly correlate with their different 
mechanisms of action. Moreover, differences between compound 1 and cisplatin in mammalian 
cells suggest more subtle disparities in their mechanistic features, which offers the possibility to 
maintain anticancer efficacy without experiencing the same resistance profile by altering the metal 
center from platinum to ruthenium. 
3.2 Comparison of compound efficacies in E. coli and mammalian cancer cells. 
The capacity of E. coli to serve as a model system for cancer cells was first evaluated by 
comparing the relative cytotoxicities of the metal complexes in the two cell types. The ruthenium 
complex prodrug (compound 1), and cisplatin were tested in dose response, along with the 
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antibiotics rifampicin, tetracycline and nalidixic acid. Optical density was used to quantify the 
response in E. coli. The activity of 1 was evaluated both in the absence of light and after light 
activation (described as “dark” and “light”; irradiation results in the formation of compound 2; 
Figure 3.1). The half maximal inhibitory concentration (IC50) value was compared with the 
minimum inhibitory concentration (MIC),184 an important clinical standard parameter184, 185, 186, 187 that 
effectively defines the lowest concentration to achieve a complete inhibition effect. As shown in 
Table 3.1, IC50 values of 2.6 and 2.0 μM for light-activated 1 and cisplatin were obtained in E. coli, 
with MIC values that were 2 – 3-fold higher. 
Table 3.1 Cytotoxicity values and inhibition of protein production in E. coli and HL60 cells. 
aCytotoxicity values of antibacterial antibiotics were not determined in mammalian cells.  
The biological activity of cisplatin and compound 1 was also studied in human 
promyelocytic leukemia HL60 cells. Upon light irradiation, 1 exhibited an IC50 of 3.4 μM, similar 
to the IC50 of 2.6 μM for cisplatin. No cytotoxic effect was seen for compound 1 at 300 μM in the 
dark, resulting in a phototoxicity index (PI) of > 88. As expected, the cytotoxicity of cisplatin was 
not affected by treatment with light. These experiments demonstrated that light irradiated 1, like 
cisplatin, is cytotoxic in both prokaryotic and eukaryotic cells, and with very similar potencies, 
suggesting the mechanism of action is through general cellular targets or biological processes 
present in both cell types. 
3.3 Comparison of cellular uptake and nucleic acid metallation between compound I and 
cisplatin. 
Cellular uptake of the metals in E. coli was measured by atomic absorption spectroscopy 
(AAS; see Table 3.2). Light irradiation of compound 1 resulted in a 5-fold increase in cellular 
uptake, with a total of 10% of the dosed compound localized in E. coli cells. Only 6% of the dosed 
cisplatin was found in the cells. Genomic DNA and total RNA isolation was performed after 24 h 
of treatment, followed by AAS analysis for ruthenium or platinum. While no ruthenium was found 
with either of the nucleic acids for compound 1 in the dark, 1.3% of the ruthenium was found with 
 E. coli  HL60 
 
MIC 
(μM) 
Growth Inhibition 
IC50 (μM) 
Dendra2 Production 
Inhibition IC50 (μM) 
 
Cytotoxicity IC50 
(μM) 
1 light 6.1 ± 0.8 2.6 ± 0.4 77 ± 3  3.4 ± 0.3 
1 dark > 300 > 300 > 300  > 300 
Cisplatin 4.4 ± 0.5 2.0 ± 0.1 85 ± 11  2.6 ± 0.4 
Rifampicin 0.6 ± 0.3 0.3 ± 0.1 2.8 ± 0.3  n.d.a 
Tetracycline 10 ± 1.1 4.8 ± 0.7 1.3 ± 0.2  n.d.a 
Nalidixic Acid 5.2 ± 2.0 2.6 ± 0.4 4.6 ± 0.1  n.d.a 
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the DNA when the compound had been exposed to light. This corresponds to a ratio of 2000 
nucleotide bases per metal center (nt / mc). Only 0.5% of ruthenium was found with the RNA, 
providing a ratio of 3800 nt / mc. As a result, compound 1 appears to be slightly more reactive with 
DNA than RNA, with about a 1.5–2-fold difference between the metal levels in the two nucleic 
acids. A similar trend of increased reactivity with DNA over RNA was observed for cisplatin, with 
a ratio of 3000 nc / mc in DNA and 4700 nt / mc in RNA. 
Table 3.2 Cellular metal uptake and metal content with different nucleic acids measured by AAS. 
aCellular uptake was calculated as metal content measured in cells divided by total metal content 
in both cell samples and cell culture media samples. Cellular uptake in E. coli cells were normalized 
to 109 cells and HL60 cellular uptake was normalized in 107 cells. bDNA nt /mc was calculated as 
DNA nucleotide bases (μmol) divided by metal content measured in DNA sample (μmol). cRNA 
nt /mc was calculated as RNA nucleotide bases (μmol) divided by metal content measured in DNA 
sample (μmol). dRuthenium level in DNA and RNA samples were under detection limit (< 2 ppb). 
Compound accumulation in mammalian cells was also assessed. After 24 h treatment with 
20 μM compound 1, 0.6% of dosed ruthenium was found in HL60 cells with light irradiation, in 
contrast to only 0.1% present when the cells were kept in the dark. These results indicate that the 
prodrug form is taken up much less effectively than the active species. The metal content of the 
active compound in cells is comparable to the 0.7% of cisplatin that accumulated under the same 
conditions. Isolation of DNA and RNA and metal content analysis revealed that no nucleic acid-
bound ruthenium was observed for 1 in the dark, but treatment of 1 with light resulted in 4800 nt / 
mc in DNA, and 5000 nt / mc in RNA. This corresponds to 1.3% of the cellular ruthenium found 
with the DNA and 2% in the RNA. Quantification of the metal binding of cisplatin gave 7000 nt / 
mc in DNA and 7800 nt / mc in RNA (1.1% and 1.5%). The nucleotide base to metal center ratios 
were close, but consistently a slightly higher reactivity was observed with DNA for both irradiated 
compound 1 and cisplatin. 
It has been reported by DeRose et al. that platinum accumulates more in the cellular RNA 
than DNA.188 This is partly due to the higher abundance of RNA in the cell (10–50-fold). Despite 
this difference in abundance for the different nucleic acids, DeRose demonstrated that there is a 
3.8-fold preference for cisplatin to react with DNA vs. RNA in S. cerevisiea, with 1661 nt / mc in 
DNA and 6369 nt /mc in RNA after 12 h of treatment at 100 μM.188 While our study used 20 μM 
 E. coli  HL60 
  Cellular 
uptakea 
DNA 
nt / mc b 
RNA 
nt / mcc 
 
Cellular 
uptakea 
DNA 
nt / mcb 
RNA 
nt / mcc 
1 light 10% 2000 ± 200 3800 ± 600  0.6% 4800 ± 400 5000 ± 700 
1 dark 2% -d -d  0.1% -d -d 
Cisplatin 6% 3000 ± 200 4700 ± 900  0.7% 7000 ± 200 7800 ± 700 
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of cisplatin treatment for 24 h with cells, we observed the same preferential metal binding with 
DNA over RNA in both E. coli and mammalian cancer cells, though we observed a closer nt / mc 
ratio between DNA and RNA. This similar binding trend across different cell types reveals once 
more that cisplatin exhibits a general DNA damaging ability in both eukaryotic and prokaryotic 
systems. The similar biological accumulation characteristics of compound 1 and cisplatin in 
bacterial, yeast, and mammalian cells suggest a mechanism of action through common biological 
targets or processes present in both prokaryotic and eukaryotic cell types, though multiple 
subsequent events may be involved that induce the cytotoxic effects. 
3.4 Phenotypic analysis of E. coli distinguishes DNA damaging agents from transcription and 
translation inhibitors. 
1) Filament Size. For imaging studies, the MIC was used in order to more closely mimic 
physiological conditions; data was also taken at 10x MIC. As anticipated, elongated E. coli cells 
were observed after treatment with cisplatin and compound 1 in the presence of light. Treatment 
with 1 in the absence of light didn't induce E. coli filamentous growth, and the cells were 
characterized by the same short rod shaped morphology as the untreated control. 
To gain a more quantitative understanding of filament formation in populations, cells in 
multiple views (~200 per condition) were chosen for size analysis. Treatment with compound 1 at 
10x MIC and light exposure caused a shift in population distribution, where 73% and 68% of cells 
were filamentous for 1 and cisplatin, respectively. At 100 µM compound 1, cells over 40 µm in 
length were the major population group (29%), and only 5% of the cells were in the ≤5 µm size 
range. The same trend was seen after cisplatin treatment. In contrast, at the MIC, both the filament 
length and % filamentous population were lower, with 30% and 41% of cells forming filaments for 
cisplatin and 1 (Figure 3.3E and S2.4 in Appendix). As shown in the histograms in Figure 3.2E and 
H, both the no treatment control and dark control for compound 1 exhibited a dominant population 
(over 97%) of cells in the ≤5 μm size range, which represents the normal E. coli cell size. 
It has been observed that many compounds induce filamentous growth of E. coli. In order 
to determine how this morphological feature corresponds to the compounds’ mechanisms of action, 
we compared the metal-based compounds to two commonly used antibiotics that inhibit 
transcription or translation, and one gyrase inhibitor. Rifampicin prevents transcription by binding 
and inhibiting the bacterial DNA-dependent RNA polymerase (RNAP)189, 190, 191 and tetracycline 
inhibits translation via binding to the 30S subunit of the ribosome, preventing entrance of 
aminoacyl-tRNAs to the A-site. These compounds were selected as agents that do not induce DNA 
damage.192, 193, 194 Nalidixic acid, which inhibits gyrase and induces DNA double strand breaks, was 
also investigated as a DNA damaging agent control.195 
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Figure 3.2 Complex 1 induces filamentous growth and decreased protein production in E. coli. 
Bright field and fluorescent imaging of E. coli cells. A) N. C. control, B) cisplatin, C) compound 1 
with light, D) compound 1 in the dark. Size distribution histograms of E. coli cells associated with 
the conditions for A) - D): E) N. C. control, F) cisplatin, G) compound 1 with light, H) compound 
1 in the dark. Histograms of average fluorescence intensity correlated to cell size with the different 
treatments: I) N. C. control, J) cisplatin, K) compound 1 with light, L) compound 1 in the dark. 
Cells were treated with 100 µM of each compound for 6 h before imaging. 
 
All antibiotics were able to induce E. coli filaments, but the populational size analysis 
revealed the major populations of E. coli varied significantly in length. Tetracycline treatment at 
the MIC resulted in a large fraction (88%) of the cell population of normal length, with 22% 
forming short (5–10 μm) filaments. In marked contrast, nalidixic acid induced significant 
filamentation, and the filaments were the dominant populations (100%; average length of 51 μm). 
For rifampicin, a concentration of 10x MIC was required to induce filaments. Treatment resulted 
in 70% with a length ≤5 μm, and the remaining 30% were short filaments of 5–10 µm (Figure S2.2 
in Appendix). This initial analysis made clear that compound 1, cisplatin, and nalidixic acid induced 
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longer filaments that were a more dominant portion of the population under all treatment conditions 
than the antibiotics that inhibited transcription or translation. 
2) Membrane Integrity. The membrane stain FM4-64 was used to confirm that the observed 
filaments were single cells and to visualize membrane integrity. As shown in Figure 3.3A and B, 
filaments were formed by single living cells upon compound treatment. No disruption of the cell 
membrane was observed, indicating that the phenotypic changes were not associated with cell lysis. 
This is consistent with results that were obtained utilizing trypan blue staining of HL60 cells, which 
indicated that neither of the two metal compounds act as membrane damaging agents. Thus, the 
abnormal features observed occur in living cells and are not an artifact resulting from physical 
disruptions of cellular integrity. In addition, the mechanism of action does not entail membrane 
damage. 
3) Nucleoid Morphology and Number. DNA staining and analysis of over 30 cells per 
treatment condition revealed trends for the impact of the compounds on E. coli nucleoids. Multiple 
nucleoids were observed in some cells for all treatments that induced filamentous growth. However, 
the different compound classes resulted in significant differences in DNA content and distribution. 
Both rifampicin and tetracycline treatment produced filaments with a regular distribution 
of DNA, while nalidixic acid, cisplatin, and light irradiated 1 caused expansion, fragmentation, and 
irregular distribution of nucleoids (Figure 3.3A and B). Rifampicin treatment (at 10x MIC) 
produced the fewest nucleoids, with the majority of filaments containing a single nucleoid that 
spread along the length of the cell. Tetracycline, in contrast, produced a number of nucleoids in 
each of the filaments, and the nucleoids were compact and regularly distributed throughout the cell. 
In cells treated with nalidixic acid and the metal compounds, the size and distribution of 
the nucleoids were quite varied. In order to quantify this observation, the %STD (the ratio of the 
standard deviation to the average nucleoid size, used as a measurement of variability) was 
calculated, where the %STD was 38% for the no treatment control. The %STD was 50–55% for 
the transcription and translation inhibitors. In the metal complex and nalidixic acid treated systems, 
however, the %STD was greater than 100%, indicating the standard deviation of nucleoid size 
largely exceeded the average size of the nucleoids. This wide range of nucleoid size implicates 
issues of DNA fragmentation and failure of DNA segregation after DNA replication.196 The 
morphological changes in the bacterial nucleoids treated with the metal compounds and nalidixic 
acid demonstrate a multifaceted process as a consequence of DNA damage, in contrast with 
compounds that act to inhibit transcription or translation. 
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Figure 3.3 Phenotypic profiles of compounds with different mechanisms of action in E. coli cells. 
Fluorescent imaging: A) Top: N. C. control; Middle: cisplatin; Bottom: compound 1 with light; B) 
Top: rifampicin; Middle: tetracycline; Bottom: nalidixic acid. The merge is the combination of the 
Hoechst and FM4-64 membrane stain. Scale bars: 10 µm. 
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Figure 3.3 (continued) Phenotypic profiles of compounds with different mechanisms of action in 
E. coli cells (continued). Colony forming experiment with various compounds: C) Left: N. C. 
control; Middle: cisplatin; Right: compound 1 with light; D) Left: nalidixic acid; Middle: rifampicin; 
Right: tetracycline. Cells were treated with each compound at MIC for 6 h before imaging or colony 
forming. E) Quantitative and qualitative analysis of E. coli filamentous growth and nucleoid 
morphology phenotypes in response to compounds treatment.  
It is well established that the processes of transcription and translation are closely 
coordinated in E. coli, and the “transition model” posits, in part, that coupled transcription-
translation and membrane association of the growing protein impacts nucleoid morphology. Thus, 
any process that interferes with mRNA production and protein synthesis could be reflected in the 
nucleoids. A recent report has demonstrated that transcription and translation inhibitors affected E. 
coli nucleoid shape and spatial distribution, with expansion observed with treatment of rifampicin 
and compaction with tetracycline.196 This is qualitatively similar to our results. In addition, 
treatment with nalidixic acid resulted in the observation of fragmented nucleoids,196 similar to our 
imaging results with this compound and the metal complexes. This supports our hypothesis that 
nucleoid morphology can be used as a phenotypic indicator of DNA damage. 
A colony forming assay was performed to provide further support for the assignment of a 
DNA damaging mechanism of action (Figure 3.3C and D). Cells were treated at the MIC for each 
compound, the media removed, and the cells spread on an agarose plate. Only cells treated with the 
transcription and translation inhibitors were able to form colonies; the metal complexes and 
nalidixic acid were clearly cytotoxic at their MIC. This suggests that these three compounds induce 
irreversible damage to the E. coli. 
4) Protein Production. Cisplatin and other platinum-based agents are known to interfere 
with protein production. Some question remains, however, if this is an important feature that 
induces cell death. Several experiments have quantified the impact on protein production after 
transfection of already metalated plasmids into living systems.197, 198 To study the process and 
impact of DNA metalation, we treated E. coli with the metal complexes and subsequently 
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monitored protein production. This couples the quantitation of protein levels in the detection of the 
fluorescent protein to the preceding natural sequence of events that impact transcription/translation, 
and allows for observation of important features that may play a role, such as compound uptake, 
localization within the cell, or sequence-dependent interactions with the nucleic acid. 
Cells undergoing death will slow or cease protein production, which produces a similar 
phenotype to cells that are under the influence of a transcription or translation inhibitor. To 
discriminate between inhibition of protein production and induction of cell death, we used a 
photoconvertible protein, Dendra2, as a reporter, since it is able to provide information on both 
aspects of cell viability and new protein production simultaneously.199 Dendra2 undergoes a 
photochemical conversion, transforming from a green fluorescent protein to a red fluorescent 
protein when exposed to 405 nm light. The photoconverted "Red" Dendra2 emission provided a 
stable internal reference for cell health and cell number for all samples, while new protein 
production (after light exposure) is reflected in the "Green" Dendra2 emission. Both forms are 
stable and persist in living cells with half-lives (t1/2) on the order of 50 to 70 h.200, 201, 202 The two 
forms of the protein thus provide spatial and temporal tracking of Dendra2 formed before and after 
light exposure. 
A clear negative correlation was seen between protein production and cell size, where 
filamentous cells with longer filament lengths exhibited a lower fluorescence intensity, reflecting 
a reduction in the amount of new Dendra2 protein being produced. As shown in Figure 3.2, after 
24 h of treatment with compound 1, the average fluorescence intensity of the cell population with 
the largest length (> 40 μm) dropped by over 70% compared to the control population. Other 
populations with increased cell lengths exhibited a 30 – 70% decrease in fluorescence intensity. 
The same trend was seen in cisplatin treated cells, where the fluorescence intensity decreased by 
15 – 80%, depending on the length of the filament. Both compound dose and the time of treatment 
was found to have an effect on filament formation and protein production (see Figure S2.3 – S2.5 
in Appendix). 
The production of Dendra2 was quantified by dose response, providing IC50 values for 
inhibition of protein production. For this experiment, Dendra2 production was induced in E. coli 
with IPTG and allowed to proceed for 3 h prior to photoconversion, followed by compound 
treatment. Protein production was quantified using the ratio of the average fluorescent intensity of 
the two forms of Dendra2, as shown in Figure 3.4, the transcription inhibitor rifampicin and 
translation inhibitor tetracycline exhibited IC50 values for inhibition of Dendra2 production that 
matched well with growth inhibition (within 3-10 fold; see Table 3.1 and Figure 3.4). In contrast, 
both compound 1 and cisplatin displayed a greater disparity between inhibition of protein 
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production and cell growth inhibition. The 30-40 fold decrease in potency reflects that the 
mechanism of action of cisplatin and compound 1 is not solely (or primarily) through transcription 
or translation inhibition. In contrast, nalidixic acid, which induces DNA double strand breaks, was 
far more effective at inhibiting protein production, suggesting that this may contribute to its 
mechanism of action. These results implicate other biological effects as likely being responsible 
for the enhanced toxicity of the metal compounds. 
Interestingly, while cisplatin has been described as a transcription inhibitor, it was the least 
effective of the four compounds tested for inhibition of protein production. The impact of the DNA 
damage induced by platinum compounds on protein production has been comprehensively and 
conclusively proven, along with the restoration of protein production when the appropriate DNA 
repair mechanisms are activated to remove the lesions. However, our studies suggest that the 
implication of inhibition of protein production by cisplatin is of secondary importance in E. coli, 
as the concentrations required to observe significant impacts on this process in far exceed the toxic 
dose for the compound. 
In an analogous study, Lippard and coworkers tested cisplatin in mammalian cells 
containing a genetically encoded fluorescent reporter system.203 Very good agreement was 
observed between the concentrations required to inhibit protein synthesis and to induce cytotoxicity 
evaluated via a colony counting assay in that report. The reason for the disparity in the ability of 
cisplatin to inhibit protein production in E. coli compared to the HeLa cells used by Lippard is 
unclear. It is particularly surprising, given the very similar values we found for DNA and RNA 
metallation in E. coli and HL60 cells, as described above. 
5) Protein distribution. The use of a photoconvertible protein allows for a spatiotemporal 
analysis of protein content. This provides the opportunity to address intriguing questions such as 
the impact of interruption of cell division and filamentous growth on the activity of ribosomes for 
new protein production, and the redistribution of existing protein within a filamentous cell. 
Fluorescent imaging was performed to probe the effects of the different compounds on protein 
distribution in single cells. Compounds were dosed after photoconversion, and imaging was 
performed 6 h later. As shown in Figure 3.4A and B, both the "Red" Dendra2 (the internal control 
of pre-treatment protein level) and the "Green" Dendra2 (reflecting protein synthesis after treatment) 
was distributed throughout the cell as the healthy cells underwent multiple cell divisions. Both Red 
and Green forms of Dendra2 were also found within the filamentous cells where cell division was 
blocked by either DNA damaging agents or transcription/translation inhibitors. It has been reported 
that disruption of DNA replication and double strand breaks resulting from nalidixic acid treatment 
could lead to uneven distribution of ribosomes in filamentous cells.196 However, we did not observe 
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any particular spatial sequestration of active ribosomes, or alternatively, protein diffusion is 
sufficiently rapid to prevent observation of any localization. 
3.5 Comparison of in vitro and in cell protein production. 
Previously, we reported an in vitro transcription and translation assay (IVTT) with 
compound 1 and cisplatin using green fluorescent protein (GFP) as a fluorescent reporter.199 In this 
assay, either a plasmid containing the GFP gene or the mRNA transcript for GFP were allowed to 
react with varying concentration of compound 1 or cisplatin before addition of the nucleic acids to 
a cancer cell lysate containing transcription and translation machinery. Both metal compounds 
inhibited GFP production with a clear dose response. Interestingly, the IC50 value for inhibition of 
protein production was ~3 µM for both compounds. The ratio of DNA nucleotides or RNA 
nucleotides to each metal center (nt / mc) was then calculated at the IC50 for protein synthesis 
inhibition. The values for compound 1 were 1140:1 for DNA and 820:1 for RNA, while the values 
for cisplatin were 600:1 for DNA and 610:1 for RNA. 
In the current uptake studies, E. coli cells were dosed at 20 μM, which is approximately 10 
times higher than the IC50 value for growth inhibition, but well below the IC50 value for inhibition 
of protein synthesis, as determined by Dendra2 production (see Table 3.1). In order to compare the 
in vitro experiment to the cell data, extrapolation of the ratio for DNA and RNA nucleotides per 
metal center at the IC50 value for in vivo protein synthesis inhibition were performed as detailed in 
Appendix. The calculated values were remarkably close to the values from the in vitro transcription 
and translation assay, with DNA nt / mc ratios of 520:1 for compound 1 and 700:1 for cisplatin. 
The RNA nt / mc ratio was 1000:1 for compound 1 and 1090:1 for cisplatin. 
This analysis of the ratio of DNA or RNA bases to metal centers suggests the functional 
inhibition of protein synthesis by covalent adducts to DNA and mRNA by compound 1 and 
cisplatin is similar in E. coli and the in vitro assay. It is notable that in a living cell, where the 
reaction conditions are much more complex than the buffered system of IVTT assay, the IC50 values 
to inhibit protein synthesis were diminished by over 60-fold relative to the IVTT assay. However, 
the ratio between DNA or RNA bases and the metal center for inhibition of protein production 
remain quite consistent. The increase in the IC50 values in cells suggests two conclusions: 1) 
inhibition of protein synthesis is not the factor that induces cell death, and 2) both compounds suffer 
from off-target binding to biological molecules. The latter is known to be a major issue for many 
currently administered drugs, especially cisplatin
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Figure 3.4 Dendra2 distribution in E. coli cells. A) Top: N. C. control; Middle: cisplatin (100 μM); 
Bottom: compound 1, light (100 μM). B) Top: compound 1, dark (100 μM); Middle: rifampicin (3 
μM); Bottom: tetracycline (48 μM). Scale bars: 20 µm. Cells were treated for 6 h before imaging. 
C) Dose response of Dendra2 production inhibition measured at 0 and16 h after photoconversion 
of Dendra2 and treatment with cisplatin (blue), compound 1 with light (red), rifampicin (green), 
tetracycline (black). D) Dendra2 production inhibition after 16 h treatment. 
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The role of off-target binding was also supported by the AAS analysis of metal content 
with the different nucleic acids in E. coli and mammalian cells, as only a minor component of the 
metal compounds entered the cells, and of this, only 1.3% and 1.26% of cellular ruthenium from 
compound 1 and 0.98% and 1.12% of the cellular platinum from cisplatin were found with genomic 
DNA in the two systems. If one includes the < 2% of metal present in the RNA as on-target damage, 
this means over 96% of the cellular metal is reacting with potentially non-relevant targets. 
Extending this argument, if off-target binding could be eliminated, cytotoxicity IC50 values would 
be reduced to nanomolar concentrations if the same levels of cellular uptake could be maintained. 
This may lead to another method to improve the potency of currently used drugs: instead of 
focusing on the generation of analogues that are more potent against nucleic acids, analogues with 
reduced off-target binding could be more effective. It was anticipated that the ruthenium compound 
would fare better than cisplatin in avoiding off-target binding, due to its lower affinity for 
hydrophobic proteins such as human serum albumin (HSA) and thiols such as glutathione (GSH), 
but this has not been found to be the case in cells.165, 204 As the preferred binding partners are not 
the same for the platinum and ruthenium complexes, it will be important to identify the primary 
off-target biomolecules responsible for sequestering the ruthenium in order to rationally design 
derivatives that avoid these species to increase the potency of these inorganic compounds. 
3.6 Ru and Pt compounds induce distinct cellular responses in mammalian cells. 
The cellular effect of compound 1 was also studied in mammalian cells, with a focus on 
proteins involved in cell signaling and cell death. As shown in Figure 3.5, the effect of compound 
on cell cycle and apoptosis were studied using flow cytometry, immunoblotting for apoptotic 
markers, and DNA fragmentation. No cell-cycle specific arrest point was observed with compound 
1 treatment, while a sub G1 population of 20% of cells was observed after 24 h. Flow cytometry 
analysis of apoptosis vs. necrosis using Annexin V/propidium iodide (PI) indicated that compound 
1 induced cell death through apoptosis as the dominant mechanism. While cisplatin induced 
necrosis in a small fraction (5%), less than 2% of cells treated with compound 1 were characterized 
as necrotic. Immunoblotting of caspase 3 and PARP cleavage showed a time dependent induction 
of apoptosis; in addition, isolation of genomic DNA showed fragmentation, which is consistent 
with apoptotic cell death. All apoptotic reporters were clearly observed at 24 h. 
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Figure 3.5 Compound 1 induces apoptosis in HL60 cells without cell cycle arrest. A) Flow 
cytometry by PI/Annexin V in HL60 cells; Red = apoptotic cells, Blue = necrotic cells, Black = 
dead cells. B) Flow cytometry by PI in HL60 cells; Black = G1; Red = G2; White = S phase. C) 
Immunoblotting of cleaved PARP and cleaved caspase 3 in HL60 cells. GAPDH was blotted as 
loading control. D) Agarose gel electrophoresis of DNA laddering. HL60 cells were treated for 24 
h befor flow cytometry. Treatment condition in all panels: compound 1, 20 μM; cisplatin, 20 μM; 
doxorubicin, 1 μM. 
 
The tumor suppressor protein p53 regulates cell growth and cell cycle checkpoints to 
eliminate proliferation. It is one of the most commonly mutated genes in cancer, resulting in loss 
of its regulatory function.205, 206 Both p53/p21 and chk1 are involved in G1/S and G2/M cell cycle 
checkpoints in response to DNA damage.207, 208 In order to probe the role of p53 in response to 
compound 1, immunoblotting was performed in A549 cells. This non-small cell lung cancer cell 
line contains functional p53, in contrast with the p53 deficient HL60 cell line. While both cisplatin 
and doxorubicin were able to induce apoptosis in the absence of functional p53 in HL60 cells 
(Figure 3.5), the A549 cell line demonstrated clear induction of p53 for these two compounds. In 
contrast, compound 1 did not induce elevated expression of p53, and didn't significantly alter its 
phosphorylation or expression of p21 (Figure 3.6A). 
Another surprising difference observed between the platinum and ruthenium compounds 
is that p-chk1, which is involved in G2/M cell cycle arrest in response to DNA damage, was not 
induced by treatment of compound 1 in either cell line, while both cisplatin and doxorubicin both 
induced phosphorylation of chk-1. This finding is consistent with the fact that no cell cycle arrest 
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point was seen in HL60 cells upon treatment with compound 1 and light, in contrast to cisplatin 
and doxorubicin. However, phosphorylation of γ-H2AX, an early sensor of DNA damage, was 
observed after 6 h of treatment with 1, indicating DNA damage even in the absence of chk1 
activation. 
 
Figure 3.6 Immunoblotting of apoptotic markers and cell signaling proteins in A) and B) A549 
cells; C) HL60 cells. Cells were treated with 20 μM of compound 1 for specified time periods, 
cisplatin (20 μM) and doxorubicin (2 μM) at 24 h of treatment were used as controls. GAPDH was 
used as loading control. 
Pro-survival and pro-apoptotic pathways, including MAPK pathways were examined, and 
consistent signaling behaviors after compound 1 treatment were observed in both cell lines. The 
ERK pathway has been reported to facilitate cell survival and prevent apoptosis.209, 210 As shown in 
Figure 3.6, this pathway was inactivated by compound 1 in both A549 and HL60 cell lines; in 
contrast, both cisplatin and doxorubicin didn't downregulate this pro-survival pathway. The JNK 
pathway has been reported to act as a pro-apoptotic pathway in response to cellular stress induced 
by DNA damage, and is mainly activated by mismatch repair signals.209, 34 Both cisplatin and 
doxorubicin were able to induce phosphorylation of JNK in A549 and HL60 cells at 24 h, though 
different phosphorylation levels in HL60 cells were observed, which might indicate possible 
phosphorylation time course differences. Phospho-JNK was seen as early as 6 h after doxorubicin 
treatment in HL60 cells while cisplatin induced phospho-JNK was seen to increase to maximum 
level at 24 h.211, 212 Surprisingly, compound 1 didn't activate the JNK pathway to the same extent 
as cisplatin or doxorubicin. The phosphorylation level was slightly increased within 6 to 12 h of 
treatment with compound 1 in both cell lines, but then decreased over time. This, along with the 
previously discussed markers, indicate a different DNA damage response for compound 1 either 
from altered cell signaling pathways or by a different class of DNA damage. 
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3.7 Addressing the cytotoxic species, the metal center or the ligand? 
 In recently published works, Bonnet and others raised the question of the cytotoxic species 
generated in the photoejection of Ru(II) comlexes,213, 214 and the possibility of the dissociating 
ligand, rather than the metal center, being responsible for the cytotoxic effects of strained Ru(II) 
compounds. To further the understanding of the mechanisms of actions of Ru(II) compounds on 
the basis of our knowledge on compound 1 from works described in this chapter, the aquated 
species compound 2 produced in the photoejection of compound 1 (see Figure 3.1) was synthesized 
and studied in parallel with the free ligand, 6,6’-dimethyl-2,2’-bipyridine (dmbpy). 
Table 3.3 Cytotoxicity IC50 values (µM) of compound 1 and 2 in E. coli. 
 
 
  
 
 
 
As shown in Table 3.3, compound 2 showed IC50 values of 2.2 µM in both light irradiated 
and dark conditions, in close agreement with the cytotoxicity of compound 1 with light irradiation 
in E. coli. The free ligand, however, failed to induce cytotoxic effects, either in light or dark 
conditions. When dosed with the ligand, compound 2 exhibited IC50 values of 2.8 and 2.6 µM, 
which is not only close to the cytotoxic properties of compound 1 with light treatment and can be 
attributed to the cytotoxicity of compound 2.  
 Cellular metal accumulation and metal content with nucleic acid in the cell was examined 
in both E. coli and HL60 cells as described for compound 1 to determine the nucleic acid binding 
properties of compound 2. As anticipated, similar amounts of ruthenium were found in the cells 
treated with 2 in both light and dark conditions. This is in agreement with ruthenium levels in cells 
treated with 1 and subjected to light irradiation. Further studies of genomic DNA and total RNA 
isolated from both types of cells revealed compound 2 exhibits very similar nucleic binding ratios 
and preferences compared with 1. The DNA or RNA nucleotide to metal center ratio in prokaryotic 
and eukaryotic cells are consistent for both compounds, and reflect the same trend that the metal 
species bind to and react with DNA with a slightly higher preference. This result offers direct 
evidence that compound 2, as the aquated metal species generated from photoejection of 1, 
possesses similar cellular uptake and nucleic acid binding properties as the light irradiated parent 
compound 1. 
 
 Light Dark 
Compound 1 3.2 >300 
Compound 2 2.2 2.2 
Dmbpy >300 >300 
Compound 2 + dmbpy 2.8 2.6 
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Table 3.4 Cellular Ru content with different nucleic acids measured by AAS 
aCellular uptake was calculated as metal content measured in cells divided by total metal content 
in both cell samples and cell culture media samples. Cellular uptake in E. coli and HL60 cellular 
uptake was normalized in 107 cells. bDNA nt /mc was calculated as DNA nucleotide bases (μmol) 
divided by metal content measured in DNA sample (μmol). cRNA nt /mc was calculated as RNA 
nucleotide bases (μmol) divided by metal content measured in DNA sample (μmol). 
 
As discussed in section 3.4, phenotypic profiling has been used to understand the 
mechanism of action for several cytotoxic agents targeting different biological processes. With the 
prediction that compound 2 is mainly responsible for the cytotoxic effects upon light irradiation of 
compound 1, phenotypic features in E. coli cells treated with compound 2 and the free ligand dmbpy 
were studied and compared with that induced by molecules studied in section 3.4. At the MIC 
determined as in table 3.3, compound 2 was able to induce similar filamentous growth of E. coli 
cells, and 38% and 42% of the cellular populations were filamentous in light and dark conditions 
respectively. The average filament size was 11 µm either with light irradiation or just dark treatment; 
this also agreed with the filament size of cells treated with compound 1 in light condition. Further 
observation of the nucleoid morphology revealed a random distribution of irregular sized DNA 
pieces in filamentous cells, which is also consistent with the phenotypic features induced by 
compound 1. The free ligand was dosed at a much higher concentration, 300 µM, as no MIC was 
determined from the dose response studies. At this highest dose, however, only 3% to 4% of 
filamentous cells were observed, which is the same level as naturally occurred under no treatments; 
the filament size is much smaller than that induced by compound 1 and 2 treatment.  
Combine the cytotoxicity, metal content bount to cellular nucleic acids, and phenotypic 
analysis, it appears that the Ru(II) center is responsible for the biological effects observed. The free 
dmbpy ligand doesn’t show significant cytotoxicity against E. coli cells, nor does it induce 
phenotypic changes. In marked contrast to the ligand molecule, compound 2 has similar IC50 
values as compound 1 following light activation, and the cellular accumulation of compound 2 is 
comparable to that of compound 1 with consistent nucleic acid binding properties. Phenotypic 
features very similar to those induce by compound 1 were observed with compound 2 treatment. 
 E. coli  HL60 
  Cellular 
uptakea 
DNA 
nt / mc b 
RNA 
nt / mcc 
 
Cellular 
uptakea 
DNA 
nt / mcb 
RNA 
nt / mcc 
2 light 0.1% 2600 ± 300 4300 ± 500  0.7% 4200 ± 600 5400 ± 700 
2 dark 0.1% 3000 ± 400 4000 ± 400  0.5% 5200 ± 600 6000 ± 800 
1 light 0.1% 2000 ± 200 3800 ± 600  0.6% 4800 ± 400 5000 ± 700 
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The answer now to the question addressed for this section is that compound 1 generates both the 
aquated metal species compound 2 and the free ligand dmbpy, and among the two, it is the metal 
product, compound 2, that is mainly responsible for the cytotoxic effects induced by light irradiated 
compound 1 through a DNA damaging mechanism of action. 
 
Figure 3.7 Compound 2 induced filamentous growth of E. coli cells. A) Left: compound 2 light; 
Middle: compound 2 dark; Right: compound 1 light; B) Left: dmbpy light; Middle: dmbpy dark; 
Right: N. C. control. The image is the merge of the Hoechst and FM4-64 membrane stain. Scale 
bars: 10 µm. Cells were treated with each compound at MIC for 6 h before imaging. C) Quantitative 
analysis of E. coli filamentous growth and nucleoid morphology phenotypes in response to 
compounds treatment. 
3.8 Conclusion. 
This work indicates that a combination of phenotypic screening based on E. coli imaging 
and protein production using Dendra2 as a fluorescent reporter allows for rapid investigations of 
mechanisms of action for cytotoxic agents which may have similar activities in mammalian cells. 
We found that a combination of these two experimental parameters facilitates discriminating DNA 
damaging agents from agents that work solely as transcription or translation inhibitors. While 
filaments are formed by all classes of compound, filament size and population distribution was 
radically different depending on the mechanism of action. Furthermore, the observation of irregular 
bacterial nucleoids, easily visualized using Hoechst staining, was associated with DNA damage, 
while regular nucleoid size, shape, and distribution was associated with compounds that do not 
directly affect DNA.  
These studies in bacterial and mammalian cells highlight the capacity of performing rapid 
studies of anticancer agents in a simple biological model system. Phenotypic studies and 
quantitative analysis reveal similarities in biological activities between complex 1 and cisplatin. 
The different cellular response to the compounds in cancer cells, however, suggest diverse pathway 
regulation resulting from the DNA damage, which offers a possibility to maintain efficacy without 
experiencing the same resistance by altering the metal center. 
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Last but not the least, phenotypic profiling in E. coli provides identification of the cytotoxic 
species generated from the photoejection of compound 1 that is relevant to the mechanism of action 
of the parent compound, proving the metal center product, compound 2, not the free ligand, is 
responsible for the DNA damaging mechanism and the sequential cytotoxic effects.  
E. coli have been used in the past as model systems to probe binding characteristics of 
drugs, such as cisplatin, with proteins using NMR.215, 216 Phenotypic analysis in bacteria by 
microscopy is now gaining more attention, primarily to identify the cellular pathways affected by 
antibiotics,116, 217 but a recent report identified anticancer activity for a molecule characterized by 
cytological profiling.218 We believe this is a burgeoning area that will accelerate the pace of drug 
discovery. 
While these studies bring us closer to understanding the mechanism of action of a particular 
cytotoxic ruthenium complex, it also raised several provocative questions. These include the 
following: 1) Why is the cytotoxic potency of cisplatin and other inorganic putative DNA damaging 
agents the same in E. coli and mammalian cells when DNA damage recognition and repair 
pathways that are unique to eukaryotic systems are implicated as playing a key role in their 
mechanism of action? 2) While more of the metal complexes are taken up in E. coli than the HL60 
cells, the nt / mc ratio remains quite consistent for both DNA and RNA. What biological entities 
are responsible for the enhanced sequestration of the metals in the E. coli, and is it possible that 
similar molecules play a role in cisplatin-resistant cancer cells? 3) Why does DNA packing not play 
a greater role in determining the degree of metallation? DNA is packaged in different ways and to 
different degrees of compaction in the two cells types, and if the more highly exposed, 
transcriptionally active sequences where the primary target, we would anticipate greater potency 
for inhibition of Dendra2 production. We believe that addressing these basic questions may be very 
important to the rational development of improved DNA targeting agents, and see E. coli as an 
excellent system to seek the answers. 
3.9 Materials and methods. 
E. coli culture maintenance. The Dendra2 gene was cloned into a pCW-ori plasmid 
modified to contain an N-terminal 6x histidine tag with multiple restriction enzyme cloning sites. 
Escherichia coli BL21(DE3) competent cells transformed with pCWori plasmid containing 
Dendra2 gene (pCWori-Dendra2) were cultured in Luria Broth (LB) at 37℃ with 180 rpm shaking.  
Mammalian cell maintenance. Human promyelocytic leukemia HL60 cells were purchased 
from ATCC. Dulbecco's modified eagle medium (DMEM), Iscove's modified Dulbecco's medium 
(IMDM), Opti-MEM I reduced serum medium, heat inactivated fetal bovine serum (FBS), 
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Penicillin/Streptomycin (5, 000U/mL), Trypsin-EDTA (0.5%), Dulbecco's phosphate buffered 
saline (DPBS), Trypan Blue Solution (0.4%) were purchased from Life Technologies.  
HL60 cells were maintained in IMDM supplemented with 10% FBS and 50 U/mL of 
Penicillin/Streptomycin. A549 cells were maintained in DMEM with the same supplements. Cells 
were maintained at 37℃ with 5% CO2. 
Cytotoxicity determination. E. coli BL21(DE3) cells transformed with pCWori-Dendra2 
plasmid were plated in M63 minimal medium at 4 x 106 cells per well in 96 well flat bottom 
transparent tissue culture treated plates (Greiner Bio One). Compounds were dosed from 0 – 300 
µM, followed by 3 min of light irradiation (7 J/cm2 blue light (> 400 nm)). The cells were then 
incubated for 16 hours with the compounds, and cell growth was determined by measurement of 
the optical density at 600 nm using a SpectraMax Multiwell Plate Reader (Molecular Devices). 
HL60 cells were plated in Opti-MEM supplemented with 1% FBS and 50 U/mL of 
Penicillin/Streptomycin at 30,000 cells per well in 96 well flat bottom transparent tissue culture 
treated plates (Greiner Bio One). Compounds were dosed from 0 – 300 µM, and incubated for 16 
hours, followed by light irradiation with 7 J/cm2 blue light (> 400 nm) in 30 second pulses for a 
total light exposure of 3 minutes. The cells were then incubated for 72 hours, and cell viability 
determined by conversion of resazurin to resorufin. Dark controls were run in parallel. The 
emission of resorufin was measured on a SpectraFluor Plus Plate Reader (Tecan).  The data were 
normalized to the untreated control and fitted to a sigmoidal dose response model using Prism 6.02 
to determine IC50 values. Minimal inhibitory concentration (MIC) was fitted to the model published 
by Lambert et al using Prism 6.02.185 
Protein synthesis inhibition. E. coli BL21DE3 cells transformed with pCWori-Dendra2 
were cultured in LB medium to an OD600 of 0.8. Cells were then resuspended in M63 minimal 
media and induced with 0.5 mM IPTG for 3 hours at 37℃ with 180 rpm shaking. Photoconversion 
of Dendra2 was carried out with a 405 nm LED flood array (Loctite) with a total light exposure 
time of 2 minutes. Cells were then plated in 96 well plates at 6 x 107 cells per well. Green and red 
emission was measured directly after photoconversion using a SpectraMax Multiwell Plate Reader 
(Molecular Devices) for a baseline evaluation of Dendra2 protein (t = 0 hour). For green emission, 
an excitation wavelength of 491 nm and emission wavelength of 538 nm was used; for red emission, 
the excitation wavelength was 544nm and emission wavelength was 590 nm.  Compounds were 
then dosed from 0 μM to 300 μM, and compound 1 was activated with light as described above. 
The cells were incubated for 16 hours before the green and red emission was measured again for 
an evaluation of protein synthesis with compound treatment (t = 16 hours). The average 
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fluorescence ratio of green/red at t = 0 hour and t = 16 hours was calculated, the values were 
normalized, and the data fitted to a sigmoidal dose response. 
E. coli filamentous growth. E. coli were cultured as above and plated at 3 x 108 cells per 
well in 24 well flat bottom transparent tissue culture treated plates (Greiner Bio One). IPTG was 
added at a concentration of 0.5 mM for induction of Dendra2 production. Compound treatment was 
then carried out, with cells dosed at the MIC or 10 x MIC for each compound and cultured at 37℃ 
with 180 rpm of shaking for 6 and 16 hours before imaging. 
E. coli cell imaging. After compound treatment, E. coli cells were centrifuged at 5, 510 x 
g for 2 minutes, washed twice with PBS, and 3 x 107 cells were resuspended in 1 mL of PBS. The 
fluorescent dyes FM4-64 and Hoechst 33342 were added to a final concentration of 5 μg/mL and 
10 μg/mL respectively. The cells were protected from light for 20 minutes, and then 2 μL of cell 
suspension was placed on a slide and a cover glass was applied before imaging. Imaging was carried 
out on an Olympus IX2-RFAEVA-2 microscope with the following filter settings: Dendra2 (green), 
excitation filter: 473/10 nm BrightLine® single-band bandpass filter, FF01-473/10-25 (Semrock, 
Rochester, NY, USA); emission filter: 525/50 nm BrightLine® single-band bandpass filter, FF03-
525/50-25 (Semrock, Rochester, NY, USA). Dendra2 (red) and FM4-64, excitation filter: HQ 
550/30 (Chroma, Bellows Falls, VT, USA); emission filter: 664 nm EdgeBasic long-pass edge filter, 
BLP01-664R-25 (Semrock, Rochester, NY, USA). Hoechst 33342, excitation filter: BP 360-390 
(Chroma, Bellows Falls, VT, USA); emission filter, HQ470/30 M (Chroma, Bellows Falls, VT, 
USA). Imaging data was processed and analyzed with ImageJ. 
Metal uptake in bacterial cells. E. coli were cultured in M63 minimal medium as discussed 
above and dosed with 20 µM compound 1 or cisplatin. Cells treated with compound 1 were 
irradiated with 7 J/cm2 blue filtered light (> 400 nm) for a total of 3 minutes, or were protected 
from light. Cells were collected 24 hours after compound addition by centrifugation at 5, 510 x g 
for 5 minutes. The culture medium was separated for analysis, and cells were washed twice with 
PBS and pelleted. Both cell content and medium were heated at 110 ℃ for 3 hours with 20% (v/v) 
HNO3. Total RNA and genomic DNA were isolated using Qiagen kits. RNA and DNA samples 
were digested in HNO3 as described above.  Following sample digestion, the metal content was 
analyzed using a Varian AAS with a replicate reading and a spiked reading. Cellular uptake was 
calculated as following: 
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Genomic DNA and total RNA were quantified by measuring their absorbance at 260 nm. Mass to 
DNA nucleotide pair conversion was calculated using the average molecular weight of DNA 
nucleotide pairs. The number of DNA nucleotide bases per metal center was calculated as following: 
 
Mass to RNA nucleotide base conversion was calculated using the average molecular weight of 
RNA nucleotide bases. Number of RNA nucleotide bases per metal center was calculated as 
following: 
 
Metal uptake in HL60 cells. HL60 cells were plated in Opti-MEM supplemented with 1% 
FBS and 50 U/mL Penicillin/Streptomycin at a density of 1x 106 cells/mL in 25 cm2 cell culture 
flasks, and dosed with 20 µM compound 1 or cisplatin. Cells treated with compound 1 were 
incubated 12 hours protected from light before irradiating with 7 J/cm2 blue filtered light (> 400 
nm) in 30 second pulses for a total of 3 minutes, or protected from light. Cells were collected 24 
hours after compound addition by centrifugation at 124 x g for 5 minutes. The culture media was 
separated for analysis, and cells were washed twice with PBS. Total RNA and genomic DNA were 
also isolated, and the nucleic acids, cell content, and media were prepared for analysis as described 
above.  
Immunoblotting. HL60 cells were harvested 0, 1, 3, 6, 12, 24, 30 and 48 hours after 
treatment, pelleted by centrifugation at 124 x g for 5 minutes, washed twice with DPBS. A549 cells 
were plated at 2 x 105 cells per well in 6 well flat bottom transparent tissue culture treated multiwell 
plates and in the same treatment condition detailed for HL60 cells. Cells were harvested at 0, 6, 12, 
24 and 48 hours after treatment. All cells were lysed in RIPA buffer supplemented with 5 mM 
sodium pyrophosphate (2 x 106 cells/100 μL) for 15 minutes on ice. The insoluble fraction was 
removed by centrifugation at 20, 817 x g for 10 minutes at 4 °C. The supernatant was collected and 
the protein concentration was determined by BCA assay. 20 μg of protein was loaded onto 4-12% 
bis-tris gels and followed by transfer to nitrocellulose membranes. After blocking with 2.5% BSA 
in DPBS with 0.1% Tween20 (PBST) for 1 hour at room temperature, the membrane was 
immunoblotted with the following primary antibodies and correspondence dilutions. Cleaved 
caspase 3, cleaved PARP, p-p53, p21, p-Chk1, p-JNK and γ-H2AX at 1: 1, 000 dilutions; p53 and 
p-ERK at 1: 500 dilutions; and GAPDH at a 1: 2, 000 dilution in 2.5% BSA overnight at 4 °C. 
Immunoblots were washed with PBST for 10 minutes for four times and incubated for 1 hour with 
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secondary antibodies at a 1: 10, 000 dilution for GAPDH and 1: 5, 000 dilutions for all other 
antibodies. Detection was carried out with Clarity Western ECL Substrate and imaged with a 
ChemiDoc MP System (Bio-Rad).  
DNA fragmentation. HL60 cells were cultured, and treated as described above. Cells were 
harvested at 0, 3, 8, 12, 24 and 30 hours after treatment, pelleted by centrifugation at 124 x g for 5 
minutes, washed twice with DPBS, and prepared with an apoptotic DNA-ladder kit as per 
manufacturer instructions (Rosch). Gel electrophoresis was carried out using a 1 % agarose gel 
containing 0.5 μg/mL ethidium bromide for 90 minutes at 75 V. Gel imaging was performed with 
the ChemiDoc MP. 
Flow cytometry. HL60 cells were cultured, and treated as detailed previously. Cells were 
harvested at 24 hours after treatment, pelleted by centrifugation at 124 x g for 5 minutes, washed 
twice with DPBS. For cell death mechanism analysis, cells were stained 15 minutes with FITC-
Annexin V and PI; for cell cycle analysis, cells were stained 15 minutes with PI only. Cells were 
analyzed with a FACSCalibur (Becton-Dickenson). A minimum of 20, 000 events were measured 
for each sample.  
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Chapter 4. Bacterial cytological profiling differentiates anticancer agents with various 
mechanisms of actions 
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4.1 Introduction. 
Small molecule compound screening as starting a point for the development of a drug is 
traditionally evaluated for biological effects by one of two methods. The first involves isolating the 
biological molecule target and identifying chemical “hits” by assaying activity of the target in the 
presence of compound libraries. The second focuses on screening compound libraries in complex 
systems, such as bacterial or mammalian cells. While the first approach allows one to have clear 
knowledge of the effect of compounds on the specific biological target, the second approach is 
necessary when the target cannot be isolated, or when efforts must be focused on its cell based 
activity.   
When screening compounds in complex systems, elucidating the mechanism of action 
through target identification is an essential step. It also remains one of the most challenging 
problems in drug discovery.219 Though the precise mechanism or functional target is not required 
for a drug to be approved by the FDA, as illustrated by the fact that many medications are prescribed 
without mechanistic understanding, knowledge of the biological mechanisms and targets of 
potential drugs could, however, reduce the chances of clinical trial failure.220, 100 Knowing the 
mechanism not only improves our understanding of how the compound results in a biological 
activity, but can be used to improve potency while minimizing adverse effects in treatments as a 
single or combination medication.221, 222 Current drug discovery progress can also benefit from 
mechanistic studies of therapeutic agents that are either approved by the FDA or in clinical trials.   
Mechanistic studies and target identification are common methods used to solve the “black 
box” problem, and involve considerable time and effort, due to the enormous number of 
biomolecules present in the cellular environment and the complex networks involving all possible 
molecular and cellular processes.223, 224, 98, 225 Affinity based techniques have played an important 
role in target validation and mechanism elucidation studies, either independently or in combination 
with computational approaches.226, 227, 173 This approach, however, is time consuming and requires 
stringent validation to remove false targets identified in the isolation process. Phenotypic screening, 
on the other hand, offers insights into the performance of drugs in more biologically relevant 
environments, allowing the possibility to discover novel cellular targets and mechanisms.228, 122, 229, 
230 Recent advancements in microscopy have made it possible to carry out imaging-based 
phenotypic profiling with semi-automated or automated settings, combined with statistical 
evaluation of parameters extracted from imaging results.116, 231, 232, 233  
Mammalian cell systems have been in dominant use in phenotypic profiling for anti-cancer 
agents.230, 234 The role of microbial system, especially bacterial system, however, has been 
underestimated despite their role in the discovery of novel antibiotics,235, 115, 236, 237 some of which 
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also possess anticancer activity. Ever since the discovery of the first commonly used platinum based 
anti-cancer agent cisplatin in E. coli by Rosenberg,16, 18 there have been studies showing cytotoxic 
effects of anti-cancer agents in this simple system related to their known mechanisms.45, 238 Lippard 
recently reported phenotypic changes in E. coli induced by a platinum molecule and the correlation 
between cytotoxic effects in cancer cells and bacterial cells.239 In the bacterial cytological profiling 
results of Pogliano, three molecules used for anti-cancer chemotherapy were included and induced 
significantly distinct phenotypic changes.116   
Here in this chapter, we describe phenotypic profiling with anti-cancer molecules in E. coli. 
A combination of cytotoxic and cytostatic analysis helped to distinguish molecules with 
mechanisms involving DNA damage, transcription inhibition, and translation inhibition. Cellular 
imaging was performed with statistical evaluation of phenotypic feature changes, and the 
comprehensive data evaluation led to classification and separation of molecules inducing DNA 
damage, transcription inhibition, and translation inhibition, proving that a fast assessment of 
mechanisms of actions can be done in this simple system for anti-cancer agents that target common 
biological targets in mammalian and bacterial cell systems.  
4.2 Correlation of cytotoxicity in mammalian cells and bacterial cells. 
In order to study anticancer agents in E. coli, it was essential to determine if they possessed 
cytotoxicity in bacterial cells first. As prokaryotic system lacks eukaryotic-exclusive organelles 
and biological processes, anticancer agents with DNA damaging mechanism were chosen for this 
study as DNA has been the most common target for many chemotherapeutic agents, and is a 
common biological target in both prokaryotic and eukaryotic cells. Determination of cytotoxicoty 
in human promyelocytic leukemia HL60 cells and E. coli cells were done by the resorufin assay 
and by the OD600 assay, as described in previous chapters. As shown in Figure 4.1, all the studied 
molecules exhibit cytotoxicity in E. coli, despite the fact that their cytotoxicities have previously 
been primarily studied in mammalian cells. For most of the studied anticancer molecules, the ratio 
of IC50 values in HL60 cells and E. coli cells falls into a one log unit range, which means the 
cytotoxicity in two cell types are within a 10-fold range. This relatively small shift in cytotoxicity 
suggests these anticancer molecules act through mechanisms involving common targets in cancer 
cells and E. coli. 
A translational inhibitor, puromycin, was also chosen for this study for its ability to inhibit 
translation by inducing premature chain termination of translation in both prokaryotic and 
eukaryotic cells.240 Notably, puromycin clustered with the molecules that had IC50 values in both 
HL60 and E. coli cells that fell in the one log unit range. The nitrogen mustard compound bis(2-
chloroethyl) amine (BCEA), and the topoisomerase II inhibitor, doxorubicin, however, were both 
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shifted significantly from this range. As shown in Figure S3.7 in the Appendix, the linear regression 
of IC50 values in E. coli and in HL60 cells for all molecules was y = 0.009x + 3.936, with the R2 
value being 0.001, suggesting the linear regression poorly fitted the data. When the two data points 
for BCEA and doxorubicin were removed, the linear regression was y = 0.045x + 1.191 and the  R2 
incresed to 0.368. This improvement in goodness of fit suggested that BCEA and doxorubicin 
largely affected the linear regression. Doxorubicin has been known to possess multiple mechanisms 
to induce cytotoxic effects including DNA intercalation and reactive oxygen species (ROS) 
associated mechanism.241, 242 One possible explanation is that doxorubicin induces cytotoxic effects 
in HL60 cells through both eukaryotic-exclusive mechanisms and common mechanisms, while the 
cytotoxicy in E. coli cells were only induced through mechanisms that are commonly present in 
both cell types. The shift of BCEA cytoxicity in E. coli cells compared with other two nitrogen 
mustard compounds could be possibly explained by the reduced reactivity of the nitrogen in the 
secondary amine BCEA in the SN2 reactions that alkylate DNA bases. 
 
 
Figure 4.1 Correlation of cytotoxicity in cancer cells and E. coli. IC50 values in HL60 cells were 
determined 72 hours after treatement; IC50 values in E. coli cells were determined 16 hours after 
treatments. The fit line on the scatter plot represent a y = 0.1x linear correlation.  
 
 
59 
 
 
Figure 4.2 The ratio of IC50 values for growth inhibition vs. translation inhibition depend on the 
class of drug. IC50 values for growth inhibition in E. coli were measured 16 hours after drug 
treatment, while inhibition of translation was measured by following the production of Dendra2 in 
a 16-hour time course after drug treatment. The IC50 index is defined as the IC50 value for translation 
inhibition/IC50 value for growth inhibition. 
4.3. Relationship between cytotxicicty and translation inhibition. 
The concentration of drug required to induce growth inhibition and the concentration to 
prevent protein synthesis were independently measured in E. coli. For each compound, the ratio of 
the IC50 values from translation inhibition and growth inhibition was established to determine the 
“IC50 index”. Compounds known to inhibit translation displayed a negative IC50 index value, 
indicating that the IC50 value for translation was more potent than for growth inhibition (Figure 
4.2). Compounds with other mechanisms of action had much higher IC50 values for translation 
inhibition. Among the molecules with DNA damaging mechanisms, cisplatin and chlorambucil, 
two DNA alkylating and crosslinking agents which require nucleotide excision repair (NER) as the 
major DNA damage repair mechanism, had translation inhibition IC50 values that were 43-fold and 
9.7-fold above their IC50 value for growth inhibition respectively. Bacterial gyrase inhibitors 
(nalidixic acid, ciprofloxacin), topoisomerase II inhibitors (doxorubicin, etoposide) and the 
commonly used chemotherapeutic agents mitomycin C and bleomycin are all DNA damaging 
molecules resulting in strand breaks and therefore requiring homologous recombination repair (HR) 
in E. coli. In contrast to the DNA alkylating agents, these molecules had a smaller IC50 index value, 
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which was less than 5. The IC50 index analysis was not able to clearly distinguish the difference 
between inhibitors of transcription from the single strand break DNA damaging molecules, as the 
IC50 index values of transcription inhibitors (rifampicin, rifaximin) and nitrogen mustard 
compounds (chlorambucil, BCEA, and BCEMA) fell in a close range. 
 
Figure 4.3 Drugs with a DNA damaging mechanism of action are cytotoxic, while drugs that inhibit 
transcription and translation are cytostatic in a colony forming assay.  E. coli were treated with 
drugs at their minimal inhibitory concentration (MIC) for 6 hours, and then the cells were washed 
to remove the drugs.  The cells (~500) were plated on LB agar and colonies allowed to form for 16 
hours. Colonies were counted and normalized to the untreated control.  
4.4 Establishing a relationship between cytostatic and cytotoxic drugs. 
In order to discriminate between transcription inhibitors and the single strand DNA 
damaging agents, compounds were evaluated for their ability to inhibit colony formation. E. coli 
were treated with compound for 6 hrs at their MIC before the cells were transferred to fresh media 
without drug. Most DNA damaging molecules induced total inhibition of colony formation, 
regardless of their mechanism of action (Figure 4.3). Interestingly, bis(2-chloroethyl) amine and 4-
nitroquinoline-1-oxide treatment were only able to reduce colony formation by 40%, similar to that 
seen for the translation inhibitors, where a 60% reduction was observed. This result suggests that 
altered kinetics in DNA damage repair and responses result in intermediate colony formation 
inhibition.  The colony formation assay could distinguish between transcription inhibition and DNA 
damage, as the number of detected colonies decreased by 80% after rifampicin treatment, while no 
colonies were detected for any of the DNA damaging agents. This result is consistent with 
cytostatic effects associated with inhibition of transcription and/or translation, in contrast to 
cytotoxic effects caused by DNA damaging molecules.  
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4.5 E. coli phenotypic changes as a function of drug class. 
The IC50 index and colony formation could be used to narrow down the mechanism of 
action for several drug classes, but it was found that the combination of the two experiments could 
not conclusively define the mechanism. It was hypothesized that imaging of E. coli could be used 
to quickly measure several phenotypic parameters which could correlate more effectively with drug 
class. Accordingly, high resolution imaging was performed using stains to visualize DNA and the 
cell wall, providing additional cytological features for analysis. Hoechst 33342 (cyan) was used for 
DNA and FM4-64 (red) was used to stain the cell wall. 
Normal E. coli cells have length of 2 µm and diameter of 1 µm, giving two-dimensional 
cellular size of 2 µm2. Most cells were observed to contain one nucleoid, though cells about to 
undergo division were observed with two equal sized nucleoids. Upon treatment of molecules 
targeting different stages of protein production, dramatic changes in single E. coli cell and DNA 
morphology were observed (Figure 4.4). Regardless of drug treatment, the diameter remained 
constant, but significant changes in length were observed. Cells treated with nalidixic acid exhibited 
an increase in length that was on average 35 times longer than untreated E. coli. They also displayed 
many fragments of DNA that were irregular in both size and distribution within the cell (Figure 
4.4B). Staining of the cell walls confirmed that the changes in length are the result of filamentous 
growth of a single E. coli cell, and not due to the alignment of multiple E. coli cells that were 
adjacent to one another after cell division. Both rifampicin and tetracycline treated cells formed 
shorter filaments than nalidixic acid, and the DNA morphology was distinct between the two drugs. 
Cells treated with rifampicin exhibited an expanded, diffuse nuclear staining, distributed 
throughout the cell with equal intensity. Tetracycline resulted in punctate staining of the DNA, with 
multiple pieces of similar size occurring with a relatively regular distribution within the cell.  
Given the distinctive phenotypic changes observed for these drugs, the study was expanded 
to include several representatives from each drug class to determine if the correlation between the 
phenotypic parameters of cell length and DNA morphology and each drug’s mechanism of action 
was robust. All molecules tested were quantified as to the percentage of cells that formed filaments, 
the average length of the filaments, the number of distinct DNA pieces identified per cell, and the 
variation in the size of DNA pieces per cell (Figure 4.5). Among the studied molecules, all were 
able to induce filaments, though both the percent of the cellular population and filament sizes varied 
significantly. Molecules that induce DNA strand breaks, including bacterial gyrase inhibitors 
(ciprofloxacin, nalidixic acid), topoisomerase II inhibitors (etoposide, doxorubicin, mitoxantrone), 
molecules that mimic ionizing radiation (MMS, EMS), bleomycin, and mitomycin C, all induced 
filamentous populations of over 50% of cells. Other DNA damaging molecules that induce DNA 
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crosslinking (Pt containing molecules and nitrogen mustards) were only able to induce filaments in 
less than 50% of cells (17% - 40%; average = 28% ± 11%). Transcription inhibitors (rifampicin, 
rifaximin) and translation inhibitors (tetracycline, kanamycin, chloramphenicol, and puromycin) 
induced filamentous populations of 25% - 30% and 23% - 29%, respectively. Notably, translation 
inhibitors had to be dosed as 10x MIC to observe filaments; all other drugs were dosed at 1x MIC. 
Under those conditions, the values for the filamentous populations for transcription (1x MIC) and 
translation (10x MIC) inhibitors were very close (standard deviation = 2.7%). 
 
 
Figure 4.4 Distinctive DNA morphology is observed with treatments targeting different stages of 
protein production. A) Untreated; B) Nalidixic Acid; C) Rifampicin; D) Tetracycline. E. coli cells 
were treated at their MIC for 6 hours and then stained and imaged. FM4-64 (red) was used to stain 
the cell wall while Hoechst 33342 (cyan) was used for DNA. The stains were incubated with the 
cells for 15 minutes prior to imaging with wide-field epifluorescence microscopy. Scale bar 
represent 5 µm in all images.  
The average filament size, as shown in Figure 4.5B, varies upon treatments with different 
molecules at biologically relevant concentrations. Both transcription inhibitors and translation 
inhibitors induced filaments with average length within 5-fold of normal cells. Molecules inducing 
DNA strand breaks resulted in filaments with average lengths that were over 10-fold that of normal 
cells, and the filaments induced by these molecules also have considerably wider distribution of 
filament size, resulting in correspondingly long whiskers in the box and whisker plot (Figure 4.5B; 
representative histograms shown in 4.5C). Treatments with DNA crosslinking molecules resulted 
in average filament sizes that were generally within 5-fold of normal E. coli, with oxaliplatin and 
chlormethine identified as outliers, inducing more filaments with increased length, and resultantly 
large error whiskers. 
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Figure 4.5 Phenotypic change observed in E. coli correlates with drugs’ mechanism of action. Cells 
were treated with drugs at their MIC for 6 hours prior to imaging, translation inhibitors were dosed 
at 10 x MIC for phenotypic changes. To quantify the population distribution, multiple fields of 
view were analyzed for a total of 300-500 cells. A) Graph of filament population induced by 
different drug molecules; a cutoff of 5 µm was used for identification as a filament. B) The overall 
(in whisker)and major 50% (25% to 75%, in box) range of the E. coli filaments size. Error bars 
depict the maximum and minimum size of E. coli filaments. C) Histograms of E. coli cell length 
for DNA strand breakers (orange, top) and translation inhibitors (cyan, bottom). The histograms 
reflect the standard deviations associated with the data in B).  D) The average number of DNA 
pieces in each filament. Error bars depict the standard deviation, which is a reflection of the 
population distribution. E) The coefficient of variation (CV) for the size of the DNA piece in each 
filament. F) Histograms of the number of DNA pieces per E. coli for topoisomerase II inhibitors 
(maroon, top) and translation inhibitors (cyan, bottom). The histograms reflect the standard 
deviations associated with the data in D). Molecules of diverse mechanisms are color coded as 
follows: ● Pt based DNA crosslinker; ● nitrogen mustard; ● oxidizing agent; ● bacterial gyrase 
inhibitor; ● topoisomerase II inhibitor; ● ionizing radiation mimicking agent; ● DNA strand 
breaker; ● transcription inhibitor; ● translation inhibitor. 
 
The DNA material in the filaments was characterized by two phenotypic features: the 
average number of DNA pieces per filament (Figure 4.5D) and the degree of variation of the sizes 
of DNA pieces in the filaments, described as the “coefficient of variation” (CV) of the size of the 
DNA pieces (Figure 4.5E). Nearly all molecules resulted in the observation of multiple pieces of 
DNA in the filaments; the exception was transcription inhibitors, which resulted in single nucleoids 
per cell. DNA damaging molecules that induce strand breaks, in particular, produced the greatest 
number of DNA pieces in the filaments; there was also significant variation in the size of each 
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piece, resulting in high CV values. Fewer pieces of DNA were observed with other classes of DNA 
damaging molecules and translation inhibitors, as shown in Figure 4.5D and F. 
All four translation inhibitors in the study produced DNA pieces that were condensed into 
similar size, resulting in very small CV values, as shown in Figure 4.5E; the DNA pieces were 
distributed at regular distances within the filaments. A histogram depicting the number of DNA 
pieces per cell is shown in 4.5F, which revealed that the vast majority of cells treated with 
translation inhibitors contain 4 nucleoids. DNA damaging molecules that work by various 
mechanisms, in contrast, all induced DNA pieces of irregular sizes, so the CV values for DNA 
piece sizes were above 50 or more (5.4E). There was also greater variation in the number of pieces 
of DNA from cell to cell, leading to larger standard deviations (5.4D) and histograms that show 
large populations of cells containing each 4, 5, 6–10, and >10 DNA pieces.  
  
 
 
Figure 4.6. Distinguishing anticancer agents with different mechanisms based on phenotypic 
characteristics in E. coli. Cells were treated with molecules at their MIC for 6 hours prior to imaging. 
Translation inhibitors were dosed at 10 x MIC for analysis of phenotypic changes. The same 
phenotypic features are shown as used for Figure 4.5.  
As each individual phenotypic feature does not fully provide the information needed to 
distinguish molecules with different mechanisms of action, a comprehensive analysis with multiple 
phenotypic features was used to generate a multidimensional scatter plot in Figure 4.6. The 
similarity in the phenotypic features observed upon treatments with compounds with the same 
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mechanism of action resulted in clustering in this 3D plot, as exemplified by all translation 
inhibitors; the transcription inhibitors formed a similarly tight cluster. Based on variation in 
phenotypic features, molecule that directly damage DNA formed two loosely clustered groups. The 
bacterial gyrase inhibitors, topoisomerase II inhibitors, DNA alkylating molecules that mimic 
ionizing radiation, and DNA strand breaking molecule bleomycin, formed one cluster group to the 
upper left of the cluster plot. Notably, mitomycin C, with a known mechanism of action involving 
DNA intrastrand and inter strand crosslinks, was also found in this cluster. This observation could 
be associated with the reported DNA double strand breaks and the involvement of DNA double 
strand break repair following mitomycin C treatment.243, 244, 245 Another loose cluster formed 
containing the Pt based DNA crosslinking molecules, nitrogen mustard molecules, and oxidizing 
molecule 4-NQO. 
4.6 Dose effects on the phenotypic profiling of DNA damaging molecules. 
 While it was possible to distinguish some mechanisms of action through the preceding 
analysis, only loose clusters formed for certain classes of molecules, indicating that additional 
parameters would be needed to obtain diagnostic information that correlated to specific 
mechanisms of DNA damage. Initial studies indicated that there were compound dose- and time-
dependent effects on E. coli phenotypic features that might prove helpful to distinguish between 
different compound classes. Accordingly, a phenotypic profiling study was performed with three 
Pt-containing molecules (cisplatin, carboplatin, and oxaliplatin) at 0.1 x MIC, 1 x MIC, and 5 x 
MIC, and with three topoisomerase II inhibitors (etoposide, doxorubicin, and mitoxantrone) at 0.1 
x MIC and 1 x MIC.  
 As shown in Figure 4.7, when dosed at different concentrations, distinct phenotypic 
features were observed for the studied molecules. Fewer E. coli cells formed filaments in response 
to treatments at the lower compounds dose, 0.1 x MIC, and the filaments were of much smaller 
size. As the drug concentration increased, the profiles were similar among the three Pt containing 
molecules, with a relatively steady increase in the filamentous population. However, the profile for 
the average filament size varied for oxaliplatin in comparison to carboplatin and cisplatin, with 
oxaliplatin forming filaments of the same size at both 1 and 5 x MIC. In contrast, both cisplatin and 
carboplatin exhibited a greater increase in filament length for the last two concentrations, from 1 
to 5 x MIC, resulting in a greater relative increase in size vs. the 10-fold increase in concentration 
at lower doses (0.1 to 1 x MIC). This analysis suggests that there is a notable difference in the 
mechanism of action of oxaliplatin compared to the two other platin agents. 
66 
 
Figure 4.7 Drugs that damage DNA via different mechanisms of action can be distinguished using 
bacterial cytological profiling as a function of drug concentration. E. coli cells were treated with 
drugs for 6 hours before imaging and cytological profiling. A) Representative image of E. Coli 
treated with cisplatin at a dose corresponding to 0.1 x MIC and B) 1 x MIC. C) Plot of the average 
filament size and distribution for platinum drugs at 0.1, 1, and 5 x the MIC value. D) Plot of the 
population of filaments over 5 µm for the platinum drugs as function of MIC value. E) Image of E. 
coli treated with doxorubicin at 0.1 x MIC and F) 1 x MIC. Scatter plots of the filament population 
versus the CV for the DNA size in cells treated at G) 0.1 x MIC and H) 1 x MIC of different DNA 
damaging agents. The scale bar in all microscope images corresponds to 10 µm. 
 A dose effect study was also performed for three topoisomerase II inhibitors at 0.1 x MIC 
and 1 x MIC; higher doses were not possible due to the high cytotoxicity of these compounds in E. 
coli. Similar dose effects were observed on phenotypic features such as filament population, 
average filament size, and the number of DNA pieces per filament. The lower concentration led to 
smaller filamentous populations (ca. 70% vs. ca. 80%) and smaller filament size. The CV for DNA 
piece size, however, remained similar at the two treatment conditions.  
The three molecules were compared to two other DNA damaging agents with different 
mechanisms: cisplatin, a DNA crosslinker, and EMS, an alkylating agent that can result in multiple 
strand breaks and is used as a ionizing radiation mimic.246, 247  All five DNA damaging compounds 
have similar CV values (as is the case for all the DNA damaging agents; see Figure 4.5E). When 
examined in 2D scatter plots of filament population and CV (DNA), the three topoisomerase II 
inhibitors formed a tight cluster that could be easily separated from cisplatin at both dose 
concentrations. The effects of EMS could be distinguished from the topo II inhibitors when the 
filament population was compared at both 0.1 x MIC and 1 x MIC; EMS produced a larger shift 
(from ca. 45% to 90%) over this concentration range than the topo II inhibitors (from ca. 40% to 
60%). This analysis suggests that the phenotypic profiling of DNA damaging molecules can be 
used to identify compounds with the same mechanism of action and distinguish them from others 
that appear similar but have different mechanisms by comparison of suitable features over a dose 
range. 
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4.7 Discussion. 
E. coli have been extensively used as model systems in the discovery and mechanistic 
studies of antibiotics236, 235, 115, but are not usually considered in studies for the mechanisms of action 
for anti-cancer agents. The results from our phenotypic profiling, however, prove it is feasible to 
use this simple bacterial system to rapidly elucidate mechanisms of anticancer agents. The 
combination of phenotypic profiling features distinguishes DNA damaging agents, transcription 
inhibitors, and translation inhibitors; furthermore, anticancer agents inducing different types of 
DNA damage can be distinguished.  
Previously, cytotoxic effects in E. coli have been reported for FDA approved Pt-based 
agents and some other anti-cancer agents238a, 238b, 248. For our approach it was essential to understand 
the cytotoxicity correlation in mammalian cells and E. coli cells. To our satisfaction, all the studied 
agents showed cytotoxic effects, and the cytotoxicity in E. coli is usually within one log range of 
that in mammalian cells (Figure 4.1). This correlation validates the proposal to study anti-cancer 
agents with specific mechanisms in E. coli, and  is consistent with  Rosenberg’s original 
experiments and Lippard’s findings for some more recent Pt compounds239.  
The colony formation assay and study of protein synthesis inhibition study were used to 
further understand the correlation between the mechanism of action and cytotoxic vs. cytostatic 
effects. In the colony formation study, most DNA damaging molecules showed cytotoxic effects, 
with inhibition of the formation of any colony after treatment at a biologically relevant 
concentration (the MIC). Transcription and translation inhibitors, however, showed mainly 
cytostatic effects, resulting in 20 – 40% of colony formation with treatment at the same condition. 
Among the categories of molecules being studied, DNA damaging agents and transcription 
inhibitors require higher concentration to achieve inhibition of protein production, while translation 
inhibitors exhibited lower IC50 values for translation inhibition than that needed for growth 
inhibition (resulting in negative values for the log IC50 ratio shown in Figure 4.2). This allows for 
identification of translation inhibitors. Combining these simple studies, the studied molecules were 
categorized into groups by mechanisms for DNA damage, transcription inhibition, and translation 
inhibition, which agrees with the known individual mechanisms of the molecules. 
Further studies of single cell and DNA morphological changes, using statistical evaluation, 
offered clearer separation of molecules with various mechanisms. Observations of DNA spreading 
along the length of the cells in response to transcription inhibition and the compact DNA pieces of 
similar size regularly distributing in the cell for translation inhibition were consistent with previous 
reports249, 117. DNA damaging agents, in sharp contrast, induced generally larger population of E. 
coli cells that were filamentous, and the filament lengths exceed those of cells treated with 
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transcription inhibitors and translation inhibitors (Figure 4.4). The filaments induced by DNA 
damaging agents also had highly variable number of DNA pieces per cell, and with much more 
irregular sizes, which, in combination with the filament population and average filament size, 
created different phenotypic profiles of E. coli in response to treatments of molecules with different 
mechanisms of DNA damage. A key feature of our analysis is to use biologically relevant 
concentrations (generally at MIC) and to recognize the effect of drug concentration on phenotype. 
We found that both transcription inhibitors and translation inhibitors can be distinguished from 
DNA damaging molecules as shown in both a 2D bar graph (Figure 4.5) and the 3D scatter plot 
(Figure 4.6) utilizing the key phenotypic features. Transcription inhibitors, rifampicin and rifaximin, 
are closely cluster in the 3D scatter plot, and feature smaller filament population, small average 
filament size, and generally a single piece of DNA spreading throughout the entire filament. All 
four translation inhibitors, including three antibiotics and one mammalian and bacterial translation 
inhibitor, puromycin, were distinguished from other molecules as they exhibited more regularly 
sized and evenly spaced DNA pieces in each filament, which is reflected by the smaller CV values. 
The clustering of puromycin with other antibiotics (tetracycline, kanamycin, and chloramphenicol) 
supports the capacity of E. coli phenotypic profiling to study mammalian translation inhibitors. 
DNA damaging molecules, depending on their individual mechanisms of actions, were separated 
into different groups as they induce 1) different types of DNA damage and 2) DNA repair 
mechanisms. DNA double strand breaks can be induced by direct interactions with molecules such 
as bleomycin, or molecules that alkylate DNA and lead to subsequent DNA damage repair 
processes generating double strand breaks. Ionizing radiation mimicking molecules methyl 
methanesulfonate (MMS) and ethyl methanesulfonate (EMS), and DNA strand breaking molecules 
mitomycin C directly alkylate DNA and induces base excision repair (BER) and nucleotide 
excision repair (NER); these repair processes can lead to secondary DNA damage which is usually 
double strand break. Another major source of DNA double strand break is the failure of re-ligation 
process of type II DNA topoisomerase as a result of interference with the enzyme by type II DNA 
topoisomerase inhibitors. Bacterial gyrase inhibitors ciprofloxacin and nalidixic acid, and 
topoisomerase II inhibitors doxorubicin, etoposide, and mitoxantrone all induce DNA double 
strand breaks through this mechanism. DNA double strand breaks induced by the antitumor 
antibiotics bleomycin is mainly through reactive oxygen species associated DNA cleavage. DNA 
damage induced by these molecules requires double strand break repair which is homology directed 
repair (HDR) due the lack of non-homologous end joining (NHEJ) in E. coli250. Topoisomerase II 
inhibitors (doxorubicin, etoposide, and mitoxantrone), bleomycin, and mitomycin C have been 
commonly used in cancer chemotherapy, and the relatively similar phenotypic features observed 
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after treatments with these molecules and bacterial gyrase inhibitors (ciprofloxacin and nalidixic 
acid) offer insights that molecules inducing DNA strand breaks in mammalian cells can also induce 
DNA damage and repair responses in E. coli of the same type. Other molecules that mainly induce 
covalent adducts with DNA bases include nitrogen mustard compounds (chlorambucil, 
chlormethine, and BCEA), and Pt-containing DNA crosslinkers (cisplatin, carboplatin, and 
oxaliplatin). The DNA damage induced by these molecules is usually repaired by base excision 
repair (BER) and nucleotide excision repair (NER)238d, 251. A comprehensive analysis of phenotypic 
features including filament population, average filament size, and DNA morphology show that 
DNA damaging molecules inducing double strand breaks and HDR are separated from DNA 
damaging molecules that mainly induces DNA adduct formation and BER and NER repair. Slightly 
different is a molecule that induces direct oxidative damage, 4-NQO, which also showed a similar 
phenotypic profile to those requiring BER and NER as major repair mechanism252.  
Thus far, there have been three Pt-containing agents approved by the FDA for cancer 
chemotherapy, and their therapeutic effects are considered to be associated with DNA damage 
induced from DNA crosslinking. In a dose-dependent phenotype analysis of the three Pt-containing 
molecules, however, we are surprised to discover that oxaliplatin showed phenotypic features that 
are different from cisplatin and carboplatin. While it has long been assumed that all Pt agents share 
the same mechanism of action, a previous report showed that oxaliplatin induces altered DNA 
damage responses in E. coli compared with cisplatin and carboplatin45. In a recent report by Lippard 
and Hemann, an RNAi signature study showed mechanism of oxaliplatin may involve ribosome 
toxicity over DNA damage44. The shifted oxaliplatin phenotypic profile we observed in E. coli 
provided insights into a novel mechanism of oxaliplatin before it was demonstrated in mammalian 
cells. This study highlights that compounds with potentially multiple mechanisms of action can be 
distinguished from similar compounds that have fewer biological effects. 
Similar dose dependent studies were performed with topoisomerase inhibitors that induce 
DNA double strand breaks. As expected, some phenotypic features such as the filament population 
were dose dependent at 0.1 x MIC and 1 x MIC. However, other phenotypic features like the CV 
for DNA piece size showed consistency over the dose range. We propose that this consistency in 
DNA morphology indicates this is a key phenotypic feature associated with the compounds’ 
mechanisms of action. The phenotypic feature profiles for the topoisomerase inhibitors were 
differentiable when compared with the DNA crosslinking agent cisplatin and the ionizing 
mimicking molecule EMS at 0.1 x MIC and 1 x MIC, suggesting the phenotypic profiling results 
are consistent across dose points for molecules with the same mechanism of action, but differ when 
the mechanisms of action are different. This provides separation of these molecules over a wide 
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dose range and provides another simple method to differentiate molecules with similar phenotypic 
features at a single dose point.  
Research on morphological features of bacteria involving microscopy techniques have 
been performed in antibiotic research, but it is only recently that compilation and systematic 
analysis of various phenotypic features of cell and DNA morphology have been performed116. 
Reports from Pogliano prove that phenotypic features in E. coli are associated with the mechanisms 
of action for antibiotics, and the profiling can be used to classify anti-bacterial agents by their 
mechanisms. Our research includes commonly used chemotherapeutic agents that are usually 
studied only in mammalian cells and proves that when the mechanisms of actions involve general 
steps of the central dogma, it is feasible to study and identify the mechanism in E. coli. This would 
offer much faster insights into the possible mechanism of action and help to direct subsequent 
studies. As prokaryotic cell system lack organelles and biological processes exclusively found in 
mammalian cells, it is impossible to study those targets in E. coil. This disadvantage, however, 
could also be used as a fast method to discover if the mechanism involves common targets in both 
cell types, or rather only mammalian cell-exclusive targets, leading to rapid elimination of several 
potential mechanisms of action.  
4.8 Materials and Methods 
Cloning and expression of Dendra2 in E. coli. The gene encoding the photoconvertable 
protein, Dendra2, was cloned into a pCWori plasmid modified to contain an N-terminal 6x histidine 
tag with multiple restriction enzyme cloning sites.253 The pCWori-dendra2 plasmid was 
transformed into BL21(DE3) competent cells and selected on carbenicillin containing LB-Agar 
plates. A single colony was selected and cultured in Luria Broth (LB) at 37°C with 180 rpm shaking.  
The density of the E. Coli was calculated using the equation OD600 of 1.0 = 8 x 108 cells/ml. 
(http://www.genomics.agilent.com/biocalculators/calcODBacterial.jsp)  
Cytotoxicity determination. BL21(DE3) cells transformed with pCWori-Dendra2 plasmid 
were plated in M63 minimal medium at 4 x 106 cells per well in a 96 well flat bottom transparent 
tissue culture treated plate (Greiner Bio One). Compounds were added to the E. Coli such that the 
final concentration ranged from 0 - 300 µM. The cells were incubated for an additional 16 hours in 
an incubated shaker at 180 rpm and 37 ˚C. After 16 hours, the cell density was measured as 
described above. The OD600 values were normalized to the untreated E. coli cell control and fitted 
to a sigmoidal dose response equation using GraphPad Prism 6.02 to determine the IC50 values. To 
obtain the minimal inhibitory concentration (MIC), the OD600 values were fitted to the model 
published by Lambert et al. using GraphPad Prism 6.02.185  
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Protein synthesis and degradation measurements in E. coli with Dendra2. BL21(DE3) 
cells transformed with pCWori-Dendra2 were cultured in LB medium to an OD600 of 0.8. Cells 
were pelleted, the LB removed, the cells resuspended in M63 minimal medium, and induced with 
0.5 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) for 3 hours at 37 °C with 180 rpm shaking. 
Photoconversion of Dendra2 was carried out with a 405 nm LED flood array (Loctite, 0.6mW) with 
a total light exposure time of 2 minutes. Cells were then plated in 96 well plates at 6 x 107 cells per 
well. Green and red emission was measured immediately after photoconversion using a SpectraMax 
Multiwell Plate Reader (Molecular Devices) for a baseline evaluation of Dendra2 protein (t = 0 
hours). For the green emission, an excitation wavelength of 491 nm and an emission wavelength 
of 538 nm were used; for the red emission, the excitation wavelength was 544 nm and the emission 
wavelength was 590 nm. Compounds were then added to the cells at concentrations ranging from 
0 to 300 µM. The cells were incubated for an additional 16 hours before the green and red emission 
was measured again to quantify the change in protein synthesis due to compound treatment (t = 16 
hours). The average fluorescence ratio of green/red at t = 0 hour and t = 16 hours was calculated, 
the values were normalized, and the data were fitted to a sigmoidal dose response using GraphPad 
Prism 6.02.  
E. coli colony formation assay. BL21(DE3) cells transformed with pCWori-Dendra2 were 
cultured in LB medium to an OD600 of 0.08. Cells were resuspended in M63 minimal medium and 
plated at 3 x 108 cells per well in 24 well flat bottom transparent tissue culture treated plates 
(Greiner Bio One). Cells were dosed at MIC for each compound and cultured for 6 hours in an 
incubator shaker set to 37 °C and 180 rpm. The OD600 was measured for each treatment condition 
followed by the removal of culture that contained ca. 500 cells. Cells were pelleted by centrifuging 
at 8,600 xg for 2 minutes and the media was removed. Cells were then washed twice in 1 mL of 
sterile filtered PBS by centrifuging at 8,600 x g for 2 minutes, and the PBS was removed. Cells 
were resuspended in 50 µL of M63 medium and spread on agar coated wells prepared in 6 well 
plates. The agar plates were incubated at 37 °C for 16 hours. Images of the colonies were obtained 
using a ChemiDoc imager (Bio-Rad). Data analysis was done with object analysis function in 
ImageJ to quantify the number of colonies for each treatment condition, and normalized to the 
untreated control.  
E. coli filamentous growth. E. coli BL21(DE3) cells transformed with pCWori-Dendra2 
were cultured in LB medium to an OD600 of 0.08. Cells were then resuspended in M63 minimal 
medium and plated at 3 x 108 cells per well in 24 well flat bottom transparent tissue culture treated 
plates (Greiner Bio One). IPTG was added at a final concentration of 0.5 mM, followed by the 
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addition of compounds at desired concentrations. The cells were cultured for 6 hours in an incubator 
shaker set to 37 °C and 180 rpm.  
E. coli cell imaging. After compound treatment, the OD600 was measured for each treatment 
condition followed by the removal of culture that contained 4 x 105 cells. The cells were centrifuged 
at 8,600 xg for 1 minute, aspirated, and washed twice with 1 mL of sterile filtered PBS with 
centrifugation at 8,600 xg for 1 minute, and PBS was removed. Cells were then resuspended in 150 
µL of sterile filtered MilliQ water, and plated on a poly-D-Lysine (100 µg/mL) coated 1.5# cover 
glass bottom 35 mm culture dish. Cells were allowed to settle on the culture dish for 1 hour before 
gently rinsing with 150 µL of PBS. FM4-64 and Hoechst 33342 were added to the cells at 
concentrations of 5 and 10 µg/mL respectively. The cells were incubated at room temperature and 
protected from light for 20 minutes. The solution was removed from the cells followed by rinsing 
with 150 µL of PBS. Imaging was carried out on an Olympus IX2-RFAEVA-2 microscope or a 
Nikon A1R+ confocal microscope. For the Olympus microscope, a 60 x oil or a 100 x oil objective 
was used. Hoechst 33342 was visualized using the excitation filter BP 360-390 (Chroma, Bellows 
Falls, VT, USA), and emission filter HQ470/30 M (Chroma, Bellows Falls, VT, USA). To view 
Dendra2 (green), a 473/10 nm BrightLine® single-band bandpass filter FF01-473/10-25 (Semrock, 
Rochester, NY, USA) was used as the excitation filter, and a 525/50 nm BrightLine® single-band 
bandpass filter, FF03-525/50-25 (Semrock, Rochester, NY, USA) was used as the emission filter. 
FM4-64 was visualized with a HQ 550/30 (Chroma, Bellows Falls, VT, USA) as the excitation 
filter, and a 664 nm EdgeBasic long-pass edge filter, BLP01-664R-25 (Semrock, Rochester, NY, 
USA) as the emission filter. The imaging channel sequential was set as FM4-64, Dendra2 (green), 
and Hoechst 33342. For each single field of view, a 1024 x 1024 pixel image was taken. Imaging 
on the Nikon A1R+ confocal microscope was performed with a 100 x oil objective and the zoom 
in factor was 1 x. Hoechst 33342 was visualized on the 405 nm channel with 5% laser excitation 
and 100% gain, offset was -25% to -50%. Dendra2 (green) was viewed on the 488 nm channel with 
1% laser excitation and 25% gain, offset was -25% to -50%. FM4-64 was visualized on the 561 nm 
channel with 5% laser excitation and 50% gain, offset was -25% to -50%. Imaging channel 
sequential was set as FM4-64, Dendra2 (green), and Hoechst 33342. For each single field of view, 
a 1024 x 1024 pixel image was taken, and a 3 x 3 image stitch was taken using the same setting.  
Analysis of E. Coli images for filaments and DNA morphology quantification. Images were 
processed and analyzed using the ImageJ software. For each single image, to analyze cell filaments, 
the threshold of FM4-64 channel was adjusted to match the original image, and any particles 
smaller than 0.2 µm2 were excluded from measurements; size exclusion was only applied in FM4-
64 channel for cell size and number analysis. All measurement results from “Analyze Particles” 
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were saved in a Microsoft Excel file. The filament population (%) was calculated as the percentage 
of all particles larger than 5µm2, and the average filament size and standard deviation of filament 
size was also calculated using the statistical function of Microsoft Excel. To analyze DNA 
morphology, the threshold for Hoechst 33342 channel was adjusted to match original image. The 
ROI manager was used to match the DNA with the cell, and a certain filament was selected and set 
as region of interest (ROI). Then the number of DNA pieces of each filament was obtained by 
“Analyze Particles”. In each treatment condition, 30-50 filaments were selected and analyzed. All 
measurement data were saved in Microsoft Excel files. The average DNA pieces in filaments were 
calculated by dividing the number of all DNA pieces by number of filaments. The average size of 
DNA pieces, and standard deviation of DNA pieces, were also calculated with the statistical 
function of Microsoft Excel. To obtain the magnitude of variation in sizes of DNA pieces, the 
coefficient of variation (CV) was calculated by dividing the standard deviation of DNA pieces by 
the average size of DNA pieces.  
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Chapter 5. Elucidation of the mechanism of action of Ru(II) polypyridyl compounds 
containing hydroxyquinoline (HQ) ligand 
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5.1 Introduction. 
 The small molecule 8-hydroxyquinoline (HQ) and its derivatives have a broad variety of 
medicinal applications including anticancer, antibacterial, and antifungal effects.254, 255 In the past 
few decades, research interest in HQ and its derivatives has been focused on both developing novel 
chemically modified molecules and understanding the mechanism of actions of HQs.256 The 
presence of nitrogen and oxygen atoms in the HQ makes it a suitable bidentate chelating agent for 
metals.256 Free HQ ligands can thus bind endogenous metals and aid in their transport, or 
alternatively, can form metal complexes with new properties. 
 The metal chelating property of HQ and derivatives have raised research interest in 
synthesizing metal complexes containing HQs as ligands. Many transition metal compounds 
bearing HQ ligands have been synthesized and studied for their biological activities including 
antimicrobial and anticancer properties. Liu and co-workers have reported ruthenium polypyridyl 
compounds containing HQ ligand showing antitumor activities.257 A series of antitumor metal 
compounds containing HQ ligands with platinum (II), copper (II), and iron (III) as metal centers 
have been reported by Hong Liang and co-workers.258, 259, 260 A gallium (III) compound, KP46, 
containing the HQ ligand (tris(8-quinolinolato)gallium) has been successfully tested in renal cancer 
in a Phase I clinical trial.261 
 Efforts have also been made to understand the mechanisms of actions for the metal 
compounds containing HQ and derivative ligands. Given the fact that classical metal compounds 
approved by the FDA for chemotherapy are mostly DNA damaging agents, much of the previous 
and current research focused on the nucleic acid interacting ability of metal compounds with HQ 
ligands. Liang and Alemán have both reported DNA binding properties and associated 
cytotoxicities of zinc and gold compounds with HQ ligands.262, 263 Studies on ruthenium compounds 
with HQ ligand by Liu, however, indicate alternative mechanisms that are not DNA related, but 
rather through interactions with basic fibroblast growth factors (bFGF) and inhibition of ERK and 
Akt pathways.257 
 It has been previously reported by our group that by chelating HQ ligands with ruthenium 
metal centers, the cytotoxicity of the HQ compounds is significantly increased in cancer cells.264 
The mechanism of action of Ru(II) HQ compounds, however, remains unclear. In addition to 
understanding of the structure activity relationship (SAR), it is also important to elucidate the 
functional targets and mechanisms of actions to improve the chemical design of HQ compounds, 
and to increase the possibility of the HQ compounds serving as potential candidates for cancer 
chemotherapy. 
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Chart 5.1 Structures of compounds HQ-1 to HQ-7. 
 
5.2 Cell death kinetics and uptake of HQ compounds in mammalian cells. 
 Cell death kinetics and cellular accumulation were studied in human promyelocytic 
leukemia HL60 cells. As shown in Figure 5.1, both Ru(dmphen)2-8-hydroxy-2-methylquinoline 
(HQ-1) and Ru(dmphen)2-clioquinol (HQ-2) were able to induce > 50% and > 90% cell death in 
24 hours for HQ-1 and HQ-2 respectively. In a washout study, HL60 cells were treated with a 
certain concentration (20 µM) of both compounds for specified periods of time (3, 6, 12, 24 hours), 
followed by removal of compound and incubation with compound free media for 72 hours before 
cell death was quantified. In all treatment conditions, over 95% of cell death was observed, even 
with only 3 hours of treatments with HQ-1 and HQ-2. A detailed washout study performed with 
HQ-1 examining the effects of decreased treatment time showed that 30 minutes of HQ-1 treatment 
lead to 90% of cell death. This suggests that treatment of 30 minutes or less with HQ compound is 
able to induce the maximum cytotoxic effects.  
As the cytotoxicity could be affected by the cellular accumulation of compounds, 
ruthenium content was determined using inductively coupled plasma optical emission spectrometry 
(ICP-OES) in HL60 cells (Figure 5.1C). After 6 hours of treatment with HQ-1, the cellular 
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ruthenium content level was 1.18 x 109 ruthenium atoms per HL60 cell, which was 10-fold more 
than the ruthenium content in cells treated with Ru(bpy)2dmbpy (compound 1), a light-activated 
Ru(II) polypyridyl compound described in Chapter 3. The ruthenium content level increased to 
1.68 x 109 ruthenium atoms per HL60 cell after 20 hours; treatment of HQ-1, comparing to 1.30 x 
108 ruthenium atoms per HL60 cell in compound 1 treated cells. The cellular metal content study 
revealed the fact that HQ-1 accumulates in HL60 cells much faster than compound 1, and this fast 
accumulation primarily occurs during the first 6 hours after treatment.   
 
 
Figure 5.1 HQ compounds induce quick cell death and fast cellular accumulation in HL60 cells. In 
both A) and B), HQ-1 is represented in red, and HQ-2 is represented in blue. A) Time dependence 
for cell death. HL60 cells were treated with 2 µM of compounds, and cell death was determined by 
Trypan Blue staining of membrane corruption at various time points. B) Wash out experiment. 
HL60 cells were treated with 2 µM of compounds, and after certain periods of time (3, 6, 12, 24 
hours) the cells were washed and incubated in compound free media. Cell death was determined 
72 hours later by resorufin conversation. C) Relative metal uptake. HL60 cells were treated with 
20 µM of compounds, after 6 hour and 20 hour, cells were isolated and Ru(II) metal content was 
determined with ICP-OES. 
 
The rapid cellular accumulation of HQ-1 could possibly contribute to the fast cell death 
and the very short treatment time needed to exhibit maximum cytotoxicity. Given the lack of direct 
correlation of cytotoxicity values to measured ruthenium level in the cell (IC50 values in Table 3.3, 
and Table S4.1 in Appendix), the shift in cell death kinetics can’t be solely attributed to elevated 
cellular uptake or different uptake kinetics. Thus, the cytotoxicity of HQ-1 and HQ-2 likely 
involves a mechanism of action where the two compounds have different potencies.  Though it can 
be predicted that other HQ compounds likely accumulate in cells at similar level, further studies on 
cellular uptake of other HQ compounds listed in Table S4.1 is to be done in future work. 
5.3 HQ compounds induce apoptosis in mammalian cells through a p53 independent pathway. 
Apoptosis induced by HQ-1 and HQ-2 was confirmed by immunoblotting in the human 
alveolar adenocarcinoma A549 cell line and flow cytometry in HL60 cell line (see Figure 5.2). 
A549 cells were used for the immunoblot analysis rather than HL60 cells because HL60 cells are 
naturally p53 deficient and therefore A549 cells were used to study p53 related mechanism.Cells 
at early apoptotic and late apoptotic phases were determined in HL60 cells by propidium iodide 
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(PI) and fluorescein isothiocyanate (FITC)-Annexin V staining. The cells positively stained with 
FITC-Annexin V but not PI are characterized as early apoptotic, while cells positively stained with 
both PI and FITC-Annexin V are identified as late apoptotic cells, and therefore can be 
distinguished from the viable cells that are not stained by either of the fluorophore. As shown in 
Figure 5.2B and C, treatment with HQ-1 didn’t induce significant apoptosis at 3 hour; by 8 hour, 
there were 10% of cells at early apoptotic phase and 5% of cells at late apoptotic phase, similar to 
the untreated control. These number increased to 25% and 40% at 16 hour. In HQ-2 treated cells, 
a similar trend was observed; after 8 hours of treatment, there were 6% of early apoptotic cells and 
7% of late apoptotic cells, while at 16 hour, 20% of early apoptotic cells and 43% of late apoptotic 
cells were observed. This flow cytometry determination of apoptotic cells over 16 hours after 
treatment confirmed that the cytotoxic effects happen quickly after HQ compound treatments. 
 
 
Figure 5.2 HQ compound induces apoptosis in cancer cells through p53 independent pathways. A) 
A549 cells were treated with 2 µM of HQ-1 for specific periods (3, 6, 12, and 24 hours respectively); 
cisplatin (20 μM) and doxorubicin (2 μM) at 24 hours of treatment were used as controls. GAPDH 
was used as loading control. HL60 cells were treated with 2 µM of HQ compounds for specific 
periods (3, 8, and 16 hours) before analysis by flow cytometry. Cells with positive FITC-Annexin 
V staining and negative PI staining were identified as early apoptotic cells as in B); cells with both 
positive FITC-Annexin V and PI staining were identified as late apoptotic cells as in C). Red, 3 
hour; blue, 8 hour; green, 16 hour. 
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Hallmarks of apoptosis such as PARP and caspase 9 cleavage were observed by 
immunoblotting in A549 cells as early as 12 hours. The cleavage of PARP and caspase 9 indicate 
the executionary phase of intrinsic apoptosis downstream of mitochondria permeabilization and 
release of cytochrome c into cytoplasm. Interestingly, no significant changes in p53 expression and 
phosphorylation were seen in A549 cells, and p21 expression was not changed as well. This result 
suggests the cytotoxicity and apoptosis induced by HQ-1 is not through p53 dependent pathways, 
which play central roles in cellular stress responses. In contrast, the commonly used 
chemotherapeutic agents doxorubicin and cisplatin both induced dramatic increases in p53 and p21 
expression and p53 phosphorylation. This result indicates the HQ compounds likely have different 
mechanism of action compared with doxorubicin and cisplatin as they induce alternations in 
signaling pathways that are key components of cellular activities. 
 
 
 
Figure 5.3 HQ compound induces downregulation of Akt pathways in A549 cells. A549 cells were 
treated with 2 µM of HQ-1 for specific periods (3, 6, 12, and 24 hours respectively). Cell lysates 
were made for immunoblotting, with cisplatin (20 μM) and doxorubicin (2 μM) at 24 hours of 
treatment used as controls. GAPDH was used as loading control. 
 
 Detailed studies on cell signaling pathways involved in cellular stress response, cell growth, 
and proliferation by immunoblotting in A549 cells revealed that HQ compounds induce altered 
signaling pathways (Figure 5.3). Compared with doxorubicin and cisplatin, HQ-1 induced down 
regulation of both JNK and c-jun phosphorylation, suggesting the JNK mitogen-activated protein 
kinases (MAPKs) pathway was inhibited upon treatment of HQ-1; the treatment also didn’t activate 
p38 phosphorylation, suggesting the p38 MAPK pathway was not activated in response to HQ-1 
treatment; ERK phosphorylation remained at basal level for all treatment conditions. These three 
MAPKs pathways are mainly responsible for cell proliferation, survival and apoptosis regulation 
in response to cellular stress.265, 266, 267 Another significant change in signal transduction was down 
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regulation of the Akt pathway upon treatment of HQ-1. Both Akt expression (pan Akt) and the 
phosphorylation (p-Akt) were inhibited as early as 6 hours after treatment of HQ-1, the same 
inhibition was also observed for PDK-1 phosphorylation, the upstream activator of Akt pathway, 
proving that down regulation of the Akt pathway occurs in response to HQ-1 treatment. The Akt 
pathway is a key signal transduction pathway in cell survival and growth by regulating a wide range 
of downstream signals.268, 269, 270 The down regulation of the Akt pathway by HQ-1 reveals that the 
mechanism of action is associated with the inhibition of cell growth and proliferation activities. 
Notably, similar inhibition of the Akt pathway was also reported by Jie Liu et al., with inhibition 
of ERK pathway.257 These results also suggest that the mechanisms of HQ compounds possibly 
involve Akt inhibition to promote cell death.  
 
Figure 5.4 DNA gel electrophoresis of compound HQ-1. Agarose gel electrophoresis of pUC19 
plasmid treated with compound HQ-1. Lane 1, and 12: molecular weight marker; Lane 2: double 
strand breaks caused by EcoR1 (linear DNA); Lane 3: single strand breaks caused by Cu(phen)2 
reaction (relax circle); Lane 4 – 11, DNA treated with compounds dosed at increasing concentration 
(2-fold dilution per lane) from 0 to 500 μM. 
5.4 Cytotoxicity of HQ compounds is not associated with cell membrane disruption or DNA 
damage. 
 The rapid cell death kinetics and cellular ruthenium accumulation raised the question if the 
HQ compounds exhibit cytotoxic effects through corruption of the cell membrane. Both 
mammalian cells and E. coli cells were studied to understand if the cell membrane was 
compromised with HQ compound treatment. In the cell death kinetics studies, HL60 cells were 
stained with Trypan Blue which is commonly used in the dye exclusion test as it enters the cells 
that are permeable during apoptosis or necrosis and is excluded from viable cells. Upon treatment 
with compound HQ-1 and HQ-2, the dead cells that were stained as dark color by Trypan Blue had 
intact membranes. In a microscopy study of human embryonic kidney (HEK) cells to be discussed 
in detail in later sections (Figure 5.9 – 5.13), the lack of fluorophore-conjugated HQ compounds 
highlighting the cell membrane also suggested that the cell membrane is not the primary target of 
HQ compounds in mammalian cells. In the bacterial cytological profiling studies in E. coli used to 
further understand the mechanism of action of the HQ compounds, it was also observed the E. coli 
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cells were intact after HQ compounds treatment (Figure 5.6). Studies in both eukaryotic cells and 
prokaryotic cells have demonstrated the HQ compounds don’t act through disrupting the cell 
membrane as a detergent.  
 It has been reported that metal complexes bearing HQ ligand may interact with DNA as 
intercalators271, 272 or alkylating agents273; a previous study by Glazer lab members Mr. Brock 
Howerton and Dr. David Heidary, however, proved the ruthenium compound, HQ-2, didn’t affect 
the function of DNA in the process of central dogma.264 DNA gel electrophoresis also confirmed 
there was no visible DNA mobility shift at the cytotoxic concentrations (the IC50 in HL60 and E. 
coli) observed with HQ-1 treated pUC19 plasmid DNA. In fact, the concentrations needed for HQ-
1 to induce a DNA mobility shift was significantly higher than the concentrations to induce 
cytotoxic effects in both eukaryotic and bacterial cells, suggesting DNA was not the target involved 
in HQ compounds’ activity. 
 
Figure 5.5 HQ compounds induce translation inhibition in E. coli. IC50 values for growth inhibition 
in E. coli were measured 16 hours after drug treatment, while inhibition of translation was measured 
by following the production of Dendra2 in a 16-hour time course study after drug treatment. The 
IC50 index is defined as the IC50 value for translation inhibition/IC50 value for growth inhibition. 
5.5 HQ compounds exhibit cytotoxicity in association with translation inhibition in E. coli. 
 Given the complexity of the eukaryotic cells, E. coli was employed as a simple model 
system to study the mechanism of action of the HQ compounds. By comparing the IC50 values for 
growth inhibition and translation inhibition in E. coli, the IC50 index was determined. This index is 
described in Chapter 4; in brief, the IC50 index is the IC50 for translation inhibition/IC50 of growth 
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inhibition. The Log value of the IC50 index was used to get a quick comparison of the two IC50 
values, as shown in Figure 5.5. DNA damaging molecules and transcription inhibitors all have 
positive Log IC50 index values, which means the concentration needed for translation inhibition is 
larger than that needed to achieve growth inhibition, suggesting the mechanism of cytotoxicity of 
these molecules are unlikely to be through translation inhibition. The translation inhibitors, 
however, all have negative Log IC50 index values, suggesting a smaller IC50 value of translation 
inhibition compared with growth inhibition, and indicating that the mechanism of cytotoxicity is 
likely through translation inhibition. Interestingly, most of the HQ compounds studied also have a 
negative Log IC50 index value, indicating that the mechanism of action of HQ compounds could be 
associated with translation inhibition effects. 
 
Figure 5.6 HQ compounds induce phenotypic feature changes in E. coli that are typical of 
translation inhibitors. A) HQ-2; B) HQ-3; C) HQ-4; D) HQ-5; E) HQ-6; F) HQ-7. E. coli cells were 
treated at 5 x MIC of each compound for 6 hours and then stained and imaged. FM4-64 (red) was 
used to stain the cell wall while Hoechst 33342 (cyan) was used for DNA. The stains were incubated 
with the cells for 15 minutes prior to imaging with Nikon A1R confocal epifluorescence 
microscopy. Scale bar represent 10 μm in all images. 
 In a previous research, Glazer group members, Dr. Heidary and Mr. Brock Howerton 
studied the ability of HQ-2 to inhibit transcription and/or translation activity using a coupled in 
vitro transcription and translation (IVTT) assay, and reported that HQ-2 didn’t affect the 
transcription or translation process.264 While it seems the observation of translation inhibitory 
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effects in E. coli is not consistent with the reported IVTT results, it is noteworthy that the IVTT 
assay uses the T7 promoter and an EMCV IRES (encephalomyocarditis virus internal ribosomal 
entry site) to facilitate in vitro protein synthesis using Hela cell lysate(1-Step Human Coupled IVT 
Kit, Thermo Fisher Scientific). The incorporation of the two viral RNA elements could possibly 
explain the results that HQ-2 didn’t show inhibitory effects in the IVTT assay. The IRES is a RNA 
element that allows the ribosome to initiate translation bypassing the 5’-cap of eukaryotic mRNA 
which is essential for the majority of eukaryotic translation activities.274, 275 The 5’-cap independent 
translation through IRES, therefore, don’t require certain eukaryotic initiation factors (eIFs) to 
initiate translation process in eukaryotic cells while those specific eIFs and the bacterial analogous 
initial factors (IFs) could be the target of HQ compounds to achieve translation inhibitions as the 
translation initiation factors are relatively conserved.276, 277, 278 Moreover, the 5’-cap independent 
translation has been reported to contribute to cell survival in response to cell stress and translation 
inhibition. 279 It could then be explained that HQ-2 didn’t show effects in the IVTT assay was 
because of the introduction of a possible salvage mechanism.   
5.6 E. coli phenotypic profiling identifies HQ compounds as potential translation inhibitors. 
 To further understand the mechanism of action of HQ compounds, microscopy based 
cytological profiling was performed as described in Chapter 4. Similar to the translation inhibitors 
tetracycline, kanamycin, and chloramphenicol, HQ compounds didn’t induce significant 
phenotypic changes in E. coli when dosed at the minimal inhibitory concentration (MIC). Instead, 
a concentration of 5 x MIC was required for each HQ compound to induce the phenotypic changes 
without significant cell killing. Surprisingly, all HQ compounds were able to induce similar 
phenotypic changes as those induced by classical antibiotics with direct translation inhibition 
mechanisms. In response to HQ compounds treatments, a subpopulation of E. coli cells formed 
filaments with multiple DNA pieces of uniform size distributing evenly in the cells (Figure 5.6, 
Figure 4.4D). This is different from transcription inhibitors, for which there was a single piece of 
DNA spreading the length of the filament observed though the population of cells forming 
filaments; the average filament sizes were similar for the two treatments. Compared with molecules 
with DNA damaging mechanisms, HQ compounds didn’t induce irregularly sized DNA pieces, and 
the population percent forming filaments and the average filament size were generally smaller than 
most DNA damaging molecules. 
 Detailed statistical evaluation of the data was performed for the same phenotypic features 
as described in Chapter 4. The key features that serve to distinguish molecules with different 
mechanism of action include the % filament population, average filament size, average DNA pieces 
per filament, and the coefficient of variation (CV) of DNA piece size. These features were analyzed 
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and compared between molecules with known mechanisms of actions and the HQ compounds with 
unknown mechanisms. As shown in Figure 5.7, in response to HQ compound treatments, about 30% 
to 40% of cells formed filaments that were over 5 µm in length and the average size of the observed 
filaments was below 10 µm. These data were consistent with imaging observations, and 
distinguished HQ compounds from most DNA damaging molecules. An analysis of the average 
DNA pieces in each filament revealed differences between HQ compounds, transcription inhibitors, 
and DNA damaging molecules. Unlike transcription inhibitors, most HQ compounds induced 
multiple pieces of DNA in filaments, but the number of DNA pieces were generally smaller than 
those induced by DNA damaging molecules. The HQ compounds also induced DNA pieces of 
regular sizes, similar to the translation inhibitors, generating smaller CV values of DNA piece sizes 
compared with all DNA damaging molecules. These phenotypic profiling results helped to separate 
HQ compounds from molecules with DNA damaging or transcription inhibition mechanisms. 
 
Figure 5.7 HQ compounds induce similar phenotypic profiles to translation inhibitors. Cells were 
treated with drugs at the MIC for 6 hours prior to imaging, while translation inhibitors were dosed 
at 10 x MIC and HQ compounds were dosed at 5 x MIC. Multiple fields of view were analyzed for 
300-500 cells. A) Graph of filament population (%) as a function of drug where E. coli of over 5 
µm were identified as filaments. B) Box and whisker plot shows the dispersity of the overall 
(whisker) and major 50% (25% to 75%, in box) range of the E. coli filaments. C) The average 
number of DNA pieces in each filament as a function of drug. The error bar is not an error in 
measurement; rather it is a reflection of dispersity in the number of DNA pieces per cell, similar to 
the variation in the DNA piece size. D) The coefficient of variation (CV) for the size of the DNA 
piece in each filament. Molecules of diverse mechanisms are color coded as follows: ● Pt based 
DNA crosslinker; ● nitrogen mustard; ● oxidizing agent; ● bacterial gyrase inhibitor; ● 
topoisomerase II inhibitor; ● ionizing radiation mimicking agent; ● DNA strand breaker; ● 
transcription inhibitor; ● translation inhibitor; ● HQ compounds. 
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 Data from phenotypic profiling were also used in a multi-dimensional data analysis. The 
filament population (%), average number of DNA pieces in filament, and CV of DNA piece sizes 
were used for all molecules with a known mechanism of action and the HQ compounds. In the 3D 
scatter plot, all HQ compounds (shown in purple, Figure 5.8) clustered with translation inhibitors 
(shown in cyan), and this cluster is well separated from transcription inhibitors and molecules with 
DNA damaging mechanisms. This multi-parameter phenotypic profiling in E. coli strongly 
suggested HQ compounds possess a mechanism of action involving translation inhibition. Though 
this result is obtained in a bacterial system, given that the translation process is a common step in 
the central dogma of molecular biology and is present in both prokaryotic and eukaryotic cell 
system, the cytotoxic effects of HQ compounds in cancer cells could possibly involve translation 
inhibition as well. Indeed, these results were consistent with concurrent studies on inhibition of 
protein translation in mammalian cells (performed by Dr. David Heidary; unpublished results). 
 
 
 
Figure 5.8 Distinguishing HQ compounds from molecules with DNA damaging or transcription 
mechanisms based on the phenotypic change observed in E. coli. Cells were treated with molecules 
at their MIC for 6 hours prior to imaging, translation inhibitors were dosed at 10 x MIC, HQ 
compounds were dosed at 5 x MIC for phenotypic changes. Same phenotypic features as used for 
Figure 5.6 were analyzed with OriginPro 2017. 
 
 
86 
 
 
Chart 5.2 Structures of probes and conjugated HQ compounds used in live cell imaging for 
subcellular localization study. 
 
5.7 Investigation of subcellular localization of HQ compounds in living cells through BODIPY 
conjugation. 
 Bacterial cytological profiling suggested the mechanism of action of HQ compounds likely 
involves translation inhibition. Given the complexity of eukaryotic cell structure and the 
significantly increased number of possible targets, any conclusions obtained from bacterial cells 
required confirmation in mammalian cells. Additional imaging studies offered an approach to 
rapidly determine if the HQ might be interacting with the translational machinery in mammalian 
cells. For this purpose, a red fluorophore boron-dipyrromethene TR-X (BODIPY) was conjugated 
to the ruthenium polypyridyl compound containing the hydroxyquinoline ligand (Ru(dmphen)2-
5,7-dichloro-8-hydroxyquinoline) to form the conjugated compound (HQ-BODIPY) by a group 
member Dr. Dmytro Havrylyuk. The biological activity of HQ-BODIPY was confirmed in 
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mammalian cells by another group member, Dr. David Heidary. With the efforts and support of 
scientists in the group, it was possible to directly study the localization of HQ compounds in 
mammalian cells, and detect the colocalization with eukaryotic organelles. Multicolor fluorescence 
confocal microscopy was employed using Human Embryonic Kidney cell lines (HEK) stably 
expressing GFP conjugated organelle marker proteins to determine the localization of the BODIPY 
conjugated HQ compound (HQ-BODIPY); Hoechst 33342 dye was used to stain the nucleus. 
 Protein synthesis associated organelles were of primary interest; as bacterial cytological 
profiling revealed translation inhibition effects, the endoplasmic reticulum (ER) and ribosome were 
therefore studied first. ER targeted transmembrane domain (CytERM) with enhanced green 
fluorescent protein (EGFP)280, 281  and large ribosomal subunit protein 10A (RPL10A) with GFP282 
have been used to visualize the two organelles.  HEK cells expressing either ER targeted 
transmembrane domain with GFP (CytERM-GFP) or large ribosomal subunit protein 10A with 
GFP (RPL10A-GFP) were treated with HQ-BODIPY for 6 hours and stained with Hoechst 33342. 
As shown in Figure 5.9, the overlay of red fluorescent channel from HQ-BODIPY and the green 
channel from CytERM-GFP generated the bright yellow region in the cells, suggesting that there 
was colocalization of HQ-BODIPY at the ER. Further analysis of GFP (green) and BODIPY (red) 
showed a strong correlation with the Pearson’s correlation coefficient (PCC) of 0.80, as listed in 
Table S4.3 in the Appendix, which revealed the correlation of HQ compound and the protein 
synthesis organelle. Notably, the cytoplasmic accumulation of free BODIPY dye also resulted in 
partial colocalization in the ER with a PCC value of 0.60, suggesting BODIPY could contribute to 
the localization of HQ-BODIPY (Figure 5.18). The ribosome, however, was not identified as a 
direct target of HQ-BODIPY, as the compound didn’t accumulate in this structure (Figure 5.10). 
This ribosomal protein has both nuclear and cytoplasmic distribution as ribosomal proteins are 
normally transported into nucleus for ribosome biogenesis.283 Both HQ-BODIPY and free 
BODIPY localized in cytosol, so there was no overlap with nuclear ribosomal protein. In both HQ-
BODIPY and free BIDOPY treated cells, there was no detectable colocalization of the BODIPY 
fluorescence and GFP fluorescence as indicated by the lack of a yellow region in the merged images, 
and the poor PCCs listed in Table S4.3 in Appendix (-0.03 for HQ-BODIPY and 0.03 for free 
BODIPY, respectively). 
The Golgi apparatus is the organelle responsible for packing protein into vesicles that are 
involved in protein transportation and secretion, and therefore could be one of the possible target 
of the HQ compounds. Direct visualization of HQ-BODIPY in HEK cells expressing the Golgi 
apparatus marker, human galactosyltransferase (GalT) with GFP (GalT-GFP)284, showed that HQ-
BODIPY didn’t localize in this organelle (Figure 5.11), nor did the free BODIPY control. The well 
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separated BODIPY fluorescence (red) and the GalT-GFP fluorescence (green) in the merged 
images clearly showed the lack of colocalization of HQ-BODIPY and the Golgi apparatus. Low 
correlation between the Golgi marker and the BODIPY including both free BODIPY and HQ-
BODIPY is also reflected by the low PCC values listed in Table S4.3. As the organelle with a 
dominant role to produce energy needed for all cellular activities, mitochondria has drawn 
significant research interest and there have been several ruthenium compounds targeting 
mitochondria,285, 158, 286 including a ruthenium polypyridyl complex targeting mitochondria reported 
in Chapter 2. For this reason, a mitochondria marker mitochondrial matrix-targeted photoactivable 
GFP (mito-paGFP)287 was used to visualize this organelle. As shown in Figure 5.12 and Figure 
5.18, there was medium overlap of red fluorescence from HQ-BODIPY and the green fluorescence 
from mito-paGFP, the correlation level as indicated by PCC (0.33 to 0.3 for HQ-BODIPY, and 
0.55 to 0.34 for free BODIPY) also suggested that the observed HQ compound accumulated in the 
mitochondria is most likely the artificial effects of BODIPY localization. 
 Human purine nucleoside phosphorylase with GFP (PNP-GFP) was used as the marker 
protein of peroxisomes. As shown in Figure 5.13 and Figure 5.18, the BODIPY conjugated HQ 
compound HQ-BODIPY and the fluorophore BODIPY both had partial colocalization with 
peroxisome as indicated by the yellow region observed in the merged images.  Pearson’s correlation 
coefficients also suggest a medium to strong correlation with the green fluorescence detected from 
PNP-GFP and the red fluorescence detected from HQ-BODIPY and free BODIPY. The PCC 
values ranged from 0.6 to 0.7 in both HQ-BODIPY and BODIPY treated cells (Table S4.3 in 
Appendix). It is again indication of the localization of HQ compounds could be affected by the 
localization of the conjugated fluorophore.  
The same organelle imaging was done with BODIPY conjugated to another HQ compound 
Ru(bpy)2-5,7-dichloro-8-hydroxyquinoline (HQ-BODIPY-2). This compound was also 
synthesized by Dr. Dmytro Havrylyuk by using a different polypyridyl scaffold which produces 
less active compounds. Dr. David Heidary evaluated the biological activity in mammalian cells. 
Since HQ-BODIPY-2 didn’t show cytotoxic effects in HL60 cells, it was used as a negative control 
to understand the localization of HQ compounds and the connections between the localization and 
cytotoxic effects. Similar results were observed in HEK cells showing partial colocalization of HQ-
BODIPY-2 with the ER (PCC was 0.80). The similar colocalization of HQ-BODIPY, HQ-
BODIPY-2, and BODIPY at the ER suggested the connection between translation inhibitory 
effects and the subcellular localization of HQ compounds is to be further validated by isolating 
organelles for direct metal amount analysis or conjugating a different fluorophore to HQ 
compounds (Figure S4.1, S4.2, and Table S4.3 in Appendix). 
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5.8 HQ compounds partially colocalize with endoplasmic reticulum (ER). 
 The highly consistent imaging results for HQ-BODIPY, HQ-BODIPY-2, and the 
BODIPY control indicated that the subcellular localization of both BODIPY conjugated HQ 
compounds is largely dominated by the subcellular localization of the commonly applied 
commercial organic probe BODIPY. It was therefore necessary to use an alternative probe to 
visualize the HQ compounds in mammalian cells. Certain luminescent ruthenium(II) polypyridyl 
complexes have the potential to be used as novel probes in cellular imaging because they have 
many appropriate properties, including low cytotoxicity and high photostability.288, 289 Our group 
has extensively studied the photophysical and photochemical properties of Ru(II) polypyridyl 
complexes, and as described in Chapter 2, the subcellular localization of two Ru(II) polypyridyl 
complexes has been studied utilizing the intrinsic luminescence of those two molecules. To further 
understand the subcellular localization of HQ compounds, Dr. Dmytro Havrylyuk used a Ru(II) 
compound, Ru(bpy)2phenamine (PA), as the alternative probe, and a HQ compound was conjugated 
to the probe. The conjugated compound (HQ-PA) was then used to study the subcellular 
localization of HQ compounds. As shown in Figure 5.14 to 5.17, no clear subcellular localization 
of PA in the selected organelles were detected as the red fluorescence from PA and green 
fluorescence from organelle markers were not observed, suggesting PA has no organelle localizing 
preferences. This result is consistent with the low PCC values for PA and all organelle markers. 
The conjugated molecule HQ-PA exhibited subcellular localization in the ER as shown by the 
yellow region from the overlap of HQ-PA (red) and the organelle marker CytERM-GFP (green). 
The result was also confirmed by the high PCC values, suggesting a strong correlation as shown in 
Table S4.4 in the Appendix. However, unlike HQ-BODIPY and HQ-BODIPY-2, the molecule 
HQ-PA didn’t show subcellular localization in other organelles, including the mitochondria and 
peroxisome (Figure 5.18).  
 BODIPY-based fluorophores have been frequently and widely conjugated to various 
targets as imaging probes.290, 291 The research utilizing BODIPY includes examining subcellular 
localization of targets of interests in living cells.292, 293 BODIPY has also gain commercial 
applications as manufactured imaging reagents because of the low cytotoxicity and broad 
fluorescent properties that can be easily tuned by simple chemical modifications.290, 294 However, 
the live cell imaging results of HQ-BODIPY, HQ-BODIPY-2, and BODIPY showed that 
BODIPY may preferably localize in certain organelles (ER and peroxisome in this study) and alter 
the subcellular localization of the molecules of interest conjugated to BODIPY. Recently, Zhang 
et al. reported silver mediated modification of BODIPY produced a derivative with enhanced ER 
localization.295 This research has also confirmed the BODIPY derivatives have certain subcellular 
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localization preferences. Ru (II) chromophores have been used as staining reagents such as SYPRO 
Ruby in proteomics researches.296 Increased research interests have been drawn to utilize Ru (II) 
complexes as novel imaging probes as they have low cytotoxicity and rich photophysical and 
photochemical properties that allow easy chemical designs.297, 298, 299 The imaging results of 
luminescent Ru (II) molecule PA and the conjugated HQ molecule HQ-PA described in this 
chapter has also shown that Ru (II) polypyridyl complexes are superior in live cell imaging studies 
of subcellular localization as they have minimized subcellular localization preferences.  
5.9 Conclusion. 
 Ruthenium polypyridyl compounds bearing HQ ligands have received much research 
interest, with most previous and current research still focused on nucleic acid associated biological 
activity.300, Our research, however, developed HQ-containing Ru(II) complexes that are highly 
potent, and the potency depended on not only the HQ structure, but also the structure of the Ru(II) 
complex co-ligands. Moreover, the HQ compounds induce cytotoxicity through a non-DNA target, 
and the mechanism of action of HQ compounds is associated with translation inhibition in both 
bacterial and mammalian cells.  
The mammalian cell death kinetics and cellular uptake studies showed the HQ compounds 
were more efficient in accumulating in cells and inducing cell death compared with cisplatin or 
ruthenium compounds described in previous chapters that have a DNA related mechanism. The 
cell signaling pathway studied in cancer cells revealed downregulation of the Akt pathway which 
plays a central role in cell proliferation, growth, and survival regulation.270, 269 Liu et al. has reported 
consistent Akt pathway inhibition in cancer cells by ruthenium polypyridyl compounds containing 
HQ ligand by immunoblottings257, suggesting a common cell signaling pathway in response to HQ 
compound treatment. To further elucidate the possible target and mechanism of action, bacterial 
cytological profiling obtained using high-resolution imaging as described in previous chapters was 
employed. Quite to our surprise, all studied HQ compounds induced phenotypic feature changes 
that were typical of translation inhibitors, and the statistical evaluation of multiparameter plots 
revealed the tight cluster of translation inhibitors and HQ compounds, indicating HQ compounds 
have translation inhibition effects in bacterial cells. Organelle labeling in live mammalian cells also 
showed HQ compounds were partially localized in the ER, a primary protein synthesis machinery, 
supporting the premise that HQ compound act through translation associated mechanisms. No HQ 
compound was observed in either the nucleus or mitochondria, the two targets that have been 
extensively studied. With this data, in combination with bacterial cytological profiling and 
mammalian cell signaling studies, it could be concluded that ruthenium polypyridyl compounds 
with a HQ ligands act through direct or indirect translation inhibition effects other than DNA 
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damaging mechanisms that have been previously assumed. In this study, the possibility of utilizing 
luminescent Ru (II) polypyridyl compounds as novel imaging probes were also investigated 
through the conjugation of PA to HQ compound, in comparison to the commonly applied 
commercial fluorophore BODIPY, the Ru (II) molecule PA showed no preference of localizing in 
organelles and therefore was more suitable for the study of subcellular localization in living cells. 
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Figure 5.9 HQ compound shows partial colocalization with the endoplasmic reticulum (ER). HEK 
cells stably expressing ER targeted transmembrane domain with GFP (CytERM-GFP) were treated 
with 2 µM of HQ-BODIPY or free BODIPY for 6 hours prior to imaging; untreated cells were used 
as controls. Cells were incubated with Hoechst 33342 for 15 minutes before being imaged with a 
Nikon A1R confocal microscope. Red, BODIPY; Green, CytERM-GFP; Cyan, Hoechst 33342. All 
scale bars represent 20 µm. 
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Figure 5.10 HQ compound shows no colocalization with the ribosome. HEK cells transfected with 
large ribosomal subunit protein 10A with GFP (RPL10A-GFP) were treated with 2 µM of HQ-
BODIPY or free BODIPY for 6 hours prior to imaging; untreated cells were used as controls. Cells 
were incubated with Hoechst 33342 for 15 minutes before being imaged with a Nikon A1R 
confocal microscope. Red, BODIPY; Green, RPL10A-GFP; Cyan, Hoechst 33342. All scale bars 
represent 20 µm. 
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Figure 5.11 HQ compound shows no colocalization with the Golgi apparatus. HEK cells stably 
expressing human galactosyltransferase (GalT) with GFP (GalT-GFP) were treated with 2 µM of 
HQ-BODIPY or free BODIPY for 6 hours prior to imaging; untreated cells were used as controls. 
Cells were incubated with Hoechst 33342 for 15 minutes before being imaged with Nikon A1R 
confocal microscope. Red, BODIPY; Green, GalT-GFP; Cyan, Hoechst 33342. All scale bars 
represent 20 µm. 
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Figure 5.12 HQ compound shows no colocalization with mitochondria. HEK cells stably 
expressing mitochondrial matrix-targeted photoactivable GFP (mito-paGFP) were treated with 2 
µM of HQ-BODIPY or free BODIPY for 6 hours prior to imaging; untreated cells were used as 
controls. Cells were incubated with Hoechst 33342 for 15 minutes before being imaged with a 
Nikon A1R confocal microscope. Red, BODIPY; Green, mito-paGFP; Cyan, Hoechst 33342. All 
scale bars represent 20 µm. 
 
 
96 
 
 
 
Figure 5.13 HQ compound shows partial colocalization with peroxisomes. HEK cells stably 
expressing human purine nucleoside phosphorylase with GFP (PNP-GFP) were treated with 2 µM 
of HQ-BODIPY or free BODIPY for 6 hours prior to imaging; untreated cells were used as controls. 
Cells were incubated with Hoechst 33342 for 15 minutes before being imaged with a Nikon A1R 
confocal microscope. Red, BODIPY; Green, PNP-GFP; Cyan, Hoechst 33342. All scale bars 
represent 20 µm. 
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Figure 5.14 HQ compound shows partial colocalization with the endoplasmic reticulum (ER). HEK 
cells stably expressing ER targeted transmembrane domain with GFP (CytERM-GFP) were treated 
with 2 µM of HQ-PA or free PA for 6 hours prior to imaging; untreated cells were used as controls. 
Cells were incubated with Hoechst 33342 for 15 minutes before being imaged with a Nikon A1R 
confocal microscope. Red, PA; Green, CytERM-GFP; Cyan, Hoechst 33342. All scale bars 
represent 20 µm. 
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Figure 5.15 HQ compound shows no colocalization with the golgi apparatus. HEK cells stably 
expressing human galactosyltransferase with GFP (GalT-GFP) were treated with 2 µM of HQ-PA 
or free PA for 6 hours prior to imaging; untreated cells were used as controls. Cells were incubated 
with Hoechst 33342 for 15 minutes before being imaged with a Nikon A1R confocal microscope. 
Red, PA; Green, GalT-GFP; Cyan, Hoechst 33342. All scale bars represent 20 µm. 
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Figure 5.16 HQ compound shows no colocalization with mitochondria. HEK cells stably 
expressing mitochondrial matrix‐targeted photoactivable GFP (mito‐paGFP) were treated with 2 
µM of HQ-PA or free PA for 6 hours prior to imaging; untreated cells were used as controls. Cells 
were incubated with Hoechst 33342 for 15 minutes before being imaged with a Nikon A1R 
confocal microscope. Red, PA; Green, mito-paGFP; Cyan, Hoechst 33342. All scale bars represent 
20 µm. 
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Figure 5.17 HQ compound shows no colocalization with peroxisome. HEK cells stably expressing 
human purine nucleoside phosphorylase with GFP (PNP‐GFP) were treated with 2 µM of HQ-PA 
or free PA for 6 hours prior to imaging; untreated cells were used as controls. Cells were incubated 
with Hoechst 33342 for 15 minutes before being imaged with a Nikon A1R confocal microscope. 
Red, PA; Green, PNP-GFP; Cyan, Hoechst 33342. All scale bars represent 20 µm. 
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Figure 5.18 BODIPY alters subcellular localization of HQ compound while PA doesn’t. Pearson’s 
Correlation Coefficients (PCCs) between red channel (BODIPY, PA, HQ-BODIPY, and HQ-PA) 
and green channel (organelle markers) were determined for A) BODIPY conjugation; B) PA 
conjugation in HEK cell lines stably expressing different organelle markers using NIS Elements 
AR software. Red circle(solid), HQ-BODIPY; black circle (solid) BODIPY; red circle (open), HQ-
PA; blue circle (open), PA. Organelle markers: CytERM, endoplasmic reticulum marker; MitoPA, 
mitochondria marker; GalT, Golgi apparatus marker; Lys20, lysosome marker; PNP, peroxisome 
marker. Medium correlation is indicated at the dot line at 0.4. 
 
 
5.10 Materials and methods. 
 
Note: all studied compounds were synthesized by Dr. Dmytro Havrylyuk or Mr. Brock Howerton. 
All HEK cell lines containing clonal, stably expressed organeller markers were generated by Dr. 
David Heidary.  
 
E. coli culture maintenance. The Dendra2 gene was cloned into a pCW-ori plasmid 
modified to contain an N-terminal 6x histidine tag with multiple restriction enzyme cloning sites. 
Escherichia coli BL21(DE3) competent cells transformed with pCWori plasmid containing 
Dendra2 gene (pCWori-Dendra2) were cultured in Luria Broth (LB) at 37℃ with 180 rpm shaking.  
Mammalian cell maintenance. Human promyelocytic leukemia HL60 cells were purchased from 
ATCC. Dulbecco's modified eagle medium (DMEM), Iscove's modified Dulbecco's medium 
(IMDM), Opti-MEM I reduced serum medium, heat inactivated fetal bovine serum (FBS), 
Penicillin/Streptomycin (5, 000U/mL), Trypsin-EDTA (0.5%), Dulbecco's phosphate buffered 
saline (DPBS), Trypan Blue Solution (0.4%) were purchased from Life Technologies. HL60 cells 
were maintained in IMDM supplemented with 10% FBS and 50 U/mL of Penicillin/Streptomycin. 
A549 cells and HEK cells were maintained in DMEM with the same supplements. Cells were 
maintained at 37℃ with 5% CO2. 
Cytotoxicity determination. E. coli BL21(DE3) cells transformed with pCWori-Dendra2 
plasmid were plated in M63 minimal medium at 4 x 106 cells per well in 96 well flat bottom 
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transparent tissue culture treated plates (Greiner Bio One). Compounds were dosed from 0 – 300 
µM, followed by 3 min of light irradiation (7 J/cm2 blue light (> 400 nm)). The cells were then 
incubated for 16 hours with the compounds, and cell growth was determined by measurement of 
the optical density at 600 nm using a SpectraMax Multiwell Plate Reader (Molecular Devices). 
HL60 cells were plated in Opti-MEM supplemented with 1% FBS and 50 U/mL of 
Penicillin/Streptomycin at 30,000 cells per well in 96 well flat bottom transparent tissue culture 
treated plates (Greiner Bio One). Compounds were dosed from 0 – 300 µM, and incubated for 16 
hours. The cells were then incubated for 72 hours, and cell viability determined by conversion of 
resazurin to resorufin. The emission of resorufin was measured on a SpectraFluor Plus Plate Reader 
(Tecan). The data were normalized to the untreated control and fitted to a sigmoidal dose response 
model using Prism 6.02 to determine IC50 values. Minimal inhibitory concentration (MIC) was 
fitted to the model published by Lambert et al using Prism 6.02.185 
Protein synthesis and degradation measurements in E. coli with Dendra2. E. coli 
BL21DE3 cells transformed with pCWori-Dendra2 were cultured in LB medium to an OD600 of 
0.8. Cells were then resuspended in M63 minimal media and induced with 0.5 mM IPTG for 3 
hours at 37℃ with 180 rpm shaking. Photoconversion of Dendra2 was carried out with a 405 nm 
LED flood array (Loctite) with a total light exposure time of 2 minutes. Cells were then plated in 
96 well plates at 6 x 107 cells per well. Green and red emission was measured directly after 
photoconversion using a SpectraMax Multiwell Plate Reader (Molecular Devices) for a baseline 
evaluation of Dendra2 protein (t = 0 hour). For green emission, an excitation wavelength of 491 
nm and emission wavelength of 538 nm was used; for red emission, the excitation wavelength was 
544nm and emission wavelength was 590 nm. Compounds were then dosed from 0 μM to 300 μM, 
the cells were incubated for 16 hours before the green and red emission was measured again for an 
evaluation of protein synthesis with compound treatment (t = 16 hours). The average fluorescence 
ratio of green/red at t = 0 hour and t = 16 hours was calculated, the values were normalized, and 
the data fitted to a sigmoidal dose response. 
E. coli filamentous growth. E. coli were cultured as above and plated at 3 x 108 cells per 
well in 24 well flat bottom transparent tissue culture treated plates (Greiner Bio One). IPTG was 
added at a concentration of 0.5 mM for induction of Dendra2 production. Compound treatment was 
then carried out, with cells dosed at the desired concentration for each compound and cultured at 
37℃ with 180 rpm of shaking for 6 hours before imaging. 
E. coli cell imaging. After compound treatment, the OD600 was measured for each treatment 
condition followed by the removal of culture that contained 4 x 105 cells. The cells were centrifuged 
at 8,600 xg for 1 minute, aspirated, and washed twice with 1 mL of sterile filtered PBS with 
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centrifuging at 8,600 xg for 1 minute and PBS was removed. Cells were then resuspended in 150 
µL of sterile filtered MilliQ water, and plated on a poly-D-Lysine (100 µg/mL) coated 1.5# cover 
glass bottom 35 mm culture dish. Cells were allowed to settle on the culture dish for 1 hour before 
gently rinsing with 150 µL of PBS. FM4-64 and Hoechst 33342 were added to the cells at 
concentrations of 5 and 10 µg/mL respectively. The cells were incubated at room temperature and 
protected from light for 20 minutes. The solution was removed from the cells followed by rinsing 
with 150 µL of PBS. Imaging was carried out on an Olympus IX2-RFAEVA-2 microscope or a 
Nikon A1R+ confocal microscope. For the Olympus microscope, a 60 x oil or a 100 x oil objective 
was used. Hoechst 33342 was visualized using the excitation filter BP 360-390 (Chroma, Bellows 
Falls, VT, USA), and emission filter HQ470/30 M (Chroma, Bellows Falls, VT, USA). To view 
Dendra2 (green), a 473/10 nm BrightLine® single-band bandpass filter FF01-473/10-25 (Semrock, 
Rochester, NY, USA) was used as the excitation filter, and a 525/50 nm BrightLine® single-band 
bandpass filter, FF03-525/50-25 (Semrock, Rochester, NY, USA) was used as the emission filter. 
FM4-64 was visualized with a HQ 550/30 (Chroma, Bellows Falls, VT, USA) as the excitation 
filter, and a 664 nm EdgeBasic long-pass edge filter, BLP01-664R-25 (Semrock, Rochester, NY, 
USA) as the emission filter. The imaging channel sequential was set as FM4-64, Dendra2 (green), 
and Hoechst 33342. For each single field of view, a 1024 x 1024 pixel image was taken. Imaging 
on the Nikon A1R+ confocal microscope was performed with a 100 x oil objective and the zoom 
in factor was 1 x. Hoechst 33342 was visualized on the 405 nm channel with 5% laser excitation 
and 100% gain, offset was -25% to -50%. Dendra2 (green) was viewed on the 488 nm channel with 
1% laser excitation and 25% gain, offset was -25% to -50%. FM4-64 was visualized on the 561 nm 
channel with 5% laser excitation and 50% gain, offset was -25% to -50%. Imaging channel 
sequential was set as FM4-64, Dendra2 (green), and Hoechst 33342. For each single field of view, 
a 1024 x 1024 pixel image was taken, and a 3 x 3 image stitch was taken using the same setting.  
Analysis of E. coli images for filaments and DNA morphology quantification. Images were 
processed and analyzed using the ImageJ software. For each single image, to analyze cell filaments, 
the threshold of FM4-64 channel was adjusted to match the original image, and any particles 
smaller than 0.2 µm2 were excluded from measurements, size exclusion was only applied in FM4-
64 channel for cell size and number analysis. All measurement results from “Analyze Particles” 
were saved in Microsoft Excel file. The filament population (%) was calculated as the percentage 
of all particles larger than 5µm2, and the average filament size and standard deviation of filament 
size was also calculated using the statistical function of Microsoft Excel. To analyze DNA 
morphology with the most accuracy, in each field of view, a duplication image of the original image 
was made. The original image was used as the reference to adjust the threshold of the duplicate 
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image to make sure only the correct pixels that were present in the original image were captured 
and included for image analysis. ROI manager was used to match DNA with cell, and a certain 
filament was selected and set as region of interest (ROI). Then the number of DNA pieces of each 
filament was obtained by “Analyze Particles”. In each treatment condition, 30-50 filaments were 
selected and analyzed. All measurement data were saved in Microsoft Excel files. The average 
DNA pieces in filaments were calculated by dividing the number of all DNA pieces by number of 
filaments. The average size of DNA pieces, and standard deviation of DNA pieces, were also 
calculated with the statistical function of Microsoft Excel. To obtain the magnitude of variation in 
sizes of DNA pieces, coefficient of variation (CV) was calculated by dividing the standard 
deviation of DNA pieces by the average size of DNA pieces. 
HQ compound uptake in HL60 cells. HL60 cells were plated in Opti-MEM supplemented 
with 1% FBS and 50 U/mL Penicillin/Streptomycin at a density of 1x 106 cells/mL in 25 cm2 cell 
culture flasks, and dosed with 20 µM compound HQ-1. Cells were collected 6 hours and 20 hours 
after compound addition by centrifugation at 124 x g for 5 minutes. The culture media was 
separated for analysis, and cells were washed twice with PBS. Total RNA and genomic DNA were 
also isolated, and the nucleic acids, cell content, and media were prepared for analysis as described 
in Chapter 4.  
Immunoblotting. HL60 cells were treated with 2 µM of HQ-1, harvested 3, 6, 12, and 24 
hours after treatment, pelleted by centrifugation at 124 x g for 5 minutes, washed twice with DPBS. 
A549 cells were plated at 2 x 105 cells per well in 6 well flat bottom transparent tissue culture 
treated multiwell plates and in the same treatment condition detailed for HL60 cells. Cells were 
harvested at 3, 6, 12, and 24 hours after treatment. All cells were lysed in RIPA buffer supplemented 
with 5 mM sodium pyrophosphate (2 x 106 cells/100 μL) for 15 minutes on ice. The insoluble 
fraction was removed by centrifugation at 20, 817 x g for 10 minutes at 4 °C. The supernatant was 
collected and the protein concentration was determined by BCA assay. 20 μg of protein was loaded 
onto 4-12% bis-tris gels and followed by transfer to nitrocellulose membranes. After blocking with 
2.5% BSA in DPBS with 0.1% Tween20 (PBST) for 1 hour at room temperature, the membrane 
was immunoblotted with the following primary antibodies and correspondence dilutions. Cleaved 
caspase 9, cleaved PARP, p-p53, p21, p-JNK, p-c-jun, p-PDK1, pan Akt, p-Akt, p-MK2, and p-
p38 at 1: 1, 000 dilutions; p53 and p-ERK at 1: 500 dilutions; and GAPDH at a 1: 2, 000 dilution 
in 2.5% BSA overnight at 4 °C. Immunoblots were washed with PBST for 10 minutes for four 
times and incubated for 1 hour with secondary antibodies at a 1: 10, 000 dilution for GAPDH and 
1: 5, 000 dilutions for all other antibodies. Detection was carried out with Clarity Western ECL 
Substrate and imaged with a ChemiDoc MP System (Bio-Rad).  
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Flow cytometry. HL60 cells were treated with 2 µM of HQ compounds for 3, 8, and 16 
hours respectively, cells were pelleted by centrifugation at 124 x g for 5 minutes, washed twice 
with DPBS before flow cytometry. For cell death mechanism analysis, cells were stained 15 
minutes with FITC-Annexin V and PI, cells with positive FITC-Annexin V staining and negative 
PI staining were identified as early apoptotic cells; cells with both positive FITC-Annexin V and 
PI staining were identified as late apoptotic cells. Cells were analyzed with a FACSCalibur 
(Becton-Dickenson). A minimum of 20, 000 events were measured for each sample. 
Mammalian cell organelle labeling. Cell lines were prepared by Dr. David Heidary and provided 
for imaging studies. Plasmids containing ER targeted transmembrane domain with GFP (CytERM-
GFP), large ribosomal subunit protein 10A with GFP (RPL10A-GFP), human galactosyltransferase 
(GalT) with GFP (GalT-GFP), mitochondrial matrix-targeted photoactivable GFP (mito-paGFP), 
and human purine nucleoside phosphorylase with GFP (PNP-GFP) genes were purchased from 
Addgene. The plasmids were transfected into human embryonic kidney (HEK) cells, and selected 
with corresponding selection markers respectively. HEK cells expressing CytERM-GFP, GalT-
GFP, mito-paGFP, and PNP-GFP were from selection of stable cell lines and HEK cells expressing 
RPL10A-GFP were from selection of transient transfection.  
Mammalian cell imaging of BODIPY-labeled HQ compounds. BODIPY® TR-X NHS 
Ester (Succinimidyl Ester) was purchased from Thermo Fisher Scientific. BODIPY-labeled 
compounds were synthesized and provided by Dr. Dmytro Havrylyuk. HEK cells expressing 
different organelle markers were treated with 2 µM of HQ-BODIPY, HQ-BODIPY-2, or 
BODIPY for 6 hours prior to imaging. The treatment was removed by replacing culture media with 
treatment free media, cells were stained with Hoechst 33342 for 15 minutes and then rinsed with 
PBS for three times. Imaging was done with on a Nikon A1R+ confocal microscope with a 100 x 
oil objective for ER and ribosome labeling and a 60 x oil objective for other organelle labeling, and 
the zoom in factor was 1 x. Hoechst 33342 was visualized on the 405 nm channel with 5% laser 
excitation and 100% gain, offset was -25% to -50%. Organelle labeling (green) was viewed on the 
488 nm channel with 1% laser excitation and 25% gain, offset was -25% to -50%. BODIPY was 
visualized on the 561 nm channel with 5% laser excitation and 50% gain, offset was -25% to -50%. 
Imaging channel sequential was set as BODIPY, GFP, and Hoechst 33342. For each single field of 
view, three 1024 x 1024 pixel images were taken, and the images were analyzed with ImageJ. 
Quantification of colocalization with organelle markers was performed by determination of 
Pearson’s correlation coefficient (PCC) with NIS-Elements AR software.301, 302 
Mammalian cell imaging of PA-labeled HQ compound.  PA-labeled compound was 
synthesized and provided by Dr. Dmytro Havrylyuk. HEK cells expressing different organelle 
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markers were treated with 2 µM of HQ-PA or PA for 6 hours prior to imaging. The sample 
preparation and imaging settings were the same as described above. Imaging channel sequential 
was set as PA, GFP, and Hoechst 33342. For each single field of view, three 1024 x 1024 pixel 
images were taken, and the images were analyzed with ImageJ. Quantification of colocalization 
with organelle markers was performed by determination of Pearson’s correlation coefficient (PCC) 
with NIS-Elements AR software.301, 302  
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Chapter 6 Conclusion 
 The possibility of utilizing metal complexes in cancer treatment has drawn increased 
research interest. Though many efforts have been spent on platinum-based compounds following 
the discovery and application of cisplatin, compounds containing non-platinum metal centers have 
emerged as potential improved alternatives to cisplatin to achieve enhanced anticancer spectrum 
and reduced adverse effects. Among those non-platinum metal compounds, our group has taken 
particular research interest in Ru(II) compounds because of their unique features. The octahedral 
geometry and the three-dimensional architecture of ruthenium makes it possible to bond with 
structurally diverse ligands, including heterocycles containing nitrogen and/or oxygen, and 
therefore makes more complicated structures. The Ru(II) complexes have been known to possess 
lower cytotoxicity; as Fe and Ru shares similar outermost shell electron configuration, Ru(II) 
complexes can be transported by transferrin proteins which are responsible to transport Fe for 
cellular activities. Ru(II) complexes are also known for rich photophysical properties; luminescent 
Ru(II) complexes have been developed as cellular imaging probes. Moreover, the chemical and 
physical properties of Ru(II) complexes can be easily tuned by modifying the ligands coordinated 
to ruthenium center and the anions, resulting in rich chemical diversity. 
The major goal of this research was to elucidate functional targets and mechanisms of 
action for ruthenium (II) polypyridyl complexes as potential anticancer agents. Platinum complexes 
approved by the FDA, such as cisplatin, carboplatin, and oxaliplatin, have been commonly used as 
contemporary chemotherapeutic agents. While they are considered to act through DNA damaging 
mechanisms, their clinical application has been limited by acquired or intrinsic drug resistance and 
the adverse effects due to the non-selectivity and systematic toxicity of the drugs. These platinum 
compounds have been inspiring to scientists and provided direction for designing, synthesizing, 
and studying novel compounds bearing metal centers with anticancer properties. On the other hand, 
the development of metal compounds with possible medicinal applications have called for 
mechanistic research to understand their biological targets and mechanisms of action. Mechanistic 
research aids the design of novel compounds, as with a better understanding of SAR, it is possible 
to design compounds with specific targets. It is also important to gain knowledge of the mechanism 
for any compounds that will possibly be tested in clinical trial or prescribed as medications. 
 Ruthenium compounds with different scaffolds can have different charge states and 
hydrophilicities, which are very likely to affect the biological targets and mechanisms of action. 
Elucidating the mechanisms of action for ruthenium compounds with different scaffolds is 
therefore important. As revealed in this research, Ru(II) polypyridyl compounds that were 
structurally diverse had shown the ability to interact with different functional targets involved in 
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diverse biological processes, and the ability to localize in different subcellular structures/organelles. 
In turn, understanding the mechanism of action helps logical design and synthesis of molecules 
with certain mechanisms or biological targets. 
 As many metal compounds are inspired by cisplatin, the DNA crosslinking agent, it is not 
surprising that the majority of metal compounds are designed as DNA binding molecules and 
therefore have positive charges. While many believe that negatively charged compounds may not 
enter the cell and thus can’t act as cytotoxic agents, the study of two structurally similar compounds 
with positive and negative charges led to a different conclusion. Ru(bathophenanthroline)3 is a 
hydrophobic molecule with positive charge, and Ru(bathophenanthroline disulfonate)3 is a 
negatively charged hydrophilic molecule. Both molecules generate singlet oxygen with same 
quantum yields and are luminescent. Trace metal analysis by ICP-OES proved that not only 
Ru(bathophenanthroline)3 had an elevated cellular uptake, as expected, but that 
Ru(bathophenanthroline disulfonate)3 also accumulated in human cancer cells, and at a higher level 
than cisplatin, which is neutral. Both molecules were able to induce cytotoxicity, but through 
distinct mechanisms, and microscopy imaging helped to identify different cellular localization 
patterns for the two molecules. This research has a profound impact on understanding the 
mechanism of ruthenium polypyridyl compounds, as it shows the possibility to achieve radically 
different biological activities by simple ligand modification. This study demonstrated that 
ruthenium compounds with a significantly greater range of physical properties are compatible with 
potential medicinal applications. 
 The next research focus was the mechanism of action of a cisplatin inspired molecule, 
Ru(bpy)2dmbpy, a prodrug which must be activated by light to induce biological effects. Gel 
electrophoresis confirmed DNA covalent adducts, and bioanalytical studies of nucleic acid isolated 
from in vitro treatment offered more details on the preference for reaction with DNA over RNA in 
both mammalian cells and bacterial cells. While similar results have been published on in vitro 
studies for cisplatin, our research demonstrated that this ruthenium prodrug had a similar nucleic 
acid interacting behavior as the known DNA crosslinking chemotherapeutic agent cisplatin. Cell 
biology studies showed the ruthenium compound induced altered cellular responses compared to 
cisplatin. The apoptosis induced by Ru(bpy)2dmbpy was through p53-independent pathways, and 
no cell cycle arrest was observed, so treatment with this compound didn’t trigger typical cisplatin 
response pathways. Instead, the down regulation of cell survival and growth pathways was 
observed. These facts suggest though some of the biological targets – DNA and RNA - are similar, 
the actual cellular responses are different, and it raises the possibility to retain cytotoxicity but 
minimize parallel drug resistance to cisplatin.   
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 Mechanistic studies involve a great deal of time and effort to identify the target and 
determine the mechanism for potential drug molecules. These first two studies mainly utilized the 
well-established approaches to investigate the mechanism of action for Ru(II) polypyridyl 
complexes. However, given the commonly existing metal speciation resulted from the alternations 
of charge states, geometry, and ligands, additional tools and approaches were sought to provide 
new insights for medicinal inorganic chemistry. Mammalian cell system has been the primary 
choice for mechanistic studies, requiring consideration of the huge number of biomolecules present 
in eukaryotic cellular environment and the complex networks involving all possible molecular and 
cellular processes. Bacterial cell system, especially E. coli, however, have the potential to serve as 
simplified model systems that help to rapidly distinguish mechanisms if the targets and mechanism 
of action are common to both prokaryotic and eukaryotic cells. In fact, a multiparameter cytological 
profiling evaluation, based on the phenotypic features in E. coli treated with molecules with known 
mechanisms involving different phases of the central dogma, demonstrated the capability to 
separate molecules into different categories based on their individual mechanism of action. This 
phenotypic profiling included FDA approved anticancer agents and molecules that are commonly 
known antibiotics. The drugs were classified into subgroups in agreement with previous reports, 
based on their mechanism of action. A combination of cytotoxic studies, cellular imaging, and 
statistical evaluation of phenotypic features made it possible to classify molecules inducing DNA 
damage, transcription inhibition, and translation inhibition. Molecules that induced DNA strand 
breaks or DNA alkylating and crosslinking, or molecules induced repair processes through double 
strand break repair (DSBR) pathways or nucleotide excision repair (NER) pathway could be readily 
distinguished from each other. This study proved that a fast assessment of mechanisms of actions 
can be done in a simple biological system, E. coli, for anticancer agents targeting common 
biological targets in mammalian and bacterial cell systems. 
 To validate the application of bacterial cytological profiling to enrich the understanding of 
metal complexes with unknown mechanisms of action, Ru(bpy)2dmbpy was evaluated. This light 
activated system, and its proposed Ru(II) species product, Ru(bpy)2(H2O)2, were both studied in E. 
coli. Key phenotypic features revealed similar E. coli cytological profiling in response to both light 
irradiated Ru(bpy)2dmbpy treatment and cisplatin; equally importantly, the compound 
Ru(bpy)2(H2O)2 also induced similar cytological profiling in E. coli. This result not only provided 
the evidence that the ruthenium metal species generated from photo-induced ligand ejection was 
responsible for the biological effects of Ru(II) polypyridyl compounds, but also showed that the 
similar cytological profile was the reflection of similar mechanism of action to cisplatin, the control 
compound with a known mechanism of action. 
110 
 
 Another class of ruthenium polypyridyl compounds studied were the HQ compounds, 
ruthenium compounds with hydroxyquinoline and its derivatives as a chelating ligand. The HQ 
compounds developed in the Glazer laboratory were reported with outstanding cytotoxic potency, 
but the mechanism of action was unclear. Mammalian cell studies showed fast kinetics of cellular 
accumulation and cell death in response to HQ compound treatment, but investigations into cell 
signaling pathways and cell cycle arrest failed to point to a specific mechanism of action. The E. 
coli cytological profiling analysis revealed the mechanism of action of HQ compound was 
associated with translation inhibition, which was consistent with studies in mammalian cells. Live 
cell organelle labelling and cell imaging also confirmed the colocalization of HQ compound with 
the endoplasmic reticulum (ER), the site of protein synthesis machinery. This was the first report 
on translation inhibition related mechanism of HQ Ru(II) compounds, and very few other inorganic 
systems are known with this mechanism of action. In this study, the commercially available 
fluorophore BODIPY and the Ru(II) molecule PA were both used as the imaging probes, however, 
the widely used imaging reagent BODIPY showed surprisingly high preference of subcellular 
localization in several organelles including the endoplasmic reticulum and the peroxisomes. The 
Pearson’s correlation coefficients (PCCs) were used to evaluate the localization of imaged 
molecules in the organelles. The BODIPY and the BODIPY conjugated molecules all showed 
significantly elevated PCC values in peroxisomes (BODPY, 0.71; HQ-BODIPY, 0.70; HQ-
BODIPY-2, 0.72) compared with the Ru(II) polypyridyl molecule PA (PA, 0.15; HQ-PA, 0.13). 
This result showed that the subcellular localization preference of BODIPY had artificial effects that 
dominated the localization of the molecules conjugated to this imaging probe. BODIPY is one of 
the most commonly applied imaging probes, and this calls into question its use. The live cell 
imaging study showed that Ru(II) polypyridyl compounds could be improved imaging reagents as 
they have little preference for subcellular localization. 
 To fulfill the research goal of elucidating the mechanism of action for ruthenium 
compounds, a number of established analytical, biochemical, and cell biology assays and 
techniques were employed. The research utilized direct studies such as DNA binding and damage 
assays, trace metal analysis of biological samples, and visualization of compounds in the cells; 
indirect research approaches like cellular signaling regulation, growth and death regulation, and 
phenotypic feature changes were also used to gain knowledge of cellular responses and the 
mechanisms of actions. The ruthenium compounds with different scaffolds exhibited different, and 
in some cases, novel mechanisms, involving different organelles and biomolecules. This work 
demonstrated that mechanistic studies support chemistry, providing key information to aid in the 
design and optimization of ruthenium compounds with novel mechanism or targets.   
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Appendix A. Supplemental tables and figures in chapter 2. 
Note: Compound codes are chapter-specific. 
Compound 1 = [Ru(bathophenanthroline)3]2+ 
Compound 2 = [Ru(bathophenanthroline disulfonate)3]4- 
 
Table S1.1 The % intracellular metal measured by ICP-OES. HL60 cells were treated with 5 μM 
of 1, 20 μM 2, or 20 μM cisplatin for 2 hrs and 24 hrs. The metal levels in cell and media were 
measured by ICP-OES, and % intracellular levels were normalized in 107 cells. The metal levels 
were quantified by detection at three different wavelengths (n = 3). 
 
Compound 
2 hrs 24 hrs 
Light Dark Light Dark 
1 11.64 ± 0.34% 5.37 ± 1.15% 23.30 ± 0.52% 15.42 ± 0.89% 
2 0.35 ± 0.04%  0.20 ± 0.01%  0.71 ± 0.08%  0.42 ± 0.01% 
Cisplatin 0.25 ± 0.01% 0.83 ± 0.03% 
 
 
 
Table S1.2 Metal atoms per cell measured by ICP-OES. HL60 cells were treated with 5 μM of 1, 
20 μM 2, or 20 μM cisplatin for 2 hrs and 24 hrs. The metal levels in cells and media was measured 
by ICP-OES, and the number of metal atoms per cell was calculated using the cell number obtained 
using trypan blue and manual counting. The metal levels were quantified by detection at three 
different wavelengths (n = 3). 
 
Compound 
2 hrs 24 hrs 
Light Dark Light Dark 
1 4.58 ± 0.13 x 107 2.15 ± 0.46 x 107 8.64 ± 0.18 x 107 6.42 ± 0.36 x 107 
2 1.69 ± 0.18 x 107 0.93 ± 0.03 x 107 3.38 ± 0.38 x 107 2.05 ± 0.03 x 107 
Cisplatin 3.22 ± 0.52 x 107 9.34 ± 0.28 x 107 
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Figure S1.1 Time dependence of cell death in HL60 cells. A) Compound 1; B) compound 2. Blue, 
dark; red, irradiated. Viability was determined using Trypan Blue dye exclusion and manual 
counting. 
 
 
 
Figure S1.2 Time dependence of compound uptake and average emission intensity per cell in A549 
cells determined by flow cytometry. 
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Figure 1.3 Time dependence of compound uptake in A549 cells measured by ApoTome microscope. 
The ruthenium compounds’ emissions are shown in red and Hoechst was used to stain the nucleus 
(blue). A) 1, dark; B) 1, light; C) 2, dark; D) 2, light. 
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Figure S1.4 Time dependence of compound localization in lysosomes in A549 cells measured by 
ApoTome microscope. Lysotracker green was used to visualize lysosomes. A) 1, dark; B) 1, light; 
C) 2, dark; D) 2, light. 
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Figure S1.5 Time dependence of compound localization in mitochondria in A549 cells measured 
by ApoTome microscope. Mitotracker green was used to visualize mitochondria. A) 1, dark; B) 1, 
light; C) 2, dark; D) 2, light. 
 
 
 
Figure S1.6 Western blotting of 55 kDa PARP fragment shows contribution from necrotic cell 
death for 10% ethanol, cisplatin, doxorubicin, 1, and 2. 
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Figure S1.7 Flow cytometry analysis of apoptosis induced by 1 after light exposure. Annexin V 
was used in conjunction with Propidium Iodide (left) or Hoechst (right) staining. A) and D) 2 hours; 
B) and E) 8 hours; C) and F) 24 hours. Induction of cell death is rapid, and while there are many 
cells that are classified as late apoptotic (or necrotic), a very small percentage can be classified as 
early apoptotic (Annexin V positive cells, both PI or Hoechst negative). 
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Figure S1.8 Flow cytometry analysis of apoptosis induced by 1 protected from light. Annexin V 
was used in conjunction with Propidium Iodide (left) or Hoechst (right) staining. A) and D) 2 hours; 
B) and E) 8 hours; C) and F) 24 hours. At all time points there are many cells that are classified as 
late apoptotic (or necrotic), but at 2 and 8 hours there are Annexin V negative cells that are both PI 
or Hoechst positive, indicating necrosis, along with some fraction of early apoptotic cells (Annexin 
V positive cells, both PI or Hoechst negative). 
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Figure S1.9 Flow cytometry analysis of apoptosis induced by 2 after light exposure. Annexin V 
was used in conjunction with Propidium Iodide (left) or Hoechst (right) staining. A) and C) 2 hours; 
B) and D) 24 hours. There are a significant fraction of early apoptotic cells (Annexin V positive 
cells, both PI or Hoechst negative). 
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Figure S1.10 Flow cytometry analysis of apoptosis induced by 2 protected from light. Annexin V 
was used in conjunction with Propidium Iodide (left) or Hoechst (right) staining. A) and C) 2 hours; 
B) and D) 24 hours. The compound does not induce significant cell death. 
 
 
 
Figure S1.11 Cell death study by flow cytometry comparing ratio of early apoptotic vs. dead cells. 
HL60 cells were treated with 5 μM 1 or 20 μM 2 for 2 hrs and 24 hrs and stained by Hoechst 33342 
and FITC conjugated Annexin V. The percent of A) dead cells and B) early apoptotic cells were 
measured by flow cytometry.  
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Appendix B. Supplemental tables and figures in chapter 3. 
Note: Compound codes are chapter-specific. 
 
Compound 1 = [Ru(bpy)2(6,6’-dmbpy)]2+ 
 
Table S2.1 Cellular metal content with different nucleic acids measured by AAS. 
a, bThe percentage of metal bound with genomic DNA or total RNA was calculated as follows: 
Percentage of metal bound with DNA (RNA)=
Metal measured in DNA (RNA) sample (μmol)
Metal in DNA sample + cell sample (μmol)
 
c Ruthenium level in DNA and RNA samples were under the detection limit (2ppb). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 E. coli  HL60 
  
Percentage of 
metal bound with 
genomic DNAa 
Percentage of 
metal bound 
with total RNAb 
 
Percentage of 
metal bound with 
genomic DNAa 
Percentage of 
metal bound 
with total 
RNAb 
1 light 1.3% ± 0.1% 0.5% ± 0.1%  1.3% ± 0.1% 2.0% ± 0.3% 
1 dark -c -c  -c -c 
cisplatin 1.0% ± 0.1% 0.7% ± 0.1%  1.1% ± 0.1% 1.5% ± 0.2% 
121 
 
 
Figure S2.1 Cytotoxicity dose response of complex 1 (red lines) and cisplatin (black lines) in E. 
coli following photoirradiation (solid lines, filled circles) and dark condition (dashed lines, open 
circles). 
 
 
 
 
 
 
 
 
 
 
Figure S2.2 Size distribution histograms of E. coli filaments with treatment of A) rifampicin; and 
B) tetracycline. E. coli cells were treated with 3 μM of rifampicin and 48 μM of tetracycline (10x 
IC50) for 6 hours. 
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Figure S2.3 Complex 1 induces filamentous growth and decreased protein production in E. coli. A) 
- D) Bright field and fluorescent imaging of E. coli cells under different conditions; E) - H) Size 
distribution histograms of E. coli cells under different treatments; I)- L) Histograms of average 
fluorescence intensity (Ave. Fl. Int.) correlating to cell size with different treatments. Top through 
bottom panels: N. C. control, cisplatin, compound 1with light, and compound 1 without light. Cells 
were treated with 40 μM each compound for 6 hours before imaging.  
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Figure S2.4 Complex 1 induces filamentous growth and decreased protein production in E. coli. A) 
- D) Bright field and fluorescent imaging of E. coli cells under different conditions; E) - H) Size 
distribution histograms of E. coli cells under different treatments; I)- L) Histograms of average 
fluorescence intensity (Ave. Fl. Int.) correlating to cell size with different treatments. Top through 
bottom panels: N. C. control, cisplatin, compound 1with light, and compound 1without light. Cells 
were treated with 40 μM each compound for 16 hours before imaging. 
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Figure S2.5 Complex 1 induces filamentous growth and decreased protein production in E. coli. A) 
- D) Bright field and fluorescent imaging of E. coli cells under different conditions; E) - H) Size 
distribution histograms of E. coli cells under different treatments; I)- L) Histograms of average 
fluorescence intensity (Ave. Fl. Int.) correlating to cell size with different treatments. Top through 
bottom panels: N. C. control, cisplatin, compound 1with light, and compound 1without light. Cells 
were treated with 100 μM each compound for 16 hours before imaging. 
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Figure S2.6 Supplemental fluorescent imaging of N. C. control. The merge is the combination of 
the Hoechst and FM4-64 membrane stain emission data.
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Figure S2.7 Supplemental fluorescent imaging of cisplatin. Cells were treated MIC for 6 hours 
before imaging. The merge is the combination of the Hoechst and FM4-64 membrane stain 
emission data.  
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Figure S2.8 Supplemental fluorescent imaging of compound 1 with light. Cells were treated MIC 
for 6 hours before imaging. The merge is the combination of the Hoechst and FM4-64 membrane 
stain emission data.  
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Figure S2.9 Supplemental fluorescent imaging of rifampicin. Cells were treated 10x MIC for 6 
hours before imaging. The merge is the combination of the Hoechst and FM4-64 membrane stain 
emission data.  
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Figure S2.10 Supplemental fluorescent imaging of tetracycline. Cells were treated MIC for 6 hours 
before imaging. The merge is the combination of the Hoechst and FM4-64 membrane stain 
emission data.  
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Figure S2.11 Supplemental fluorescent imaging of nalidixic acid. Cells were treated MIC for 6 
hours before imaging. The merge is the combination of the Hoechst and FM4-64 membrane stain 
emission data.  
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Figure S2.12 Flow cytometry analysis by FITC/Annexin-V and PI of apoptosis in HL60 cells. 
FITC-Annexin V (FL1-H) was used in combination with propidium iodide (FL2-H). A) N. C.  
control; B) cisplatin; C) compound 1 with light irradiation; D) compound 1 in dark. HL60 cells 
were treated with 20 μM compounds for 24 hours.  
A) B) 
D) C) 
132 
 
 
Figure S2.13 Flow cytometry analysis by propidium iodide of cell cycle arrest in HL60 cells. A) N. 
C.  control; B) cisplatin; C) compound 1 with light irradiation; D) compound 1 in dark. HL60 cells 
were treated with compounds for 24 hours. 
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Calculation of the ratio of DNA and RNA nucleotides to metal based on data reported by 
DeRose et al.188: 
The platinum content measured after 12 hours treatment of 100 μM cisplatin was used for this 
calculation. 
Pt / DNA nt = 60.2 x 10-5 
DNA nt / Pt =
1
60.2 × 10−5 
= 1661:1 
Pt / RNA nt = 15.7 x 10-5 
RNA nt / Pt =
1
15.7 × 10−5 
= 6369:1 
Calculation of the ratio of DNA and RNA nucleotides to metal based on data reported from 
an IVTT assay199 (at the IC50):  
DNA bp / Ru = 570:1  
DNA nt / Ru = 1140:1 
DNA bp / Pt = 300:1 
DNA nt / Pt = 600:1 
RNA nt / Ru = 610:1  
RNA nt / Pt = 820:1 
Calculation of the ratio of DNA and RNA nucleotides to metal at the IC50 to Dendra2 
production inhibition based on data collected in AAS: 
The DNA and RNA nt / mc ratio collected by AAS at 20μM is as follows: 
DNA nt / Ru = 2000:1  
DNA nt / Pt = 3000:1 
RNA nt / Ru = 3800:1  
RNA nt / Pt = 4700:1 
Assuming the uptake is linearly proportional to the dosed concentration, the IC50 value to inhibit 
Dendra2 production in E. coli is 77 μM for compound 1 and 85 μM for cisplatin. Thus, a correction 
coefficient can be calculated to adjust the metal content to what would be obtained at the higher 
compound dose: 
Compound 1: 
77
20
= 3.8 
Cisplatin: 
85
20
= 4.3 
Then, at the IC50 to inhibit Dendra2 production, the theoretical metal to DNA or RNA nucleotides 
to metal ratio can be calculated as follows: 
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DNA nt / Ru =
2000
3.8
= 520 ∶ 1 
RNA nt / Ru =
3800
3.8
= 1000 ∶ 1 
DNA nt / Pt =
3000
4.3
= 700 ∶ 1 
RNA nt / Pt =
4700
4.3
= 1090 ∶ 1 
The average molecular weight values used in calculation for DNA base pairs and RNA nucleotides 
are 665 g/mol and 340 g/mol.  
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Appendix C. Supplemental tables and figures in chapter 4. 
 
 
Figure S3.1 Colony formation after E. coli treated with A) untreated control, B) bleomycin, C) 
mitomycin C, D), ciprofloxacin, E) nalidixic acid, F) MMS, G) EMS, H) cisplatin, I) carboplatin, 
J) oxaliplatin, K) chlormethine, L) chlorambucil, M) BCEA, N) 4-NQO, O) puromycin, P) 
rifampicin, Q) rifaximin, R) tetracycline, S) chloramphenicol, T) kanamycin, U) doxorubicin, V) 
etoposide, W) mitoxantrone. 
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Figure S3.2 E. coli cells treated with A) untreated control, B) bleomycin, C) mitomycin C, D), 
ciprofloxacin, E) nalidixic acid, F) MMS, G) EMS, H) chlormethine, I) chlorambucil, J) BCEA, K) 
4-NQO, L) puromycin, M) rifampicin, N) rifaximin, O) tetracycline, P) chloramphenicol, Q) 
kanamycin. All scale bars represent 10 µm. 
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Figure S3.3 E. coli cells treated with carboplatin at A) 0.1 x MIC, B) 1 x MIC, and C) 5 x MIC; 
with cisplatin at D) 0.1 x MIC, E) 1 x MIC, and F) 5 x MIC; and with oxaliplatin at H) 0.1 x MIC, 
I) 1 x MIC, and J) 5 x MIC. All scale bars represent 10 µm. 
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Figure S3.4 E. coli cells treated with etoposide at A) 0.1 x MIC, B) 1 x MIC; with doxorubicin at 
C) 0.1 x MIC, D) 1 x MIC; and with mitoxantrone at E) 0.1 x MIC, F) 1 x MIC. All scale bars 
represent 10 µm. 
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Figure S3.5 Distinguishing anticancer molecules with different mechanisms based on the 
phenotypic change observed in E. coli. Cells were treated with molecules at their MIC for 6 hours 
prior to imaging, translation inhibitors were dosed at 10 x MIC for phenotypic changes. Same 
phenotypic features as used for Figure 4.5 were analyzed with Prism 7.02. 
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Figure S3.6 Distinguishing anticancer molecules with different mechanisms based on the 
phenotypic change observed in E. coli. Cells were treated with molecules at their MIC for 6 hours 
prior to imaging, translation inhibitors were dosed at 10 x MIC for phenotypic changes. Same 
phenotypic features as used for Figure 4.5 were analyzed with Prism 7.02. 
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Figure S3.7 Correlation of cytotoxicity in cancer cells and E. coli. IC50 values in HL60 cells were 
determined 72 hours after treatement; IC50 values in E. coli cells were determined 16 hours after 
treatments. A) Linear regression fitness of all molecules. Liner regression, y = 0.009x + 3.936, R2 
= 0.001. B) Linear regress fitness of molecules but BCEA and Doxorubicin. Liner regression, y = 
0.045x + 1.191, R2 = 0.368. All data analysis was done with Prism 7.02. 
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Table S3.1 Comprehensive phenotypic profiling data obtained at MIC in E. coli. 
Treatment 
Mechanism of 
Action 
DNA Damage  
DNA Damage 
Repair 
IC50 
Growth 
Inhibition 
(μM) 
IC50 
Translation 
Inhibition  
(μM) 
Cisplatin 
DNA 
alkylating 
Inter- and intra-
strand crosslink 
at N7 of 
guanine 
NER 
(nucleotide 
excision 
repair); MMR 
(mismatch 
repair) 
2 85 
Carboplatin 
DNA 
alkylating 
113.9 >300 
Oxaliplatin 
DNA 
alkylating 
Inter- and intra-
strand crosslink 
at N7 of purine 
43.7 >300 
BCEA 
DNA 
alkylating 
Inter- and intra-
strand crosslink 
at N7 and N3 of 
purine 
NER; DSBR 
(double strand 
break repair) 
6.8 123 
Chlormethine 
DNA 
alkylating 
9.7 52.6 
Chlorambucil 
DNA 
alkylating 
23.7 231 
4-NQO  
DNA oxidizing 
damage 
Oxidation at C8 
of guanine (8-
oxoG) 
NER 12.8 > 300  
Nalidixic acid 
Bacterial DNA 
gyrase inhibitor Double strand 
break 
DSBR 
1.2 4.3 
Ciprofloxacin 
Bacterial DNA 
gyrase inhibitor 
1.5 5.5 
Doxorubicin 
Topoisomerase 
2A inhibitor 
DNA 
intercalation; 
double strand 
break 
DSBR 
4.3 9.7 
Etoposide 
Topoisomerase 
2A inhibitor 
44.9 174.5 
Mitoxantrone 
Topoisomerase 
2A inhibitor 
25.9 50.0 
MMS  
DNA 
alkylating Mono adduct; 
double strand 
break 
BER (base 
excision 
repair); 
DSBR 
2.9 24.2 
EMS  
DNA 
alkylating 
13.8 84.7 
Mitomycin C  
DNA 
alkylating 
Double strand 
break 
NER; DSBR 0.04 0.07 
Bleomycin  ROS cleavage 
Single and 
double strand 
break 
DSBR 0.3 0.4 
Rifampicin 
Transcription 
inhibitor 
  0.3 2.8 
Rifaximin 
Transcription 
inhibitor 
  1.8 12.7 
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Table S3.1 Comprehensive phenotypic profiling data obtained at MIC in E. coli. (continued) 
Treatment 
MIC 
(µM) 
IC50 
Inde
x 
Filament 
Population 
(%) 
Avg. 
Filament 
Size (μm2) 
Avg. 
DNA 
Pieces Per 
Cell 
CV 
(DNA) 
Colony 
Forming 
(%) 
Cisplatin 4.4 43 34% 12 ± 6 5.1 130% 0% 
Carboplatin 
235.
2 
> 2.6 17% 7 ± 3 2.9 73% 0% 
Oxaliplatin 93.3 > 6.7 45% 36 ± 31 5.9 163% 0% 
BCEA 12.8 24 23% 9 ± 6 3.1 132% 65% 
Chlormethine 19 5.2 21% 42 ± 30 5.3 126% 0% 
Chlorambucil 63.5 9.7 19% 14 ± 10 4 108% 0% 
4-NQO  32.1 > 23 40% 10 ± 7  3.9 95% 65% 
Nalidixic acid 2.5 1.8 100% 57 ± 28 8.6 160% 0% 
Ciprofloxacin 2.6 3.6 100% 42 ± 34 6.4 115% 0% 
Doxorubicin 16.1 2.3 66% 44 ± 36 8.5 158% 0% 
Etoposide 87.2 3.9 62% 40 ± 33 8.8 133% 0% 
Mitoxantrone 62.4 1.9 54% 36 ± 24 7.5 145% 0%  
MMS  10.8 8.3 89% 61 ± 55  8.2 139% 0% 
EMS  25.7 6 88% 71 ± 34  7.5 141% 0% 
Mitomycin C  0.09 1.8 86% 48 ± 35 9.2 144% 0% 
Bleomycin  0.6 1.3 89% 55 ± 47 9.5 138% 0% 
Rifampicin 0.6 9.3 30% 8 ± 3 1.2 49% 18% 
Rifaximin 4.6 6.9 25% 8 ± 4 1.1 52%  17% 
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Table S3.2 Comprehensive phenotypic profiling data obtained at 10 x MIC in E. coli. 
 
 
 
Table S3.3 Comprehensive phenotypic profiling data obtained at 0.1 x MIC in E. coli. 
 
 
 
 
 
Treatment 
Filament 
Population 
(%) 
Avg. 
Filament 
Size (μm2) 
Avg. DNA 
Pieces Per 
Cell 
CV (DNA) 
Colony 
Forming 
(%) 
Tetracycline 25% 11 ± 3 3.9 36% 36% 
Kanamycin 29% 9 ± 5 3.5 34% 40% 
Chloramphenicol 26% 9 ± 3 4.3 29% 40% 
Puromycin 23% 8 ± 3 3.7 45%  47% 
Treatment 
Filament 
Population (%) 
Avg. Filament 
Size (μm2) 
Avg. DNA 
Pieces Per 
Cell 
CV (DNA) 
Cisplatin 23% 9 ± 4 3.7 108% 
Carboplatin 6% 7 ± 3 2.8 73% 
Oxaliplatin 21% 13 ± 9 4.5 134% 
Doxorubicin 38% 24 ± 18 5.1 122% 
Etoposide 42% 22 ± 16 5 131% 
Mitoxantrone 40% 28 ± 19 5.9 119% 
EMS  44% 15 ± 6 3.7 96% 
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Appendix D. Supplemental tables and figures in chapter 5. 
Note: Compound codes are chapter-specific. See Chapter 5 for HQ compound structures. 
Table S4.1 Comprehensive phenotypic profiling data in E. coli. 
 
Table S4.2 HQ-1 cytotoxicity and cellular metal uptake measured by ICP-OES in E. coli.  
 
 IC50 (µM) Cellular uptakea 
HQ-1 1.3 50% 
 
aCellular uptake was calculated as metal content measured in cells divided by total metal content 
in both cell samples and cell culture media samples. Cellular uptake in E. coli cells were normalized 
to 109 cells. E. coli cells were treated with 2 μM of HQ-1 for 2 hrs and 24 hrs. The metal levels in 
cells and media was measured by ICP-OES, and the number of metal atoms per cell was calculated 
using the cell number obtained using OD600 measurement. The metal levels were quantified by 
detection at three different wavelengths (n = 3). 
 
 
 
 
 
 
 
Treatment 
IC50 
Growth 
Inhibition 
(μM) 
IC50 
Translation 
Inhibition 
(μM) 
MIC 
(μM) 
IC50 
Index 
Filament 
Population 
(%) 
Avg. 
Filam
ent 
Size 
(μm2) 
Avg. 
DNA 
Pieces 
Per 
Cell 
CV 
(DNA) 
HQ-2 3.9 20.5 8.5 3.6 39% 12 ± 5 41% 5.1 
HQ-3 3.6 5.2 4.1 1.4 36% 9 ± 4 44% 3.3 
HQ-4 27.5 5.5 41.9 0.2 30% 9 ± 5 59% 3.8 
HQ-5 31.3 11.2 37.9 0.4 29% 8 ± 3 38% 3.2 
HQ-6 26.2 2.9 32.7 0.1 18% 7 ± 3 41% 4.3 
HQ-7 100.2 5.9 112.8 0.1 33% 10 ± 5 50% 3.8 
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Table S4.3 Pearson’s correlation coefficients (PCC) of BODIPY conjugated HQ compounds with 
organelle markers. 
 HQ-BODIPY HQ-BODIPY-2 BODIPY 
CytERM-GFP 0.82 0.8 0.76 0.83 0.82 0.74 0.69 0.68 0.64 
Mito-paGFP 0.33 0.31 0.3 0.49 0.34 0.27 0.55 0.41 0.34 
GalT-GFP 0.45 0.4 0.3 0.47 0.45 0.25 0.46 0.43 0.33 
Lys20-GFP 0.26 0.18 0.13 0.42 0.32 0.25 0.31 0.29 0.21 
PNP-GFP 0.7 0.65 0.59 0.72 0.69 0.68 0.71 0.7 0.65 
RPL10A-GFP -0.04 -0.02 -0.02 N. D.a 0.03 0.029 0.02 
aThe colocalization of ribosome marker with HQ-BODIPY-2 was not determined. 
 
 
Table S4.4 Pearson’s correlation coefficients (PCC) of PA-conjugated HQ compounds with 
organelle markers. 
 HQ-PA PA 
CytERM-GFP 0.79 0.72 0.64 0.13 0.11 0.08 
Mito-paGFP 0.2 0.17 0.15 0.28 0.24 0.23 
GalT-GFP 0.17 0.16 0.12 0.21 0.19 0.18 
Lys20-GFP 0.18 0.16 0.1 0.25 0.19 0.18 
PNP-GFP 0.13 0.09 0.05 0.15 0.11 0.07 
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Figure S4.1 HQ compound shows partial colocalization with endoplasmic reticulum (ER). HEK 
cells stably expressing ER targeted transmembrane domain with GFP (CyTERM-GFP) were 
treated with 2 µM of HQ-BODIPY-2 or free BODIPY for 6 hours prior to imaging, untreated cells 
were used as controls. Cells were incubated with Hoechst 33342 for 15 minutes before imaged with 
Nikon A1R confocal microscope. Red, BODIPY; Green, CytERM-GFP; Cyan, Hoechst 33342. All 
scale bars represent 20 µm. 
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Figure S4.2 Cellular localization of HQ compound. HEK cells stably expressing human 
galactosyltransferase (GalT) with GFP (GalT-GFP, top), mitochondrial matrix-targeted 
photoactivable GFP (mito-PAGFP, middle), and human purine nucleoside phosphorylase with GFP 
(PNP-GFP, bottom) were treated with 2 µM of HQ-BODIPY-2 or free BODIPY for 6 hours prior 
to imaging, untreated cells were used as controls. Cells were incubated with Hoechst 33342 for 15 
minutes before imaged with Nikon A1R confocal microscope. Red, BODIPY; Green, GFP; Cyan, 
Hoechst 33342. All scale bars represent 20 µm.  
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